FORMAS CRISTALINAS DE (R)-2-AMINO-5-(4-(2-(3,5-DIFLUOROFENIL)-2-HIDROXIACETAMIDO)-2-METILFENIL)-N-ISOPROPILNICOTINAMIDA E MÉTODOS PARA USO DAS MESMAS
Crystalline forms of PERK inhibitor compounds, like fumarate and L-tartrate salts, provide stable and effective pharmaceutical compositions for treating cancer, overcoming the unpredictability in solid form development and ensuring therapeutic efficacy.
Patent Information
- Application Number
- BR112025020993
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-30
- Filing Date
- 2024-03-29
- Publication Date
- 2026-11-10
AI Technical Summary
The development of solid forms of PERK inhibitor compounds faces challenges due to unpredictability in screening outcomes and physicochemical properties, necessitating novel crystalline forms with stability and efficacy for treating conditions like cancer.
Development of crystalline forms, including crystalline salt forms and crystalline free base forms, of a compound of formula (I), such as fumarate, L-tartrate, tosylate, and succinate salts, providing pharmaceutical compositions and methods for treating conditions like cancer.
The crystalline forms offer stable and effective pharmaceutical compositions for treating cancer by addressing the unpredictability in solid form development, ensuring desired physicochemical properties and therapeutic efficacy.
Abstract
Description
[0001] This application claims the benefit and priority of International Application No. PCT / CN2023 / 085125, filed on March 30, 2023, the contents of which are incorporated herein by reference in their entirety. Foundation
[0002] Endoplasmic reticulum-like protein kinase R (PKR) (PERK), an eIF2 kinase involved in the unfolded protein response that regulates protein synthesis, helps cells alleviate the impact of endoplasmic reticulum stress and has been implicated in tumorigenesis, cancer cell survival, and viral infections (e.g., coronavirus). Thus, PERK-modulating compounds (e.g., PERK-inhibiting compounds) are believed to be useful in treating a wide variety of conditions, diseases, and disorders including, but not limited to, various types of cancer.The development of solid forms, including crystalline forms, of PERK inhibitor compounds that provide the necessary physicochemical properties to manufacture a drug with the required stability and efficacy represents a significant challenge due to the unpredictability in the outcome of screening solid forms for a compound and the subsequent unpredictability of the physicochemical properties of any identified solid forms. Therefore, there is an unmet need for novel solid forms of PERK inhibitor compounds that provide the necessary physicochemical properties. Summary
[0003] The present disclosure provides crystalline forms (e.g., crystalline salt forms and crystalline free base forms) of a compound of formula (I) Petition 870260106343, dated 10 / 15 / 2026, page 7 / 289 2 / 280 (I) .
[0004] The disclosure further provides pharmaceutical compositions comprising a crystalline form (e.g., crystalline salt form or crystalline free base form) of the compound of formula (I) described herein. The salt forms of the compound of formula (I) or pharmaceutical compositions of the disclosure are useful in the treatment of a condition, disease or disorder described herein (e.g., a cancer).
[0005] In one aspect, the revelation provides a fumarate salt of a compound of formula (I) (I).
[0006] In another aspect, the revelation provides a crystalline fumarate salt of a compound of formula (I) (I).
[0007] In another aspect, the revelation provides a crystalline monofumarate salt of a compound of formula (I) (I).
[0008] In another aspect, the revelation provides Form A of a monofumarate salt of a compound of formula (I) Petition 870260106343, dated 10 / 15 / 2026, p. 8 / 289 3 / 280 (I) .
[0009] In another aspect, the revelation provides Form B of a monofumarate salt of a compound of formula (I) (I).
[0010] In another aspect, the revelation provides Form C of a monofumarate salt of a compound of formula (I) (I).
[0011] In another aspect, the revelation provides a crystalline hemifumarate salt of a compound of formula (I) (I).
[0012] In another aspect, the revelation provides Form A of a hemifumarate salt of a compound of formula (I) (I).
[0013] In another aspect, the revelation provides Form B of a hemifumarate salt of a compound of formula (I) Petition 870260106343, dated 10 / 15 / 2026, p. 9 / 289 4 / 280 (I) .
[0014] In another aspect, the disclosure provides pharmaceutical compositions that generally comprise a salt form (e.g., a crystalline salt form) of the compound of formula (I) described herein and a pharmaceutically acceptable excipient.
[0015] In another aspect, the disclosure provides dosage forms (e.g., capsules) generally comprising a pharmaceutical composition described herein.
[0016] In another aspect, the disclosure provides methods of treating cancer in an individual who needs it, the methods generally comprise administering an effective amount of a salt form (e.g., a crystalline salt form) of the compound of formula (I) or of a pharmaceutical composition described herein. Brief Description of the Figures
[0017] Figure 1 is an exemplary X-ray powder diffraction (XRPD) pattern of Form A of the monofumarate salt of the compound of formula (I), prepared in accordance with Example 3.
[0018] Figure 2 is a superposition of differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) thermograms of Form A of the monofumarate salt of the compound of formula (I), prepared according to Example 3.
[0019] Figure 3 is an exemplary XRPD standard of Form B of the monofumarate salt of the compound of formula (I), prepared in accordance with Example 8.
[0020] Figure 4 is an overlay of DSC and TGA thermograms of Form B of the monofumarate salt of the compound of formula (I), prepared according to Example 8.
[0021] Figure 5 is an exemplary XRPD pattern of Form C of the monofumarate salt of the compound of formula (I), prepared from Petition 870260106343, dated 10 / 15 / 2026, page 10 / 289 5 / 280 according to Example 9.
[0022] Figure 6 is an overlay of DSC thermograms and TGA of Form C of the monofumarate salt of the compound of formula (I), prepared according to Example 9.
[0023] Figure 7 is an exemplary XRPD pattern of a crystalline fumarate salt of the compound of formula (I) crystallized from 0.5 or 1.1 equivalents of 0.1 M fumaric acid in methanol solution at room temperature, obtained in accordance with Example 10.
[0024] Figure 8 is an exemplary XRPD pattern of Form A of the hemifumarate salt of the compound of formula (I), prepared in accordance with Example 11.
[0025] Figure 9 is an overlay of DSC thermograms and TGA of Form A of the hemifumarate salt of the compound of formula (I), prepared according to Example 11.
[0026] Figure 10 is an exemplary dynamic vapor sorption (DVS) isotherm plot of Form A of the hemifumarate salt of the compound of formula (I), prepared in accordance with Example 11.
[0027] Figure 11 is an overlay graph of XRPD patterns of Form A of the hemifumarate salt of compound formula (I) obtained from the suspension of Form A of the hemifumarate salt of compound formula (I) and Form B of the hemifumarate salt of compound formula (I) in isopropanol, carried out in accordance with Example 14.
[0028] Figure 12 is an overlay graph of the XRPD pattern of solids obtained after the addition of Form A of the hemifumarate salt of the compound of formula (I), prepared according to Example 15, to water, FeSSIF and FaSSIF solution. Sampling of solids occurred after 24 hours.
[0029] Figure 13 is an exemplary XRPD standard of Form B of the hemifumarate salt of the compound of formula (I), prepared in accordance with Example 16.
[0030] Figure 14 is an overlay of DSC thermograms and Petition 870260106343, dated 10 / 15 / 2026, page 11 / 289 6 / 280 TGA of Form B of the hemifumarate salt of the compound of formula (I), prepared according to Example 16.
[0031] Figure 15 is an overlay graph of the XRPD pattern of a competitive suspension of Form A of the hemifumarate salt of compound formula (I) and Form B of the hemifumarate salt of compound formula (I) in isopropanol at room temperature and at 50°C, performed according to Example 17. Sampling of the solids occurred after 3 days.
[0032] Figure 16 is an exemplary XRPD standard of the L-tartrate salt of the compound of formula (I), prepared in accordance with Example 19.
[0033] Figure 17 is an overlay of DSC and TGA thermograms of the L-tartrate salt of the compound of formula (I), prepared according to Example 19.
[0034] Figure 18 is an exemplary XRPD standard of Form A of the tosylate salt of the compound of formula (I), prepared in accordance with Example 20.
[0035] Figure 19 is an overlay of DSC and TGA thermograms of Form A of the tosylate salt of the compound of formula (I), prepared according to Example 20.
[0036] Figure 20 is an exemplary XRPD standard of a solid material comprising the tosylate salt of the compound of formula (I) crystallized from 1.1 equivalents of 0.1 M p-toluenesulfonic acid in MeOH, prepared in accordance with Example 21.
[0037] Figure 21 is an exemplary XRPD pattern of a solid material comprising the tosylate salt of compound of formula (I) crystallized from 14 V of EtOAc as an antisolvent and a seed of the tosylate salt of compound of formula isolated from the salt screening experiment (Example 18), prepared in accordance with Example 22.
[0038] Figure 22 is an exemplary XRPD standard of Form A of the succinate salt of the compound of formula (I), prepared according to Petition 870260106343, dated 10 / 15 / 2026, page 12 / 289 7 / 280 with Example 23.
[0039] Figure 23 is an overlay of DSC and TGA thermograms of Form A of the succinate salt of the compound of formula (I), prepared according to Example 23.
[0040] Figure 24 is an exemplary XRPD standard of a solid material comprising the succinate salt of the compound of formula (I) crystallized from 1.1 equivalents of 0.1 M succinic acid solution in MeOH, prepared in accordance with Example 24.
[0041] Figure 25 is an exemplary XRPD standard of a solid material comprising the succinate salt of the compound of formula (I) crystallized from 1.05 equivalents of 0.1 M succinic acid solution in MeOH and the seed of a succinate salt from the salt screening experiment (Example 18), prepared in accordance with Example 25.
[0042] Figure 26A is an exemplary XRPD pattern of Form A of the compound of formula (I), prepared in accordance with Example 27.
[0043] Figure 26B is an XRPD pattern of Form A of the compound of formula (I) calculated from single crystal X-ray diffraction data, prepared in accordance with Example 27.
[0044] Figure 27 is an exemplary DSC thermogram of Form A of the compound of formula (I), prepared in accordance with Example 27.
[0045] Figure 28 is an atomic displacement ellipsoid diagram of Form A of the compound with formula (I).
[0046] Figure 29A is an exemplary XRPD standard of Form A of the compound of formula (I) prepared by storing Form A in a water / acetone mixture (80:20 v / v) under ambient conditions for four days, as performed in accordance with Example 29.
[0047] Figure 29B is an exemplary XRPD standard of Form C of the compound of formula (I) prepared by storing Form A of the compound of formula (I) in an acetonitrile / water mixture (92:8 v / v) under ambient conditions for four days, as Petition 870260106343, dated 10 / 15 / 2026, page 13 / 289 8 / 280 performed according to Example 29.
[0048] Figure 29C is an exemplary XRPD standard of Form H of the compound of formula (I) prepared by storing Form A of the compound of formula (I) in an isopropanol / water mixture (90:10 v / v) under ambient conditions for 27 days, as performed in accordance with Example 29.
[0049] Figure 29D is an exemplary XRPD standard of a mixture of Form A and Form H of the compound of formula (I) prepared by storing Form A in an isopropanol / water mixture (94:6 v / v) under ambient conditions for four days, as performed in accordance with Example 29.
[0050] Figure 30 is an exemplary XRPD pattern of Form B of the compound of formula (I), prepared in accordance with Example 30.
[0051] Figure 31 is an exemplary DSC thermogram of Form B of the compound of formula (I), prepared in accordance with Example 30.
[0052] Figure 32 is an exemplary thermogravimetric analysis (TGA) thermogram of Form B of the compound of formula (I), prepared in accordance with Example 30.
[0053] Figure 33 is a cyclic DSC thermogram (multiple heating + cooling cycles) of compound formula (I) (starting material Form B of compound formula (I)), as performed according to Example 31.
[0054] Figure 34 is an overlaid graph of XRPD patterns from a temperature-variable XRPD study of compound formula (I) (starting material Form B of compound formula (I)), as performed in accordance with Example 31.
[0055] Figure 35 is an exemplary XRPD pattern of Form C of the compound of formula (I), prepared in accordance with Example 32.
[0056] Figure 36 is an exemplary DSC thermogram of Form C of the compound of formula (I), prepared in accordance with Example 32.
[0057] Figure 37 is an exemplary TGA thermogram of Form C. Petition 870260106343, dated 10 / 15 / 2026, page 14 / 289 9 / 280 of the compound of formula (I), prepared according to Example 32.
[0058] Figure 38A is an XRPD standard of a mixture of Forms B and C of the compound of formula (I) obtained from acetone, as described in Example 33.
[0059] Figure 38B is an XRPD standard of Form B of the compound of formula (I) obtained after storing a mixture of Forms B and C of the compound of formula (I) under ambient conditions for 13 days, as described in Example 33.
[0060] Figure 38C is an XRPD standard of Form C of the compound of formula (I) obtained from acetonitrile, as described in Example 33.
[0061] Figure 38D is an XRPD standard of Form B of compound formula (I) obtained after storing Form C of compound formula (I) under ambient conditions for 25 days, as described in Example 33.
[0062] Figure 38E is an XRPD standard of Form C of the compound of formula (I) obtained from a mixture of acetonitrile and water, as described in Example 33.
[0063] Figure 38F is an XRPD standard of a mixture of Form B and Form C of the compound of formula (I) obtained after storing Form C of the compound of formula (I) under ambient conditions for 9 days, as described in Example 33.
[0064] Figure 39 is an exemplary XRPD pattern of Form D of the compound of formula (I), prepared in accordance with Example 34.
[0065] Figure 40 is an exemplary DSC thermogram of Form D of the compound of formula (I), prepared in accordance with Example 34.
[0066] Figure 41 is an exemplary TGA thermogram of Form D of the compound of formula (I), prepared in accordance with Example 34.
[0067] Figure 42 is an exemplary DVS isotherm plot of Form D of the compound of formula (I), prepared according to Petition 870260106343, dated 10 / 15 / 2026, page 15 / 289 10 / 280 Example 34.
[0068] Figure 43 is an exemplary XRPD pattern of Form E of the compound of formula (I), prepared in accordance with Example 35.
[0069] Figure 44 is an exemplary DSC thermogram of Form E of the compound of formula (I) prepared according to Example 35.
[0070] Figure 45 is an exemplary TGA thermogram of Form E of the compound of formula (I), prepared in accordance with Example 35.
[0071] Figure 46 is an exemplary XRPD pattern of Form H of the compound of formula (I), prepared in accordance with Example 36.
[0072] Figure 47 is an exemplary DSC thermogram of Form H of the compound of formula (I), prepared in accordance with Example 36.
[0073] Figure 48 is an exemplary XRPD pattern of Material F of the compound of formula (I), prepared in accordance with Example 37.
[0074] Figure 49 is an exemplary XRPD pattern of Material G of the compound of formula (I), prepared in accordance with Example 38.
[0075] Figure 50 is an exemplary DSC thermogram of Material G of the compound of formula (I), prepared in accordance with Example 38.
[0076] Figure 51 is an exemplary TGA thermogram of Material G of the compound of formula (I), prepared in accordance with Example 38.
[0077] Figure 52 is an XRPD standard of a mixture of Form H and Form A of the compound of formula (I) obtained after storing a mixture of Form A and Form H in a heptane / ethanol mixture (67:33, v / v) at room temperature for 21 days, as performed in accordance with Example 39.
[0078] Figure 53 is an XRPD standard of Form A and Form H of the compound of formula (I) obtained after storing a mixture of Form A and Form H in an isopropanol / water mixture. Petition 870260106343, dated 10 / 15 / 2026, page 16 / 289 11 / 280 (98:2, v / v) at room temperature for 11 days, as performed according to Example 39.
[0079] Figure 54 is an XRPD standard of Form E of the compound of formula (I) obtained after storing a mixture of Form A and Form H of the compound of formula (I) in ethyl acetate at room temperature for 11 days, as performed in accordance with Example 39.
[0080] Figure 55 is an XRPD standard of a mixture of Form E, Material G and Form A of the compound of formula (I) obtained after storing a mixture of Form E and Material G in ethyl acetate at room temperature for 3 days, as performed in accordance with Example 39.
[0081] Figure 56 is an XRPD standard of a mixture of Form A and Form H of the compound of formula (I) obtained after storing Form A and Form B of the compound of formula (I) in ethanol at 21°C for 4 days, as performed in accordance with Example 39.
[0082] Figure 57 is an XRPD standard of a mixture of Form H and Form A of the compound of formula (I) obtained after storing Form A and Form B of the compound of formula (I) in ethyl acetate at 21°C for 4 days, as performed in accordance with Example 39.
[0083] Figure 58 is an exemplary XRPD pattern of Form A of the crystalline camsylate salt of the compound of formula (I), prepared in accordance with Example 40.
[0084] Figure 59 is an exemplary DSC thermogram of Form A of the crystalline camsylate salt of the compound of formula (I), prepared in accordance with Example 40.
[0085] Figure 60 is an exemplary TGA thermogram of Form A of the crystalline camsylate salt of the compound of formula (I), prepared in accordance with Example 40.
[0086] Figure 61 is an exemplary XRPD standard of Material A of the phosphate salt of the compound of formula (I), prepared in accordance with Example 41. Petition 870260106343, dated 10 / 15 / 2026, page 17 / 289 12 / 280
[0087] Figure 62 is an exemplary XRPD standard of Material B of the phosphate salt of the compound of formula (I), prepared in accordance with Example 42.
[0088] Figure 63 is an exemplary DSC thermogram of Material B of the phosphate salt of the compound of formula (I), prepared in accordance with Example 42.
[0089] Figure 64 is an exemplary TGA thermogram of Material B of the phosphate salt of the compound of formula (I), prepared in accordance with Example 42. Detailed Description
[0090] As described herein in general terms, the disclosure provides salt forms (e.g., fumarate, L-tartrate, tosylate and succinate salts), including crystalline salt forms and crystalline base forms of a compound of formula (I). The disclosure also provides pharmaceutical compositions comprising a crystalline form (e.g., crystalline salt form or crystalline free base form) of the compound of formula (I) described herein and a pharmaceutically acceptable excipient, and methods of using the crystalline forms (e.g., crystalline salt forms and crystalline free base forms) and pharmaceutical compositions described herein for treating a condition, disease or disorder disclosed herein (e.g., a cancer). Definitions
[0091] To facilitate understanding of the present invention, several terms and phrases are defined below.
[0092] Unless otherwise defined, all technical and scientific terms used herein have the same meaning commonly understood by a professional with knowledge in the area to which this invention relates. The abbreviations used herein have their conventional meaning in the chemical and biological fields. The chemical structures and formulas presented herein are constructed in accordance with known standard rules of chemical valence. Petition 870260106343, dated 10 / 15 / 2026, p. 18 / 289 13 / 280 in the chemical fields.
[0093] Throughout the description, where compositions and kits are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions and kits of the present invention that consist essentially of, or consist of, the aforementioned components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the aforementioned processing steps.
[0094] In the application, when an element or component is said to be included and / or selected from a list of recited elements or components, it should be understood that the element or component may be any of the recited elements or components, or the element or component may be selected from a group consisting of two or more of the recited elements or components.
[0095] Furthermore, it should be understood that elements and / or characteristics of a composition or method described herein may be combined in various ways without departing from the spirit and scope of the present invention, whether explicitly or implicitly. For example, when reference is made to a specific compound, that compound may be used in various embodiments of the present invention and / or in methods of the present invention, unless the context indicates otherwise. In other words, in this application, the embodiments have been described and represented in a way that allows for the writing and drawing of a clear and concise application, but it is intended and will be appreciated that the embodiments may be combined or separated in various ways without departing from the present teachings and the invention(s). For example, it will be appreciated that all the features described and represented herein may be applicable to all aspects of the invention(s) herein. Petition 870260106343, dated 10 / 15 / 2026, page 19 / 289 14 / 280 described and represented.
[0096] The articles "um" and "uma" are used in this disclosure to refer to one or more of an (i.e., at least one) grammatical object of the article, unless the context is inappropriate. By way of example, "um elemento" means one or more elements.
[0097] The term and / or is used in this disclosure to mean and or or, unless otherwise indicated.
[0098] It should be understood that the expression "at least one of" includes individually each of the objects recited after the expression and the various combinations of two or more of the objects recited, unless the context and usage indicate otherwise. The expression "and / or in connection with three or more objects recited" should be understood as having the same meaning, unless the context indicates otherwise.
[0099] The use of the term include, includes, including, have, has, having, contain, contains or containing, including their grammatical equivalents, should be understood in general as open and non-limiting, for example, not excluding additional elements or steps not recited, unless specifically stated or otherwise understood from the context.
[0100] When the term approximately is used before a quantitative value, the present invention also includes the specific quantitative value itself, unless otherwise indicated. As used herein, the term approximately refers to a variation of ±10%, ±5%, ±3%, ±2% or ±1% from the nominal value, unless otherwise indicated or inferred from the context.
[0101] Due to the sources of experimental variability well known to those skilled in the art, the values of each XRPD peak are typically preceded by the term approximately or preceded by an appropriate range that defines the experimental variability. For the purposes of the data reported here, this value is Petition 870260106343, dated 10 / 15 / 2026, page 20 / 289 15 / 280 of ±0.3° 2θ, unless otherwise indicated. The XRPD peaks cited here are generally reported with this variability of ±0.3° 2θ, unless otherwise indicated, and should be reported with this variability whenever disclosed here, regardless of the presence or absence of the word about, unless the context dictates otherwise.
[0102] Due to the sources of experimental variability well known to those skilled in the art, the values of each endotherm or exotherm from differential scanning calorimetry (DSC) are typically preceded by the term about or followed by an appropriate range that defines the experimental variability. For the purposes of the data reported here, this value is ±10°C, unless otherwise indicated. The DSC endotherms / exotherms cited here are generally reported with this variability of ±10°C, unless otherwise indicated, and should be reported with this variability whenever disclosed here, regardless of the presence or absence of the word about, unless the context dictates otherwise.
[0103] At various points in this descriptive report, variables or parameters are revealed in groups or intervals. It is specifically intended that the description include each individual subcombination of the members of such groups and intervals. For example, an integer in the range of 0 to 40 is specifically intended to individually reveal 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, and 40, and an integer in the range of 1 to 20 is specifically intended to individually reveal 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20.
[0104] The use of any examples or illustrative language contained herein, for example, such as or including, is intended only to better illustrate the present invention and does not represent a limitation to the scope of the invention. Petition 870260106343, dated 10 / 15 / 2026, p. 21 / 289 16 / 280 unless claimed. No language in the descriptive report should be interpreted as indicating any unclaimed element as essential to the practice of the present invention.
[0105] In general, compositions that specify a percentage are by weight, unless otherwise specified. Also, if a variable is not accompanied by a definition, the previous definition of the variable prevails.
[0106] As used herein, “pharmaceutical composition” or “pharmaceutical formulation” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
[0107] Pharmaceutically acceptable means approved or approvable by a federal or state government regulatory agency or the corresponding agency in countries other than the United States, or listed in the U.S. Pharmacopoeia or another generally recognized pharmacopoeia for use in animals and, more particularly, in humans.
[0108] For therapeutic use, salts of the compounds of the present invention (for example, a compound of formula (I)) are considered pharmaceutically acceptable. However, salts of acids and bases that are not pharmaceutically acceptable may also be used, for example, in the preparation or purification of a pharmaceutically acceptable compound.
[0109] As used herein, the term pharmaceutically acceptable excipient refers to a substance that assists in the administration and / or absorption of an active agent by an individual and can be included in the compositions of the present invention without causing a significant adverse toxicological effect in the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, such as a phosphate-buffered saline solution, Petition 870260106343, dated 10 / 15 / 2026, page 22 / 289 17 / 280 emulsions (for example, oil / water or water / oil emulsions), Ringer's lactate, normal sucrose, normal glucose, binders, diluents, disintegrants, lubricants, coatings, sweeteners, flavorings, saline solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates, fatty acid esters, colorants and the like. Such preparations may be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts to influence osmotic pressure, buffers, colorants and / or aromatic substances and the like that do not react detrimentally with the compounds of the invention. For examples of excipients, see Martin, Remington's Pharmaceutical Sciences, 15th edition, Mack Publ. Co., Easton, PA (1975).
[0110] An individual to whom administration is contemplated includes, but is not limited to, humans (i.e., a man or a woman of any age range, for example, a pediatric individual (e.g., infant, child, adolescent) or an adult individual (e.g., young adult, middle-aged adult, or elderly adult)) and / or a non-human animal, for example, a mammal such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the individual is a human. In certain embodiments, the individual is an adult human. In certain embodiments, the individual is a non-human animal.
[0111] As used herein, “solid pharmaceutical form” means one or more pharmaceutical doses in solid form, for example, tablets, capsules, granules, powders, sachets, reconstitutable powders, dry powder inhalers and chewable tablets.
[0112] As used herein, administer means oral administration, administration as a suppository, topical contact, intravenous administration, parenteral administration, intraperitoneal administration, intramuscular administration, Petition 870260106343, dated 10 / 15 / 2026, page 23 / 289 18 / 280 intralesional administration, intrathecal administration, intracranial administration, intranasal administration or subcutaneous administration, or the implantation of a slow-release device, for example, a mini osmotic pump, in an individual. Administration may be by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intra-arterial, intradermal, subcutaneous, intraperitoneal, intraventricular and intracranial. Other modes of administration include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. Co-administration means that a composition described herein is administered at the same time as, immediately before or immediately after the administration of one or more additional therapies (e.g., anticancer agent, chemotherapeutic or immunotherapy).The compound of formula (I), or a pharmaceutically acceptable salt thereof, may be administered alone or co-administered to the patient. Co-administration includes the simultaneous or sequential administration of the compound individually or in combination (more than one compound or agent). Thus, the preparations may also be combined, when desired, with other active substances (for example, to reduce metabolic degradation).
[0113] As used herein, “fasting state” means at least 1 hour before a meal or at least 2 hours after a meal has been consumed by an individual.
[0114] The terms “disease”, “disorder” and “condition” are used interchangeably here.
[0115] As used herein, and unless otherwise specified, the terms “treat,” “treating,” and “treatment” encompass an action that occurs while an individual is suffering from the specified disease, disorder, or condition, which Petition 870260106343, dated 10 / 15 / 2026, page 24 / 289 19 / 280 reduces the severity of the disease, disorder, or condition, or slows or delays the progression of the disease, disorder, or condition (e.g., "therapeutic treatment").
[0116] In general, an effective amount of a compound or composition (for example, a compound of formula (I), a crystalline form of a compound of formula (I) described herein, or a pharmaceutical composition described herein) refers to an amount sufficient to induce the desired biological response, for example, to treat a cancer described herein. As will be understood by those skilled in the art, the effective amount of a compound, crystalline form, or pharmaceutical composition of the disclosure may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease to be treated, the mode of administration, and the age, weight, health, and condition of the individual. Salt Forms of a Compound of Formula (I)
[0117] The compound of formula (I), as represented below, is a selective PERK inhibitor and is also known as (R)-2-amino-5-(4-(2-(3,5-difluorophenyl)-2-hydroxyacetamido)-2-methylphenyl)-N-isopropylnicotinamide: (I) .
[0118] The compound of formula (I) may also be referred to as HC-5404 throughout the present disclosure. A method for chemically synthesizing the compound of formula (I) is described in Example 2.
[0119] In one aspect, a salt form of the compound of formula (I) is given here Petition 870260106343, dated 10 / 15 / 2026, p. 25 / 289 20 / 280 (I) .
[0120] In several embodiments, the salt form of the compound of formula (I) is a fumarate salt of the compound of formula (I). In certain embodiments, the fumarate salt of the compound of formula (I) is a monofumarate salt. In certain embodiments, the fumarate salt of the compound of formula (I) is a hemifumarate salt.
[0121] In several embodiments, the salt form of the compound of formula (I) is an L-tartrate salt of the compound of formula (I).
[0122] In several embodiments, the salt form of the compound of formula (I) is a tosylate salt of the compound of formula (I).
[0123] In several embodiments, the salt form of the compound of formula (I) is a succinate salt of the compound of formula (I).
[0124] In another aspect, crystalline salt forms of the compound of formula (I) are provided here.
[0125] In several embodiments, the crystalline salt form of the compound of formula (I) is a crystalline fumarate salt of the compound of formula (I). In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is a crystalline monofumarate salt. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is a crystalline monofumarate salt. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is a crystalline hemifumarate salt. In certain embodiments, the crystalline salt form is a crystalline camsylate salt form. In certain embodiments, the crystalline salt form is a crystalline phosphate salt form. In certain embodiments, the crystalline camsylate salt form is Form A of the crystalline camsylate salt of the compound of formula (I).
[0126] In certain embodiments, the crystalline salt form of the compound of formula (I) is Form A of the monofumarate salt of the compound of formula (I). In certain embodiments, the salt form Petition 870260106343, dated 10 / 15 / 2026, p. 26 / 289 21 / 280 crystalline form of the compound of formula (I) is Form B of the monofumarate salt of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is Form C of the monofumarate salt of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is Form A of the hemifumarate salt of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is Form B of the hemifumarate salt of the compound of formula (I).
[0127] In certain embodiments, the crystalline salt form of the compound of formula (I) is a crystalline L-tartrate salt of the compound of formula (I).
[0128] In certain embodiments, the crystalline salt form of the compound of formula (I) is a crystalline tosylate salt of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is Form A of the tosylate salt of the compound of formula (I).
[0129] In certain embodiments, the crystalline salt form of the compound of formula (I) is a crystalline succinate salt of the compound of formula (I). In certain embodiments, the crystalline salt form of the compound of formula (I) is Form A of the succinate salt of the compound of formula (I). (1) Fumarate Salt Forms
[0130] In one aspect, a fumarate salt of the compound of formula (I) is provided here
[0131] In certain embodiments, the fumarate salt of the compound of formula (I) is a monofumarate salt. In certain embodiments, the fumarate salt of the compound of formula (I) is a hemifumarate salt. Petition 870260106343, dated 10 / 15 / 2026, p. 27 / 289 22 / 280
[0132] In another aspect, crystalline fumarate salts of the compound of formula (I) are provided here. (I) .
[0133] In certain embodiments, the crystalline fumarate salt has a powder X-ray diffraction (XRPD) pattern comprising one or more peaks at about 16.9°, about 17.9° and about 24.1° 2θ.
[0134] In certain embodiments, the crystalline fumarate salt is a crystalline monofumarate salt. In certain embodiments, the crystalline fumarate salt exhibits an XRPD pattern substantially the same as that shown in Figure 1. In certain embodiments, the crystalline fumarate salt exhibits an XRPD pattern substantially the same as that shown in Figure 3. In certain embodiments, the crystalline fumarate salt exhibits an XRPD pattern substantially the same as that shown in Figure 5. In certain embodiments, the crystalline fumarate salt exhibits an XRPD pattern substantially the same as that shown in Figure 7.
[0135] In certain embodiments, the crystalline fumarate salt is a crystalline hemifumarate salt. In certain embodiments, the crystalline fumarate salt exhibits an XRPD pattern substantially the same as that shown in Figure 8. In certain embodiments, the crystalline fumarate salt exhibits an XRPD pattern substantially the same as that shown in Figure 13.
[0136] In certain embodiments, the crystalline fumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 5. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 12. In certain embodiments, the Petition 870260106343, dated 10 / 15 / 2026, page 28 / 289 23 / 280 crystalline fumarate salt of compound formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 13. In certain embodiments, the crystalline fumarate salt of compound formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 14. In certain embodiments, the crystalline fumarate salt of compound formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 15. In certain embodiments, the crystalline fumarate salt of compound formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 23.
[0137] In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is an anhydrous crystalline fumarate salt.
[0138] In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is a crystalline hydrate. In certain embodiments, the crystalline hydrate is a crystalline monohydrate. (A) Crystalline Monofumarate Salt Forms
[0139] In several embodiments, a crystalline monofumarate salt of the compound of formula (I) (I) is provided here.
[0140] In certain embodiments, the crystalline monofumarate salt has an XRPD pattern comprising one or more peaks at about 5.2° 2θ.
[0141] In certain modes, the XRPD pattern additionally comprises one or more peaks at approximately 7.6° and approximately 14.4° 2θ.
[0142] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.8°, about 21.2°, about 24.5° and about 25° 2θ.
[0143] In certain forms, the XRPD standard comprises Petition 870260106343, dated 10 / 15 / 2026, p. 29 / 289 24 / 280 additionally one or more peaks at approximately 15.1°, approximately 16.7°, approximately 17.3°, approximately 17.9°, approximately 19.4°, approximately 19.9°, approximately 20.6° and approximately 22.7° 2θ.
[0144] In certain modes, the XRPD pattern additionally comprises one or more peaks at about 30.4° and about 31.4° 2θ.
[0145] In certain embodiments, the crystalline monofumarate salt has an XRPD pattern comprising one or more peaks at about 5.2°, about 7.6°, about 14.4°, about 15.1°, about 15.8°, about 16.7°, about 17.3°, about 17.9°, about 19.4°, about 19.9°, about 20.6°, about 21.2°, about 22.7°, about 24.5°, about 25.0°, about 30.4° and about 31.4° 2θ.
[0146] In certain embodiments, the crystalline monofumarate salt has an XRPD pattern comprising peaks at about 5.2°, about 7.6°, about 14.4°, about 15.1°, about 15.8°, about 16.7°, about 17.3°, about 17.9°, about 19.4°, about 19.9°, about 20.6°, about 21.2°, about 22.7°, about 24.5°, about 25.0°, about 30.4° and about 31.4° 2θ.
[0147] In certain embodiments, the crystalline monofumarate salt has an XRPD pattern comprising one or more peaks at 5.2° ± 0.3° 2θ.
[0148] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.6° ± 0.3° and 14.4° ± 0.3° 2θ.
[0149] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.8° ± 0.3°, 21.2° ± 0.3°, 24.5° ± 0.3° and 25° ± 0.3° 2θ.
[0150] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.3°, 16.7° ± 0.3°, 17.3° ± 0.3°, 17.9° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.6° ± 0.3° and 22.7° ± 0.3° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 30 / 289 25 / 280
[0151] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 30.4° ± 0.3° and 31.4° ± 0.3° 2θ.
[0152] In certain embodiments, the crystalline monofumarate salt has an XRPD pattern comprising one or more peaks at 5.2° ± 0.3°, 7.6° ± 0.3°, 14.4° ± 0.3°, 15.1° ± 0.3°, 15.8° ± 0.3°, 16.7° ± 0.3°, 17.3° ± 0.3°, 17.9° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.6° ± 0.3°, 21.2° ± 0.3°, 22.7° ± 0.3°, 24.5° ± 0.3°, 25.0° ± 0.3°, 30.4° ± 0.3° and 31.4° ± 0.3° 2θ.
[0153] In certain embodiments, the crystalline monofumarate salt has an XRPD pattern comprising peaks at 5.2° ± 0.3°, 7.6° ± 0.3°, 14.4° ± 0.3°, 15.1° ± 0.3°, 15.8° ± 0.3°, 16.7° ± 0.3°, 17.3° ± 0.3°, 17.9° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.6° ± 0.3°, 21.2° ± 0.3°, 22.7° ± 0.3°, 24.5° ± 0.3°, 25.0° ± 0.3°, 30.4° ± 0.3° and 31.4° ± 0.3° 2θ.
[0154] In certain embodiments, the crystalline monofumarate salt has an XRPD pattern comprising one or more peaks at 5.2° ± 0.2° 2θ.
[0155] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.6° ± 0.2° and 14.4° ± 0.2° 2θ.
[0156] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.8° ± 0.2°, 21.2° ± 0.2°, 24.5° ± 0.2° and 25° ± 0.2° 2θ.
[0157] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.2°, 16.7° ± 0.2°, 17.3° ± 0.2°, 17.9° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.6° ± 0.2° and 22.7° ± 0.2° 2θ.
[0158] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 30.4° ± 0.2° and 31.4° ± 0.2° 2θ.
[0159] In certain embodiments, the crystalline monofumarate salt has an XRPD pattern comprising one or more peaks Petition 870260106343, dated 10 / 15 / 2026, page 31 / 289 26 / 280 in 5.2° ± 0.2°, 7.6° ± 0.2°, 14.4° ± 0.2°, 15.1° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 17.3° ± 0.2°, 17.9° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.6° ± 0.2°, 21.2° ± 0.2°, 22.7° ± 0.2°, 24.5° ± 0.2°, 25.0° ± 0.2°, 30.4° ± 0.2° and 31.4° ± 0.2° 2θ.
[0160] In certain embodiments, the crystalline monofumarate salt has an XRPD pattern comprising peaks at 5.2° ± 0.2°, 7.6° ± 0.2°, 14.4° ± 0.2°, 15.1° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 17.3° ± 0.2°, 17.9° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.6° ± 0.2°, 21.2° ± 0.2°, 22.7° ± 0.2°, 24.5° ± 0.2°, 25.0° ± 0.2°, 30.4° ± 0.2° and 31.4° ± 0.2° 2θ.
[0161] In certain embodiments, the crystalline monofumarate salt of the compound of formula (I) is Form A of the monofumarate salt of the compound of formula (I). In certain embodiments, the crystalline monofumarate salt of the compound of formula (I) is Form B of the monofumarate salt of the compound of formula (I). In certain embodiments, the crystalline monofumarate salt of the compound of formula (I) is Form C of the monofumarate salt of the compound of formula (I).
[0162] In certain embodiments, the crystalline monofumarate salt of the compound of formula (I) is an anhydrous crystalline form.
[0163] In certain embodiments, the crystalline monofumarate of the compound of formula (I) is a crystalline hydrate. In certain embodiments, the crystalline hydrate is a monohydrate. (i) Monofumarate Salt Form A
[0164] In several embodiments, Form A of the monofumarate salt of the compound of formula (I) is given here (I) .
[0165] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has an X-ray diffraction pattern Petition 870260106343, dated 10 / 15 / 2026, p. 32 / 289 27 / 280 powder (XRPD) comprising one or more peaks at about 5.0°, about 7.4° and about 8.2° 2θ.
[0166] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 9.7°, about 10.1°, about 10.7°, about 11.4°, about 11.9°, about 13.2°, about 14.7° and about 14.8° 2θ.
[0167] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.2°, about 16.1°, about 16.6°, about 17.5°, about 19.5°, about 20.2°, about 21.1°, about 23.9° and about 24.2° 2θ.
[0168] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 17.9°, about 18.4°, about 19.2°, about 19.9°, about 20.8°, about 21.9°, about 22.9°, about 23.1°, about 23.5° and about 24.8° 2θ.
[0169] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.1°, about 25.4°, about 27.4° and about 27.8° 2θ.
[0170] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 28.9°, about 30.1°, about 30.4°, about 31.3°, about 31.5°, about 32.8° and about 33.6° 2θ.
[0171] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.0°, about 7.4°, about 8.2°, about 9.7°, about 10.1° 1, about 10.7°, about 11.4°, about 11.9°, about 13.20, about 14.7°, about 14.8°, about 15.2°, about 16.10, about 16.6°, about 17. 5°, about 17.9°, about 18.4°, about 19.2°, about 19.5°, about 19.9°, about 20.2°, about 20.8°, about 21.1°, about 21.9°, about 22.9°, about 23.1°, about 23, 5°, about 23, 9°, about 24.2°, about 24.8°, about 28.9°, about 30.1°, about 30.4°, about 31.3°, about 31.5°, Petition 870260106343, dated 10 / 15 / 2026, page 33 / 289 28 / 280 approximately 32.8° and approximately 33.6° 2θ.
[0172] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at about 9.7°, approximately 11.9°, approximately 15.2°, approximately 17.9°, approximately 19.9°, approximately 21.9°, approximately 23.9°, approximately 30.1°, approximately 32.8° and approximately 5.0°, approximately 10.1°, approximately 13.2°, approximately 16.1°, circa 18.4°, approximately 20.2°, approximately 22.9°, approximately 24.2°, approximately 30.4°, approximately 33.6°2θ. 7.4°, approximately 10.7°, approximately 14.7°, approximately 16.6°, approximately 19.2°, approximately 20.8°, approximately 23.1°, approximately 24.8°, approximately 31.3°, approximately 8.2°, approximately 11.4°, approximately 14.8°, approximately 17.5°, approximately 19.5°, approximately 21.1°, approximately 23.5°, approximately 28.9°, approximately 31.5°, approximately
[0173] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has a powder X-ray diffraction pattern (XRPD) comprising one or more peaks at 5.0° ± 0.3°, 7.4° ± 0.3° and 8.2° ± 0.3° 2θ.
[0174] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 9.7° ± 0.3°, 10.1° ± 0.3°, 10.7° ± 0.3°, 11.4° ± 0.3°, 11.9° ± 0.3°, 13.2° ± 0.3°, 14.7° ± 0.3° and 14.8° ± 0.3° 2θ.
[0175] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.2° ± 0.3°, 16.1° ± 0.3°, 16.6° ± 0.3°, 17.5° ± 0.3°, 19.5° ± 0.3°, 20.2° ± 0.3°, 21.1° ± 0.3°, 23.9° ± 0.3° and 24.2° ± 0.3° 2θ.
[0176] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 17.9° ± 0.3°, 18.4° ± 0.3°, 19.2° ± 0.3°, 19.9° ± 0.3°, 20.8° ± 0.3°, 21.9° ± 0.3°, 22.9° ± 0.3°, 23.1° ± 0.3°, 23.5° ± 0.3° and 24.8° ± 0.3° 2θ.
[0177] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.1° ± 0.3°, 25.4° ± 0.3°, 27.4° ± 0.3° and 27.8° ± 0.3° 2θ.
[0178] In certain forms, the XRPD standard comprises Petition 870260106343, dated 10 / 15 / 2026, page 34 / 289 29 / 280 additionally one or more peaks at 28.9° ± 0.3°, 30.1° ± 0.3°, 30.4° ± 0.3°, 31.3° ± 0.3°, 31.5° ± 0.3°, 32.8° ± 0.3° and 33.6° ± 0.3° 2θ.
[0179] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.0° ± 0.3°, 7.4° ± 0.3°, 8.2° ± 0.3°, 9.7° ± 0.3°, 10.1° ± 0.3°, 10.7° ± 0.3°, 11.4° ± 0.3°, 11.9° ± 0.3°, 13.2° ± 0.3°, 14.7° ± 0.3°, 14.8° ± 0.3°, 15.2° ± 0.3°, 16.1° ± 0.3°, 16.6° ± 0.3°, 17.5° ± 0.3°, 17.9° ± 0.3°, 18.4° ± 0.3°, 19.2° ± 0.3°, 19.5° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 20.8° ± 0.3°, 21.1° ± 0.3°, 21.9° ± 0.3°, 22.9° ± 0.3°, 23.1° ± 0.3°, 23.5° ± 0.3°, 23.9° ± 0.3°, 24.2° ± 0.3°, 24.8° ± 0.3°, 28.9° ± 0.3°, 30.1° ± 0.3°, 30.4° ± 0.3°, 31.3° ± 0.3°, 31.5° ± 0.3°, 32.8° ± 0.3° and 33.6° ± 0.3° 2θ.
[0180] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.0° ± 0.3°, 7.4° ± 0.3°, 8.2° ± 0.3°, 9.7° ± 0.3°, 10.1° ± 0.3°, 10.7° ± 0.3°, 11.4° ± 0.3°, 11.9° ± 0.3°, 13.2° ± 0.3°, 14.7° ± 0.3°, 14.8° ± 0.3°, 15.2° ± 0.3°, 16.1° ± 0.3°, 16.6° ± 0.3°, 17.5° ± 0.3°, 17.9° ± 0.3°, 18.4° ± 0.3°, 19.2° ± 0.3°, 19.5° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 20.8° ± 0.3°, 21.1° ± 0.3°, 21.9° ± 0.3°, 22.9° ± 0.3°, 23.1° ± 0.3°, 23.5° ± 0.3°, 23.9° ± 0.3°, 24.2° ± 0.3°, 24.8° ± 0.3°, 28.9° ± 0.3°, 30.1° ± 0.3°, 30.4° ± 0.3°, 31.3° ± 0.3°, 31.5° ± 0.3°, 32.8° ± 0.3° and 33.6° ± 0.3° 2θ.
[0181] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has a powder X-ray diffraction pattern (XRPD) comprising one or more peaks at 5.0° ± 0.2°, 7.4° ± 0.2° and 8.2° ± 0.2° 2θ.
[0182] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 9.7° ± 0.2°, 10.1° ± 0.2°, 10.7° ± 0.2°, 11.4° ± 0.2°, 11.9° ± 0.2°, 13.2° ± 0.2°, 14.7° ± 0.2° and 14.8° ± 0.2° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 35 / 289 30 / 280
[0183] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.2° ± 0.2°, 16.1° ± 0.2°, 16.6° ± 0.2°, 17.5° ± 0.2°, 19.5° ± 0.2°, 20.2° ± 0.2°, 21.1° ± 0.2°, 23.9° ± 0.2° and 24.2° ± 0.2° 2θ.
[0184] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 17.9° ± 0.2°, 18.4° ± 0.2°, 19.2° ± 0.2°, 19.9° ± 0.2°, 20.8° ± 0.2°, 21.9° ± 0.2°, 22.9° ± 0.2°, 23.1° ± 0.2°, 23.5° ± 0.2° and 24.8° ± 0.2° 2θ.
[0185] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.1° ± 0.2°, 25.4° ± 0.2°, 27.4° ± 0.2° and 27.8° ± 0.2° 2θ.
[0186] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 28.9° ± 0.2°, 30.1° ± 0.2°, 30.4° ± 0.2°, 31.3° ± 0.2°, 31.5° ± 0.2°, 32.8° ± 0.2° and 33.6° ± 0.2° 2θ.
[0187] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.0° ± 0.2°, 7.4° ± 0.2°, 8.2° ± 0.2°, 9.7° ± 0.2°, 10.1° ± 0.2°, 10.7° ± 0.2°, 11.4° ± 0.2°, 11.9° ± 0.2°, 13.2° ± 0.2°, 14.7° ± 0.2°, 14.8° ± 0.2°, 15.2° ± 0.2°, 16.1° ± 0.2°, 16.6° ± 0.2°, 17.5° ± 0.2°, 17.9° ± 0.2°, 18.4° ± 0.2°, 19.2° ± 0.2°, 19.5° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 20.8° ± 0.2°, 21.1° ± 0.2°, 21.9° ± 0.2°, 22.9° ± 0.2°, 23.1° ± 0.2°, 23.5° ± 0.2°, 23.9° ± 0.2°, 24.2° ± 0.2°, 24.8° ± 0.2°, 28.9° ± 0.2°, 30.1° ± 0.2°, 30.4° ± 0.2°, 31.3° ± 0.2°, 31.5° ± 0.2°, 32.8° ± 0.2° and 33.6° ± 0.2° 2θ.
[0188] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.0° ± 0.2°, 7.4° ± 0.2°, 8.2° ± 0.2°, 9.7° ± 0.2°, 10.1° ± 0.2°, 10.7° ± 0.2°, 11.4° ± 0.2°, 11.9° ± 0.2°, 13.2° ± 0.2°, 14.7° ± 0.2°, 14.8° ± 0.2°, 15.2° ± 0.2°, 16.1° ± 0.2°, 16.6° ± 0.2°, 17.5° ± 0.2°, 17.9° ± 0.2°, 18.4° ± 0.2°, 19.2° ± 0.2°, 19.5° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 20.8° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, p. 36 / 289 31 / 280 21.1° ± 0.2°, 21.9° ± 0.2°, 22.9° ± 0.2°, 23.1° ± 0.2°, 23.5° ± 0.2°, 23.9° ± 0.2°, 24.2° ± 0.2°, 24.8° ± 0.2°, 28.9° ± 0.2°, 30.1° ± 0.2°, 30.4° ± 0.2°, 31.3° ± 0.2°, 31.5° ± 0.2°, 32.8° ± 0.2° and 33.6° ± 0.2° 2θ.
[0189] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 1. In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 5.
[0190] In certain embodiments, Form A of the monofumarate salt of compound formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak starting at about 32°C. In certain embodiments, Form A of the monofumarate salt of compound formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak starting at about 133°C. In certain embodiments, Form A of the monofumarate salt of compound formula (I) has a differential scanning calorimetry (DSC) thermogram comprising one or more endotherms with peaks starting at about 32°C and about 133°C. In certain embodiments, Form A of the monofumarate salt of compound formula (I) has a DSC thermogram substantially the same as that shown in Figure 2.
[0191] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) exhibits a weight loss of less than or equal to about 1.2% by weight upon heating Form A of about 25°C to about 100°C. The weight loss exhibited by a crystalline form (e.g., Form A of the monofumarate salt of compound formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, Form A of the monofumarate salt of compound formula (I) has a TGA thermogram substantially the same as the Petition 870260106343, dated 10 / 15 / 2026, p. 37 / 289 32 / 280 shown in Figure 2.
[0192] In certain embodiments, Form A of the monofumarate salt of the compound of formula (I) is a crystalline hydrate. (ii) Monofumarate Salt Form B
[0193] In several embodiments, Form B of the monofumarate salt of the compound of formula (I) is given here (I) .
[0194] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has a powder X-ray diffraction pattern (XRPD) comprising a peak at about 7.5° 2θ.
[0195] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 4.7°, about 9.7°, about 13.3°, about 13.8°, about 14.0°, about 14.2° and about 15.0° 2θ.
[0196] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 17.4°, about 21.5°, about 22.2°, about 22.6°, about 23.1°, about 23.4°, about 24.4° and about 24.7° 2θ.
[0197] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.4°, about 15.8°, about 16.6°, about 17.0°, about 17.8°, about 18.5°, about 18.8°, about 19.5°, about 19.8°, about 20.3°, about 20.6° and about 24.1° 2θ.
[0198] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.4°, about 15.8°, about 16.6°, about 17.0°, about 17.4°, about 17.8°, about 18.5°, about 18.8°, about 19.5°, about 19.8°, about 20.3°, about 20.6°, about 21.5°, about 22.2°, about 22.6°, about 23.1°, about 23.4°, about 24.4°, about 24.1° and about 24.7° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 38 / 289 33 / 280
[0199] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 26.8°, about 28.1° and about 29.7° 2θ.
[0200] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.3°, about 26.0°, about 27.6°, about 30.2°, about 30.8°, about 31.5° and about 33.5° 2θ.
[0201] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.3°, about 26.0°, about 26.8°, about 27.6°, about 28.1° and about 29.7°, about 30.2°, about 30.8°, about 31.5° and about 33.5° 2θ.
[0202] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising um ou mais picos em ca rca de 4,7°, cerca de 7,5°, cerca de 9, 7° , cerca de 13,3°, cerca de 13, 8°, cerca de 14,0°, cerca de 14 ,2° e cerca de 15,0° , cerca de 15 ,4°, cerca de 15,8°, cerca de 16, 6° , cerca de 17,0°, cerca de 17, 4°, cerca de 17,8°, cerca de 18, 5° , cerca de 18,8°, cerca de 19, 5°, cerca de 19,8°, cerca de 20, 3° , cerca de 2 0,6°, cerca de 21, 5°, cerca de 22,2°, cerca de 22, 6° , cerca de 23,1°, cerca de 23, 4°, near 24.1°, near 24, 4° , near 24.7°, near 25, 3°, near 26.0°, near 26, 8° , near near 27.6°, of 30.8°, near near of 28, 31, 1°, near 29.7°, 5° and near 33.5° near 2θ. 30, 2° ,
[0203] Em certas modales, a Forma B do sal de monofumarato the compound of formula (I) has an XRPD pattern comprising peaks at about 4.7°, about 7.5°, about 9.7°, about 13.3°, about 13.8°, about 14.0°, about 14.2° and about 15.0°, about 15.4°, about 15.8°, about 16.6°, about 17.0°, about 17.4°, about 17.8°, about 18.5°, about 18.8°, about 19.5°, about 19.8°, about 20.3°, about 20.6°, about 21.5°, about 22.2°, about 22.6°, about 23.1°, about 23.4°, about 24.1°, about 24.4°, about Petition 870260106343, dated 10 / 15 / 2026, page 39 / 289 34 / 280 24.7°, approximately 25.3°, approximately 26.0°, approximately 26.8°, approximately 27.6°, approximately 28.1°, approximately 29.7°, approximately 30.2°, approximately 30.8°, approximately 31.5° and approximately 33.5° 2θ.
[0204] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising a peak at 7.5° ± 0.3° 2θ.
[0205] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 4.7° ± 0.3°, 9.7° ± 0.3°, 13.3° ± 0.3°, 13.8° ± 0.3°, 14.0° ± 0.3°, 14.2° ± 0.3° and 15.0° ± 0.3° 2θ.
[0206] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 17.4° ± 0.3°, 21.5° ± 0.3°, 22.2° ± 0.3°, 22.6° ± 0.3°, 23.1° ± 0.3°, 23.4° ± 0.3°, 24.4° ± 0.3° and 24.7° ± 0.3° 2θ.
[0207] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.4° ± 0.3°, 15.8° ± 0.3°, 16.6° ± 0.3°, 17.0° ± 0.3°, 17.8° ± 0.3°, 18.5° ± 0.3°, 18.8° ± 0.3°, 19.5° ± 0.3°, 19.8° ± 0.3°, 20.3° ± 0.3°, 20.6° ± 0.3° and 24.1° ± 0.3° 2θ.
[0208] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.4° ± 0.3°, 15.8° ± 0.3°, 16.6° ± 0.3°, 17.0° ± 0.3°, 17.4° ± 0.3°, 17.8° ± 0.3°, 18.5° ± 0.3°, 18.8° ± 0.3°, 19.5° ± 0.3°, 19.8° ± 0.3°, 20.3° ± 0.3°, 20.6° ± 0.3°, 21.5° ± 0.3°, 22.2° ± 0.3°, 22.6° ± 0.3°, 23.1° ± 0.3°, 23.4° ± 0.3°, 24.4° ± 0.3°, 24.1° ± 0.3° and 24.7° ± 0.3° 2θ.
[0209] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.8° ± 0.3°, 28.1° ± 0.3° and 29.7° ± 0.3° 2θ.
[0210] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.3° ± 0.3°, 26.0° ± 0.3°, 27.6° ± 0.3°, 30.2° ± 0.3°, 30.8° ± 0.3°, 31.5° ± 0.3° and 33.5° ± 0.3° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 40 / 289 35 / 280
[0211] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.3° ± 0.3°, 26.0° ± 0.3°, 26.8° ± 0.3°, 27.6° ± 0.3°, 28.1° ± 0.3°, 29.7° ± 0.3°, 30.2° ± 0.3°, 30.8° ± 0.3°, 31.5° ± 0.3° and 33.5° ± 0.3° 2θ.
[0212] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.7° ± 0.3°, 7.5° ± 0.3°, 9.7° ± 0.3°, 13.3° ± 0.3°, 13.8° ± 0.3°, 14.0° ± 0.3°, 14.2° ± 0.3°, 15.0° ± 0.3°, 15.4° ± 0.3°, 15.8° ± 0.3°, 16.6° ± 0.3°, 17.0° ± 0.3°, 17.4° ± 0.3°, 17.8° ± 0.3°, 18.5° ± 0.3°, 18.8° ± 0.3°, 19.5° ± 0.3°, 19.8° ± 0.3°, 20.3° ± 0.3°, 20.6° ± 0.3°, 21.5° ± 0.3°, 22.2° ± 0.3°, 22.6° ± 0.3°, 23.1° ± 0.3°, 23.4° ± 0.3°, 24.1° ± 0.3°, 24.4° ± 0.3°, 24.7° ± 0.3°, 25.3° ± 0.3°, 26.0° ± 0.3°, 26.8° ± 0.3°, 27.6° ± 0.3°, 28.1° ± 0.3°, 29.7° ± 0.3°, 30.2° ± 0.3°, 30.8° ± 0.3°, 31.5° ± 0.3° and 33.5° ± 0.3° 2θ.
[0213] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 4.7° ± 0.3°, 7.5° ± 0.3°, 9.7° ± 0.3°, 13.3° ± 0.3°, 13.8° ± 0.3°, 14.0° ± 0.3°, 14.2° ± 0.3°, 15.0° ± 0.3°, 15.4° ± 0.3°, 15.8° ± 0.3°, 16.6° ± 0.3°, 17.0° ± 0.3°, 17.4° ± 0.3°, 17.8° ± 0.3°, 18.5° ± 0.3°, 18.8° ± 0.3°, 19.5° ± 0.3°, 19.8° ± 0.3°, 20.3° ± 0.3°, 20.6° ± 0.3°, 21.5° ± 0.3°, 22.2° ± 0.3°, 22.6° ± 0.3°, 23.1° ± 0.3°, 23.4° ± 0.3°, 24.1° ± 0.3°, 24.4° ± 0.3°, 24.7° ± 0.3°, 25.3° ± 0.3°, 26.0° ± 0.3°, 26.8° ± 0.3°, 27.6° ± 0.3°, 28.1° ± 0.3°, 29.7° ± 0.3°, 30.2° ± 0.3°, 30.8° ± 0.3°, 31.5° ± 0.3° and 33.5° ± 0.3° 2θ.
[0214] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising a peak at 7.5° ± 0.2° 2θ.
[0215] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 4.7° ± 0.2°, 9.7° ± 0.2°, 13.3° ± 0.2°, 13.8° ± 0.2°, 14.0° ± 0.2°, 14.2° ± 0.2° and 15.0° ± 0.2° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 41 / 289 36 / 280
[0216] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 17.4° ± 0.2°, 21.5° ± 0.2°, 22.2° ± 0.2°, 22.6° ± 0.2°, 23.1° ± 0.2°, 23.4° ± 0.2°, 24.4° ± 0.2° and 24.7° ± 0.2° 2θ.
[0217] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.4° ± 0.2°, 15.8° ± 0.2°, 16.6° ± 0.2°, 17.0° ± 0.2°, 17.8° ± 0.2°, 18.5° ± 0.2°, 18.8° ± 0.2°, 19.5° ± 0.2°, 19.8° ± 0.2°, 20.3° ± 0.2°, 20.6° ± 0.2° and 24.1° ± 0.2° 2θ.
[0218] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.4° ± 0.2°, 15.8° ± 0.2°, 16.6° ± 0.2°, 17.0° ± 0.2°, 17.4° ± 0.2°, 17.8° ± 0.2°, 18.5° ± 0.2°, 18.8° ± 0.2°, 19.5° ± 0.2°, 19.8° ± 0.2°, 20.3° ± 0.2°, 20.6° ± 0.2°, 21.5° ± 0.2°, 22.2° ± 0.2°, 22.6° ± 0.2°, 23.1° ± 0.2°, 23.4° ± 0.2°, 24.1° ± 0.2°, 24.4° ± 0.2° and 24.7° ± 0.2° 2θ.
[0219] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.8° ± 0.2°, 28.1° ± 0.2° and 29.7° ± 0.2° 2θ.
[0220] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.3° ± 0.2°, 26.0° ± 0.2°, 27.6° ± 0.2°, 30.2° ± 0.2°, 30.8° ± 0.2°, 31.5° ± 0.2° and 33.5° ± 0.2° 2θ.
[0221] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.3° ± 0.2°, 26.0° ± 0.2°, 26.8° ± 0.2°, 27.6° ± 0.2°, 28.1° ± 0.2°, 29.7° ± 0.2°, 30.2° ± 0.2°, 30.8° ± 0.2°, 31.5° ± 0.2° and 33.5° ± 0.2° 2θ.
[0222] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.7° ± 0.2°, 7.5° ± 0.2°, 9.7° ± 0.2°, 13.3° ± 0.2°, 13.8° ± 0.2°, 14.0° ± 0.2°, 14.2° ± 0.2°, 15.0° ± 0.2°, 15.4° ± 0.2°, 15.8° ± 0.2°, 16.6° ± 0.2°, 17.0° ± 0.2°, 17.4° ± 0.2°, 17.8° ± 0.2°, 18.5° ± 0.2°, 18.8° ± 0.2°, 19.5° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, p. 42 / 289 37 / 280 19.8° ± 0.2°, 20.3° ± 0.2°, 20.6° ± 0.2°, 21.5° ± 0.2°, 22.2° ± 0.2°, 22.6° ± 0.2°, 23.1° ± 0.2°, 23.4° ± 0.2°, 24.1° ± 0.2°, 24.4° ± 0.2°, 24.7° ± 0.2°, 25.3° ± 0.2°, 26.0° ± 0.2°, 26.8° ± 0.2°, 27.6° ± 0.2°, 28.1° ± 0.2°, 29.7° ± 0.2°, 30.2° ± 0.2°, 30.8° ± 0.2°, 31.5° ± 0.2° and 33.5° ± 0.2° 2θ.
[0223] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 4.7° ± 0.2°, 7.5° ± 0.2°, 9.7° ± 0.2°, 13.3° ± 0.2°, 13.8° ± 0.2°, 14.0° ± 0.2°, 14.2° ± 0.2°, 15.0° ± 0.2°, 15.4° ± 0.2°, 15.8° ± 0.2°, 16.6° ± 0.2°, 17.0° ± 0.2°, 17.4° ± 0.2°, 17.8° ± 0.2°, 18.5° ± 0.2°, 18.8° ± 0.2°, 19.5° ± 0.2°, 19.8° ± 0.2°, 20.3° ± 0.2°, 20.6° ± 0.2°, 21.5° ± 0.2°, 22.2° ± 0.2°, 22.6° ± 0.2°, 23.1° ± 0.2°, 23.4° ± 0.2°, 24.1° ± 0.2°, 24.4° ± 0.2°, 24.7° ± 0.2°, 25.3° ± 0.2°, 26.0° ± 0.2°, 26.8° ± 0.2°, 27.6° ± 0.2°, 28.1° ± 0.2°, 29.7° ± 0.2°, 30.2° ± 0.2°, 30.8° ± 0.2°, 31.5° ± 0.2° and 33.5° ± 0.2° 2θ.
[0224] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 3. In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 12.
[0225] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak starting at about 41°C. In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 112°C. In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 122°C. In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) has a DSC thermogram Petition 870260106343, dated 10 / 15 / 2026, p. 43 / 289 38 / 280 comprising one or more endotherms with peaks starting at about 41°C, about 112°C and about 122°C. In certain embodiments, Form B of the monofumarate salt of compound of formula (I) has a DSC thermogram substantially the same as shown in Figure 4.
[0226] In certain embodiments, Form B of the monofumarate salt of compound formula (I) exhibits a weight loss of less than or equal to about 4.6% by weight when heated Form B from about 25°C to about 155°C. The weight loss exhibited by a crystalline form (e.g., Form B of the monofumarate salt of compound formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, Form B of the monofumarate salt of compound formula (I) has a TGA thermogram substantially the same as that shown in Figure 4.
[0227] In certain embodiments, Form B of the monofumarate salt of the compound of formula (I) is a crystalline hydrate. (iii) Monofumarate Salt Form C
[0228] In several embodiments, Form C of the monofumarate salt of the compound of formula (I) is given here (I) .
[0229] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has a powder X-ray diffraction pattern (XRPD) comprising a peak at about 5.2° 2θ.
[0230] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 7.6°, about 10.6°, about 13.8° and about 14.4° 2θ.
[0231] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.8°, about 21.2°, about 24.5° and about 25.0° 2θ. Petition 870260106343, dated 10 / 15 / 2026, p. 44 / 289 39 / 280
[0232] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.1°, about 16.7°, about 17.3°, about 17.9°, about 19.4°, about 19.9°, about 20.6° and about 22.7° 2θ.
[0233] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.1°, about 15.8°, about 16.7°, about 17.3°, about 17.9°, about 19.4°, about 19.9°, about 20.6°, about 21.2°, about 22.7°, about 24.5° and about 25.0° 2θ.
[0234] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.7°, about 26.6°, about 28.9°, about 30.4°, about 31.4° and about 32.0° 2θ.
[0235] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.2°, about 7.6°, about 10.6°, about 13.8°, about 14.4°, about 15.1°, about 15.8°, about 16.7°, about 17.3°, about 17.9°, about 19.4°, about 19.9°, about 20.6°, about 21.2°, about 22.7°, about 24.5°, about 25.0°, about 25.7°, about 26.6°, about 28.9°, about 30.4°, about 31.4° and about 32.0° 2θ.
[0236] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at about 5.2°, about 7.6°, about 10.6°, about 13.8°, about 14.4°, about 15.1°, about 15.8°, about 16.7°, about 17.3°, about 17.9°, about 19.4°, about 19.9°, about 20.6°, about 21.2°, about 22.7°, about 24.5°, about 25.0°, about 25.7°, about 26.6°, about 28.9°, about 30.4°, about 31.4° and about 32.0° 2θ.
[0237] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising a peak at 5.2° ± 0.3° 2θ. Petition 870260106343, dated 10 / 15 / 2026, p. 45 / 289 40 / 280
[0238] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.6° ± 0.3°, 10.6° ± 0.3°, 13.8° ± 0.3° and 14.4° ± 0.3° 2θ.
[0239] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.8° ± 0.3°, 21.2° ± 0.3°, 24.5° ± 0.3° and 25.0° ± 0.3° 2θ.
[0240] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.3°, 16.7° ± 0.3°, 17.3° ± 0.3°, 17.9° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.6° ± 0.3° and 22.7° ± 0.3° 2θ.
[0241] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.3°, 15.8° ± 0.3°, 16.7° ± 0.3°, 17.3° ± 0.3°, 17.9° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.6° ± 0.3°, 21.2° ± 0.3°, 22.7° ± 0.3°, 24.5° ± 0.3° and 25.0° ± 0.3° 2θ.
[0242] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.7° ± 0.3°, 26.6° ± 0.3°, 28.9° ± 0.3°, 30.4° ± 0.3°, 31.4° ± 0.3° and 32.0° ± 0.3° 2θ.
[0243] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.2° ± 0.3°, 7.6° ± 0.3°, 10.6° ± 0.3°, 13.8° ± 0.3°, 14.4° ± 0.3°, 15.1° ± 0.3°, 15.8° ± 0.3°, 16.7° ± 0.3°, 17.3° ± 0.3°, 17.9° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.6° ± 0.3°, 21.2° ± 0.3°, 22.7° ± 0.3°, 24.5° ± 0.3°, 25.0° ± 0.3°, 25.7° ± 0.3°, 26.6° ± 0.3°, 28.9° ± 0.3°, 30.4° ± 0.3°, 31.4° ± 0.3° and 32.0° ± 0.3° 2θ.
[0244] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.2° ± 0.3°, 7.6° ± 0.3°, 10.6° ± 0.3°, 13.8° ± 0.3°, 14.4° ± 0.3°, 15.1° ± 0.3°, 15.8° ± 0.3°, 16.7° ± 0.3°, 17.3° ± 0.3°, 17.9° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.6° ± 0.3°, 21.2° ± 0.3°, 22.7° ± 0.3°, 24.5° ± 0.3°, 25.0° ± 0.3°, 25.7° ± 0.3°, 26.6° ± 0.3°, 28.9° ± 0.3°, 30.4° ± 0.3°, 31.4° ± 0.3° and Petition 870260106343, dated 10 / 15 / 2026, page 46 / 289 41 / 280 32.0° ± 0.3° 2θ.
[0245] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising a peak at 5.2° ± 0.2° 2θ.
[0246] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.6° ± 0.2°, 10.6° ± 0.2°, 13.8° ± 0.2° and 14.4° ± 0.2° 2θ.
[0247] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.8° ± 0.2°, 21.2° ± 0.2°, 24.5° ± 0.2° and 25.0° ± 0.2° 2θ.
[0248] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.2°, 16.7° ± 0.2°, 17.3° ± 0.2°, 17.9° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.6° ± 0.2° and 22.7° ± 0.2° 2θ.
[0249] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 17.3° ± 0.2°, 17.2° ± 0.2°, 19.2° ± 0.2°, 19.9° ± 0.2°, 20.6° ± 0.2°, 21.2° ± 0.2°, 22.7° ± 0.2°, 24.5° ± 0.2° and 25.0° ± 0.2° 2θ.
[0250] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.7° ± 0.2°, 26.6° ± 0.2°, 28.9° ± 0.2°, 30.4° ± 0.2°, 31.4° ± 0.2° and 32.0° ± 0.2° 2θ.
[0251] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.2° ± 0.2°, 7.6° ± 0.2°, 10.6° ± 0.2°, 13.8° ± 0.2°, 14.4° ± 0.2°, 15.1° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 17.3° ± 0.2°, 17.9° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.6° ± 0.2°, 21.2° ± 0.2°, 22.7° ± 0.2°, 24.5° ± 0.2°, 25.0° ± 0.2°, 25.7° ± 0.2°, 26.6° ± 0.2°, 28.9° ± 0.2°, 30.4° ± 0.2°, 31.4° ± 0.2° and 32.0° ± 0.2° 2θ.
[0252] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.2° ± 0.2°, 7.6° ± 0.2°, 10.6° ± 0.2°, 13.8° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, page 47 / 289 42 / 280 14.4° ± 0.2°, 15.1° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 17.3° ± 0.2°, 17.9° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.6° ± 0.2°, 21.2° ± 0.2°, 22.7° ± 0.2°, 24.5° ± 0.2°, 25.0° ± 0.2°, 25.7° ± 0.2°, 26.6° ± 0.2°, 28.9° ± 0.2°, 30.4° ± 0.2°, 31.4° ± 0.2° and 32.0° ± 0.2° 2θ.
[0253] In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 5. In certain embodiments, Form C of the monofumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 13.
[0254] In certain embodiments, Form C of the monofumarate salt of compound formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak starting at about 30°C. In certain embodiments, Form C of the monofumarate salt of compound formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 125°C. In certain embodiments, Form C of the monofumarate salt of compound formula (I) has a DSC thermogram comprising one or more endotherms with peaks starting at about 30°C and about 125°C. In certain embodiments, Form C of the monofumarate salt of compound formula (I) has a DSC thermogram substantially the same as shown in Figure 6.
[0255] In certain embodiments, Form C of the monofumarate salt of compound formula (I) exhibits a weight loss of less than or equal to about 0.9% by weight when heated Form C from about 25°C to about 80°C. The weight loss exhibited by a crystalline form (e.g., Form C of the monofumarate salt of compound formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, Form C of the monofumarate salt of compound formula (I) has a TGA thermogram substantially the same as the Petition 870260106343, dated 10 / 15 / 2026, p. 48 / 289 43 / 280 shown in Figure 6. (B) Crystalline Forms of Hemifumarate Salt
[0256] In another aspect, a crystalline hemifumarate salt of the compound of formula (I) is provided here.
[0257] In F OH (I) . In certain embodiments, the crystalline hemifumarate salt has an XRPD pattern comprising one or more peaks at approximately 8.5°, approximately 11.0°, and approximately 12.0°. 2θ.
[0258] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.9°, about 17.9° and about 24.1° 2θ.
[0259] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.7°, about 27.7° and about 34.1° 2θ.
[0260] In certain embodiments, the crystalline hemifumarate salt has an XRPD pattern comprising one or more peaks at about 8.5°, about 11.0°, about 12.0°, about 16.9°, about 17.9°, about 24.1°, about 25.7°, about 27.7° and about 34.1° 2θ.
[0261] In certain embodiments, the crystalline hemifumarate salt has an XRPD pattern comprising peaks at about 8.5°, about 11.0°, about 12.0°, about 16.9°, about 17.9°, about 24.1°, about 25.7°, about 27.7° and about 34.1° 2θ.
[0262] In certain embodiments, the crystalline hemifumarate salt has an XRPD pattern comprising one or more peaks at 8.5° ± 0.3°, 11.0° ± 0.3° and 12.0° ± 0.3° 2θ.
[0263] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.9° ± 0.3°, 17.9° ± 0.3° and 24.1° ± 0.3° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 49 / 289 44 / 280
[0264] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.7° ± 0.3°, 27.7° ± 0.3° and 34.1° ± 0.3° 2θ.
[0265] In certain embodiments, the crystalline hemifumarate salt has an XRPD pattern comprising one or more peaks at 8.5° ± 0.3°, 11.0° ± 0.3°, 12.0° ± 0.3°, 16.9° ± 0.3°, 17.9° ± 0.3°, 24.1° ± 0.3°, 25.7° ± 0.3°, 27.7° ± 0.3° and 34.1° ± 0.3° 2θ.
[0266] In certain embodiments, the crystalline hemifumarate salt has an XRPD pattern comprising peaks at 8.5° ± 0.3°, 11.0° ± 0.3°, 12.0° ± 0.3°, 16.9° ± 0.3°, 17.9° ± 0.3°, 24.1° ± 0.3°, 25.7° ± 0.3°, 27.7° ± 0.3° and 34.1° ± 0.3° 2θ.
[0267] In certain embodiments, the crystalline hemifumarate salt has an XRPD pattern comprising one or more peaks at 8.5° ± 0.2°, 11.0° ± 0.2° and 12.0° ± 0.2° 2θ.
[0268] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.9° ± 0.2°, 17.9° ± 0.2° and 24.1° ± 0.2° 2θ.
[0269] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.7° ± 0.2°, 27.7° ± 0.2° and 34.1° ± 0.2° 2θ.
[0270] In certain embodiments, the crystalline hemifumarate salt has an XRPD pattern comprising one or more peaks at 8.5° ± 0.2°, 11.0° ± 0.2°, 12.0° ± 0.2°, 16.9° ± 0.2°, 17.9° ± 0.2°, 24.1° ± 0.2°, 25.7° ± 0.2°, 27.7° ± 0.2° and 34.1° ± 0.2° 2θ.
[0271] In certain embodiments, the crystalline hemifumarate salt has an XRPD pattern comprising peaks at 8.5° ± 0.2°, 11.0° ± 0.2°, 12.0° ± 0.2°, 16.9° ± 0.2°, 17.9° ± 0.2°, 24.1° ± 0.2°, 25.7° ± 0.2°, 27.7° ± 0.2° and 34.1° ± 0.2° 2θ.
[0272] In certain embodiments, the crystalline hemifumarate salt of the compound of formula (I) is Form A of the hemifumarate salt of the compound of formula (I). In certain embodiments, Petition 870260106343, dated 10 / 15 / 2026, page 50 / 289 45 / 280 the crystalline hemifumarate salt exhibits a substantially the same XRPD pattern as that shown in Figure 7. In certain embodiments, the crystalline hemifumarate salt of compound formula (I) is Form B of the hemifumarate salt of compound formula (I). In certain embodiments, the crystalline hemifumarate salt exhibits a substantially the same XRPD pattern as that shown in Figure 10.
[0273] In certain embodiments, the crystalline hemifumarate salt of the compound of formula (I) is an anhydrous crystalline form.
[0274] In certain embodiments, the crystalline hemifumarate salt of the compound of formula (I) is a crystalline hydrate. (i) Hemifumarate Salt Form A
[0275] In various embodiments, Form A of the hemifumarate salt of the compound of formula (I) is provided here. H2N N âjÔl IHOH (I) .
[0276] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has a powder X-ray diffraction pattern (XRPD) comprising one or more peaks at about 9.9° and about 11.0° 2Θ.
[0277] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 6.4°, about 8.3°, about 12.1°, about 13.2°, about 14.3° and about 14.5° 2Θ.
[0278] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.9°, about 17.2°, about 17.8°, about 18.5°, about 20.2°, about 22.1° and about 22.5° 2Θ.
[0279] In certain modes, the XRPD pattern additionally comprises one or more peaks at approximately 15.1°, approximately Petition 870260106343, dated 10 / 15 / 2026, p. 51 / 289 46 / 280 16.1°, approximately 19.5°, approximately 19.8°, approximately 21.2°, approximately 21.5°, approximately 23.3°, approximately 24.3°, approximately 24.5° and approximately 25.0° 2θ.
[0280] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.5°, about 26.3°, about 27.2°, about 28.9° and about 31.1° 2θ.
[0281] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 27.8°, about 28.0°, about 28.3°, about 29.5°, about 31.9°, about 32.5°, about 32.7°, about 33.6°, about 34.1° and about 34.4° 2θ.
[0282] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at approximately 6.4°, approximately 8.3°, approximately 9.9°, approximately 11.0°, approximately 12.1°, approximately 13.2°, approximately 14.3°, approximately 14.5°, approximately 15.1°, approximately 16.1°, approximately 16.9°, approximately 17.2°, approximately 17.8°, approximately 18.5°, approximately 19.5°, approximately 19.8°, approximately 20.2°, approximately 21.2°, approximately 21.5°, approximately 22.1°, approximately 22.5°, approximately 23.3°, approximately 24.3°, approximately 24.5°, approximately 25.0°, about 25.5°, about 26.3°, about 27.2°, about 27.8°, about 28.0°, about 28.3°, about 28.9°, about 29.5°, about 31.1°, about 31.9°, about 32.5°, about 32.7°, about 33.6°, about 34.1° and approximately 34.4° 2θ.
[0283] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at about 6.4°, about 8.3°, about 9.9°, about 11.0°, approximately 14.5°, approximately 17.2°, approximately 19.8°, approximately 22.1°, approximately 24.5°, approximately 12.1°, approximately 15.1°, approximately 17.8°, approximately 20.2°, approximately 22.5°, approximately 25.0°, approximately 13.2°, approximately 16.1°, circa 18.5°, approximately 21.2°, approximately 23.3°, approximately 25.5°, approximately 14.3°, approximately 16.9°, approximately 19.5°, approximately 21.5°, approximately 24.3°, approximately 26.3°, approximately Petition 870260106343, dated 10 / 15 / 2026, page 52 / 289 47 / 280 27.2°, approximately 27.8°, approximately 28.0°, approximately 28.3°, approximately 28.9°, approximately 29.5°, approximately 31.1°, approximately 31.9°, approximately 32.5°, approximately 32.7°, approximately 33.6°, approximately 34.1° and approximately 34.4° 2θ.
[0284] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has a powder X-ray diffraction pattern (XRPD) comprising one or more peaks at 9.9° ± 0.3° and 11.0° ± 0.3° 2θ.
[0285] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 6.4° ± 0.3°, 8.3° ± 0.3°, 12.1° ± 0.3°, 13.2° ± 0.3°, 14.3° ± 0.3° and 14.5° ± 0.3° 2θ.
[0286] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.9° ± 0.3°, 17.2° ± 0.3°, 17.8° ± 0.3°, 18.5° ± 0.3°, 20.2° ± 0.3°, 22.1° ± 0.3° and 22.5° ± 0.3° 2θ.
[0287] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.3°, 16.1° ± 0.3°, 19.5° ± 0.3°, 19.8° ± 0.3°, 21.2° ± 0.3°, 21.5° ± 0.3°, 23.3° ± 0.3°, 24.3° ± 0.3°, 24.5° ± 0.3° and 25.0° ± 0.3° 2θ.
[0288] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.5° ± 0.3°, 26.3° ± 0.3°, 27.2° ± 0.3°, 28.9° ± 0.3° and 31.1° ± 0.3° 2θ.
[0289] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 27.8° ± 0.3°, 28.0° ± 0.3°, 28.3° ± 0.3°, 29.5° ± 0.3°, 31.9° ± 0.3°, 32.5° ± 0.3°, 32.7° ± 0.3°, 33.6° ± 0.3°, 34.1° ± 0.3° and 34.4° ± 0.3° 2θ.
[0290] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.4° ± 0.3°, 8.3° ± 0.3°, 9.9° ± 0.3°, 11.0° ± 0.3°, 12.1° ± 0.3°, 13.2° ± 0.3°, 14.3° ± 0.3°, 14.5° ± 0.3°, 15.1° ± 0.3°, 16.1° ± 0.3°, 16.9° ± 0.3°, 17.2° ± 0.3°, 17.8° ± 0.3°, 18.5° ± 0.3°, 19.5° ± 0.3°, 19.8° ± 0.3°, 20.2° ± 0.3°, 21.2° ± 0.3°, 21.5° ± 0.3°, 22.1° ± 0.3°, 22.5° ± 0.3°, 23.3° ± Petition 870260106343, dated 10 / 15 / 2026, page 53 / 289 48 / 280 0.3°, 24.3° ± 0.3°, 24.5° ± 0.3°, 25.0° ± 0.3°, 25.5° ± 0.3°, 26.3° ± 0.3°, 27.2° ± 0.3°, 27.8° ± 0.3°, 28.0° ± 0.3°, 28.3° ± 0.3°, 28.9° ± 0.3°, 29.5° ± 0.3°, 31.1° ± 0.3°, 31.9° ± 0.3°, 32.5° ± 0.3°, 32.7° ± 0.3°, 33.6° ± 0.3°, 34.1° ± 0.3° and 34.4° ± 0.3° 2θ.
[0291] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 6.4° ± 0.3°, 8.3° ± 0.3°, 9.9° ± 0.3°, 11.0° ± 0.3°, 12.1° ± 0.3°, 13.2° ± 0.3°, 14.3° ± 0.3°, 14.5° ± 0.3°, 15.1° ± 0.3°, 16.1° ± 0.3°, 16.9° ± 0.3°, 17.2° ± 0.3°, 17.8° ± 0.3°, 18.5° ± 0.3°, 19.5° ± 0.3°, 19.8° ± 0.3°, 20.2° ± 0.3°, 21.2° ± 0.3°, 21.5° ± 0.3°, 22.1° ± 0.3°, 22.5° ± 0.3°, 23.3° ± 0.3°, 24.3° ± 0.3°, 24.5° ± 0.3°, 25.0° ± 0.3°, 25.5° ± 0.3°, 26.3° ± 0.3°, 27.2° ± 0.3°, 27.8° ± 0.3°, 28.0° ± 0.3°, 28.3° ± 0.3°, 28.9° ± 0.3°, 29.5° ± 0.3°, 31.1° ± 0.3°, 31.9° ± 0.3°, 32.5° ± 0.3°, 32.7° ± 0.3°, 33.6° ± 0.3°, 34.1° ± 0.3° and 34.4° ± 0.3° 2θ.
[0292] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has a powder X-ray diffraction pattern (XRPD) comprising one or more peaks at 9.9° ± 0.2° and 11.0° ± 0.2° 2θ.
[0293] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 6.4° ± 0.2°, 8.3° ± 0.2°, 12.1° ± 0.2°, 13.2° ± 0.2°, 14.3° ± 0.2° and 14.5° ± 0.2° 2θ.
[0294] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.9° ± 0.2°, 17.2° ± 0.2°, 17.8° ± 0.2°, 18.5° ± 0.2°, 20.2° ± 0.2°, 22.1° ± 0.2° and 22.5° ± 0.2° 2θ.
[0295] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.2°, 16.1° ± 0.2°, 19.5° ± 0.2°, 19.8° ± 0.2°, 21.2° ± 0.2°, 21.5° ± 0.2°, 23.3° ± 0.2°, 24.3° ± 0.2°, 24.5° ± 0.2° and 25.0° ± 0.2° 2θ.
[0296] In certain forms, the XRPD standard comprises Petition 870260106343, dated 10 / 15 / 2026, page 54 / 289 49 / 280 additionally one or more peaks at 25.5° ± 0.2°, 26.3° ± 0.2°, 27.2° ± 0.2°, 28.9° ± 0.2° and 31.1° ± 0.2° 2θ.
[0297] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 27.8° ± 0.2°, 28.0° ± 0.2°, 28.3° ± 0.2°, 29.5° ± 0.2°, 31.9° ± 0.2°, 32.5° ± 0.2°, 32.7° ± 0.2°, 33.6° ± 0.2°, 34.1° ± 0.2° and 34.4° ± 0.2° 2θ.
[0298] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.4° ± 0.2°, 8.3° ± 0.2°, 9.9° ± 0.2°, 11.0° ± 0.2°, 12.1° ± 0.2°, 13.2° ± 0.2°, 14.3° ± 0.2°, 14.5° ± 0.2°, 15.1° ± 0.2°, 16.1° ± 0.2°, 16.9° ± 0.2°, 17.2° ± 0.2°, 17.8° ± 0.2°, 18.5° ± 0.2°, 19.5° ± 0.2°, 19.8° ± 0.2°, 20.2° ± 0.2°, 21.2° ± 0.2°, 21.5° ± 0.2°, 22.1° ± 0.2°, 22.5° ± 0.2°, 23.3° ± 0.2°, 24.3° ± 0.2°, 24.5° ± 0.2°, 25.0° ± 0.2°, 25.5° ± 0.2°, 26.3° ± 0.2°, 27.2° ± 0.2°, 27.8° ± 0.2°, 28.0° ± 0.2°, 28.3° ± 0.2°, 28.9° ± 0.2°, 29.5° ± 0.2°, 31.1° ± 0.2°, 31.9° ± 0.2°, 32.5° ± 0.2°, 32.7° ± 0.2°, 33.6° ± 0.2°, 34.1° ± 0.2° and 34.4° ± 0.2° 2θ.
[0299] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 6.4° ± 0.2°, 8.3° ± 0.2°, 9.9° ± 0.2°, 11.0° ± 0.2°, 12.1° ± 0.2°, 13.2° ± 0.2°, 14.3° ± 0.2°, 14.5° ± 0.2°, 15.1° ± 0.2°, 16.1° ± 0.2°, 16.9° ± 0.2°, 17.2° ± 0.2°, 17.8° ± 0.2°, 18.5° ± 0.2°, 19.5° ± 0.2°, 19.8° ± 0.2°, 20.2° ± 0.2°, 21.2° ± 0.2°, 21.5° ± 0.2°, 22.1° ± 0.2°, 22.5° ± 0.2°, 23.3° ± 0.2°, 24.3° ± 0.2°, 24.5° ± 0.2°, 25.0° ± 0.2°, 25.5° ± 0.2°, 26.3° ± 0.2°, 27.2° ± 0.2°, 27.8° ± 0.2°, 28.0° ± 0.2°, 28.3° ± 0.2°, 28.9° ± 0.2°, 29.5° ± 0.2°, 31.1° ± 0.2°, 31.9° ± 0.2°, 32.5° ± 0.2°, 32.7° ± 0.2°, 33.6° ± 0.2°, 34.1° ± 0.2° and 34.4° ± 0.2° 2θ.
[0300] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) has a substantially the same XRPD pattern as shown in Figure 8. In certain embodiments, the Petition 870260106343, dated 10 / 15 / 2026, p. 55 / 289 50 / 280 Form A of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 15.
[0301] In certain embodiments, Form A of the hemifumarate salt of compound formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak beginning at about 206°C. In certain embodiments, Form B of the hemifumarate salt of compound formula (I) has a DSC thermogram substantially the same as that shown in Figure 9.
[0302] In certain embodiments, Form A of the hemifumarate salt of compound formula (I) exhibits a weight loss of less than or equal to about 0.5% by weight when heated Form A from about 25°C to about 150°C. The weight loss exhibited by a crystalline form (e.g., Form A of the hemifumarate salt of compound formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, Form A of the hemifumarate salt of compound formula (I) has a TGA thermogram substantially the same as that shown in Figure 9.
[0303] In certain embodiments, Form A of the hemifumarate salt of compound formula (I) exhibits a mass change less than or equal to about 0.7% by weight when the relative humidity varies between 0% and about 80%, measured at 25°C. The mass change shown by a crystalline form (e.g., Form A of the hemifumarate salt of compound formula (I)) can be determined, for example, using DVS. In certain embodiments, Form A of the hemifumarate salt of compound formula (I) has a water sorption isotherm substantially equal to that shown in Figure 10.
[0304] In certain embodiments, Form A of the hemifumarate salt of the compound of formula (I) is an anhydrous crystalline form. (ii) Hemifumarate Salt Form B Petition 870260106343, dated 10 / 15 / 2026, p. 56 / 289 51 / 280
[0305] In several embodiments, Form B of the hemifumarate salt of the compound of formula (I) is given here (I) .
[0306] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) shows an X-ray powder diffraction (XRPD) pattern comprising a peak at about 5.4° 2θ. In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) shows an XRPD pattern comprising a peak at about 8.7° 2θ. In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.4° and 8.7° 2θ.
[0307] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 10.4°, about 11.0°, about 11.9° and about 12.6° 2θ.
[0308] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.5°, about 16.9°, about 17.4°, about 17.9° and about 23.9°. 2θ.
[0309] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.7°, about 27.7° and about 34.1° 2θ.
[0310] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.4°, about 8.7°, about 10.4°, about 11.0°, about 11.9°, about 12.6°, about 16.5°, about 16.9°, about 17.4°, about 17.9° and about 23.9°, about 25.7°, about 27.7° and about 34.1° 2θ.
[0311] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at about 5.4°, about 8.7°, about 10.4°, about Petition 870260106343, dated 10 / 15 / 2026, p. 57 / 289 52 / 280 11.0°, approximately 11.9°, approximately 12.6°, approximately 16.5°, approximately 16.9°, approximately 17.4°, approximately 17.9° and approximately 23.9°, approximately 25.7°, approximately 27.7° and approximately 34.1° 2θ.
[0312] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) shows an XRPD pattern comprising a peak at 5.4° ± 0.3° 2θ. In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) shows an XRPD pattern comprising a peak at about 8.7° ± 0.3° 2θ. In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) shows an XRPD pattern comprising one or more peaks at about 5.4° ± 0.3° and 8.7° ± 0.3° 2θ.
[0313] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 10.4° ± 0.3°, about 11.0° ± 0.3°, about 11.9° ± 0.3° and about 12.6° ± 0.3° 2θ.
[0314] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.5° ± 0.3°, about 16.9° ± 0.3°, about 17.4° ± 0.3°, about 17.9° ± 0.3° and about 23.9° ± 0.3° 2θ.
[0315] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.7° ± 0.3°, about 27.7° ± 0.3° and about 34.1° ± 0.3° 2θ.
[0316] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.4° ± 0.3°, 8.7° ± 0.3°, 10.4° ± 0.3°, 11.0° ± 0.3°, 11.9° ± 0.3°, 12.6° ± 0.3°, 16.5° ± 0.3°, 16.9° ± 0.3°, 17.4° ± 0.3°, 17.9° ± 0.3°, 23.9° ± 0.3°, 25.7° ± 0.3°, 27.7° ± 0.3° and 34.1° ± 0.3° 2θ.
[0317] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.4° ± 0.3°, 8.7° ± 0.3°, 10.4° ± 0.3°, 11.0° ± 0.3°, 11.9° ± 0.3°, 12.6° ± 0.3°, 16.5° ± 0.3°, 16.9° ± 0.3°, 17.4° ± Petition 870260106343, dated 10 / 15 / 2026, page 58 / 289 53 / 280 0.3°, 17.9° ± 0.3°, 23.9° ± 0.3°, 25.7° ± 0.3°, 27.7° ± 0.3° and 34.1° ± 0.3° 2θ.
[0318] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) shows an XRPD pattern comprising a peak at 5.4° ± 0.2° 2θ. In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) shows an XRPD pattern comprising a peak at about 8.7° ± 0.2° 2θ. In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) shows an XRPD pattern comprising one or more peaks at about 5.4° ± 0.2° and 8.7° ± 0.2° 2θ.
[0319] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 10.4° ± 0.2°, about 11.0° ± 0.2°, about 11.9° ± 0.2° and about 12.6° ± 0.2° 2θ.
[0320] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.5° ± 0.2°, about 16.9° ± 0.2°, about 17.4° ± 0.2°, about 17.9° ± 0.2° and about 23.9° ± 0.2° 2θ.
[0321] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.7° ± 0.2°, about 27.7° ± 0.2° and about 34.1° ± 0.2° 2θ.
[0322] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.4° ± 0.2°, 8.7° ± 0.2°, 10.4° ± 0.2°, 11.0° ± 0.2°, 11.9° ± 0.2°, 12.6° ± 0.2°, 16.5° ± 0.2°, 16.9° ± 0.2°, 17.4° ± 0.2°, 17.9° ± 0.2°, 23.9° ± 0.2°, 25.7° ± 0.2°, 27.7° ± 0.2° and 34.1° ± 0.2° 2θ.
[0323] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.4° ± 0.2°, 8.7° ± 0.2°, 10.4° ± 0.2°, 11.0° ± 0.2°, 11.9° ± 0.2°, 12.6° ± 0.2°, 16.5° ± 0.2°, 16.9° ± 0.2°, 17.4° ± 0.2°, 17.9° ± 0.2°, 23.9° ± 0.2°, 25.7° ± 0.2°, 27.7° ± 0.2° and Petition 870260106343, dated 10 / 15 / 2026, page 59 / 289 54 / 280 34.1° ± 0.2° 2θ.
[0324] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 13. In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 23.
[0325] In certain embodiments, Form B of the hemifumarate salt of compound formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak starting at about 118°C. In certain embodiments, Form B of the hemifumarate salt of compound formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 182°C. In certain embodiments, Form B of the hemifumarate salt of compound formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 202°C. In certain embodiments, Form B of the hemifumarate salt of compound formula (I) has a DSC thermogram comprising one or more endotherms with peaks starting at about 118°C, about 182°C, and about 202°C. In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) has a DSC thermogram substantially the same as that shown in Figure 14.
[0326] In certain embodiments, Form B of the hemifumarate salt of compound formula (I) exhibits a weight loss of less than or equal to about 1.1% by weight when heated Form B from about 25°C to about 150°C. The weight loss exhibited by a crystalline form (e.g., Form B of the hemifumarate salt of compound formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, Form B of the hemifumarate salt of compound formula (I) has a TGA thermogram substantially the same as that shown in Figure 14. Petition 870260106343, dated 10 / 15 / 2026, p. 60 / 289 55 / 280
[0327] In certain embodiments, Form B of the hemifumarate salt of the compound of formula (I) is a crystalline hydrate. (2) Salt Forms L-tartrate
[0328] In several embodiments, a tartrate salt of the compound of formula (I) is provided here (I).
[0329] In certain embodiments, the L-tartrate salt of the compound of formula (I) is a crystalline salt form.
[0330] In several embodiments, a crystalline L-tartrate salt of the compound of formula (I) is provided here H2N N IHOH (I).
[0331] In certain embodiments, the crystalline L-tartrate salt has an XRPD pattern substantially the same as that shown in Figure 16.
[0332] In certain embodiments, the crystalline fumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 25.
[0333] In certain embodiments, the L-tartrate salt of the compound of formula (I) is a solvated crystalline form. In certain embodiments, the L-tartrate salt of the compound of formula (I) is a solvated crystalline form of MTBE.
[0334] In certain embodiments, the L-tartrate salt of the compound of formula (I) shows an X-ray powder diffraction (XRPD) pattern comprising a peak at about 3.3° 2θ. In certain embodiments, the L-tartrate salt of the compound of formula (I) shows an XRPD pattern comprising a peak at about 7.9° 2θ. In certain embodiments, the L-tartrate salt of the compound of Petition 870260106343, dated 10 / 15 / 2026, p. 61 / 289 56 / 280 formula (I) shows an XRPD pattern comprising one or more peaks at about 3.3° and about 7.9° 2θ.
[0335] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 10.2°, about 11.6°, about 12.4°, about 14.4° and about 14.8° 2θ.
[0336] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.4°, about 17.0°, about 20.6° and about 23.4° 2θ.
[0337] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.1° and about 31.2° 2θ.
[0338] In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 3.3°, about 7.9°, about 10.2°, about 11.6°, about 12.4°, about 14.4°, about 14.8°, about 15.4°, about 17.0°, about 20.6°, about 23.4°, about 25.1° and about 31.2° 2θ.
[0339] In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern comprising peaks at about 3.3°, about 7.9°, about 10.2°, about 11.6°, about 12.4°, about 14.4°, about 14.8°, about 15.4°, about 17.0°, about 20.6°, about 23.4°, about 25.1° and about 31.2° 2θ.
[0340] In certain embodiments, the L-tartrate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 3.3° ± 0.3° 2θ. In certain embodiments, the L-tartrate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 7.9° ± 0.3° 2θ. In certain embodiments, the L-tartrate salt of the compound of formula (I) exhibits a powder X-ray diffraction (XRPD) pattern comprising one or more peaks at 3.3° ± 0.3° and 7.9° ± 0.3° 2θ.
[0341] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 10.2° ± 0.3°, 11.6° ± 0.3°, Petition 870260106343, dated 10 / 15 / 2026, page 62 / 289 57 / 280 12.4° ± 0.3°, 14.4° ± 0.3° and 14.8° ± 0.3° 2θ.
[0342] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.4° ± 0.3°, 17.0° ± 0.3°, 20.6° ± 0.3° and 23.4° ± 0.3°. 2θ.
[0343] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.1° ± 0.3° and 31.2° ± 0.3° 2θ.
[0344] In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 3.3° ± 0.3°, 7.9° ± 0.3°, 10.2° ± 0.3°, 11.6° ± 0.3°, 12.4° ± 0.3°, 14.4° ± 0.3°, 14.8° ± 0.3°, 15.4° ± 0.3°, 17.0° ± 0.3°, 20.6° ± 0.3°, 23.4° ± 0.3°, 25.1° ± 0.3° and 31.2° ± 0.3° 2θ.
[0345] In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 3.3° ± 0.3°, 7.9° ± 0.3°, 10.2° ± 0.3°, 11.6° ± 0.3°, 12.4° ± 0.3°, 14.4° ± 0.3°, 14.8° ± 0.3°, 15.4° ± 0.3°, 17.0° ± 0.3°, 20.6° ± 0.3°, 23.4° ± 0.3°, 25.1° ± 0.3° and 31.2° ± 0.3° 2θ.
[0346] In certain embodiments, the L-tartrate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 3.3° ± 0.2° 2θ. In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern comprising a peak at 7.9° ± 0.2° 2θ. In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 3.3° ± 0.2° and 7.9° ± 0.2° 2θ.
[0347] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 10.2° ± 0.2°, 11.6° ± 0.2°, 12.4° ± 0.2°, 14.4° ± 0.2° and 14.8° ± 0.2° 2θ.
[0348] In certain embodiments, the pattern additionally includes one or more peaks at 15.4° ± 20.6° ± 0.2° and 23.4° ± 0.2°. 2θ.
[0349] In certain embodiments, the pattern additionally includes one or more peaks at 25.1° ± 0.2°, 17.0° ± 0.2°, and 31.2° ± 0.2°. Petition 870260106343, dated 10 / 15 / 2026, page 63 / 289 58 / 280 2θ.
[0350] In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 3.3° ± 0.2°, 7.9° ± 0.2°, 10.2° ± 0.2°, 11.6° ± 0.2°, 12.4° ± 0.2°, 14.4° ± 0.2°, 14.8° ± 0.2°, 15.4° ± 0.2°, 17.0° ± 0.2°, 20.6° ± 0.2°, 23.4° ± 0.2°, 25.1° ± 0.2° and 31.2° ± 0.2° 2θ.
[0351] In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 3.3° ± 0.2°, 7.9° ± 0.2°, 10.2° ± 0.2°, 11.6° ± 0.2°, 12.4° ± 0.2°, 14.4° ± 0.2°, 14.8° ± 0.2°, 15.4° ± 0.2°, 17.0° ± 0.2°, 20.6° ± 0.2°, 23.4° ± 0.2°, 25.1° ± 0.2° and 31.2° ± 0.2° 2θ.
[0352] In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 16. In certain embodiments, the L-tartrate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 25.
[0353] In certain embodiments, the L-tartrate salt of compound formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak starting at about 117°C. In certain embodiments, the L-tartrate salt of compound formula (I) has a DSC thermogram substantially the same as shown in Figure 17.
[0354] In certain embodiments, the L-tartrate of compound formula (I) exhibits a weight loss of less than or equal to about 2.4% by weight when heating the L-tartrate salt from about 25°C to about 150°C. The weight loss exhibited by a crystalline form (e.g., the L-tartrate salt of compound formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, the L-tartrate salt of compound formula (I) has a TGA thermogram substantially the same as that shown in Figure 17. Petition 870260106343, dated 10 / 15 / 2026, p. 64 / 289 59 / 280 (3) Tosylate Salt Forms
[0355] In various embodiments, a tosylate salt of the compound of formula (I) is provided here. (I) .
[0356] In certain embodiments, the tosylate salt of the compound of formula (I) is a crystalline salt form.
[0357] In various embodiments, a crystalline tosylate salt of the compound of formula (I) is provided herein. H2N N IHOH (I).
[0358] In certain embodiments, the crystalline tosylate salt of the compound of formula (I) is Form A of the tosylate salt of the compound of formula (I).
[0359] In certain embodiments, the crystalline tosylate salt has an XRPD pattern substantially the same as that shown in Figure 18. In certain embodiments, the crystalline tosylate salt has an XRPD pattern substantially the same as that shown in Figure 20. In certain embodiments, the crystalline tosylate salt has an XRPD pattern substantially the same as that shown in Figure 21.
[0360] In certain embodiments, the crystalline fumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 26. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 27. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) Petition 870260106343, dated 10 / 15 / 2026, p. 65 / 289 60 / 280 revealed in Table 28.
[0361] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) is a solvated crystalline form. In certain embodiments, Form A of the tosylate salt of the compound of formula (I) is a solvated crystalline form of IPAc. (A) Tosylate Salt Form A
[0362] In several embodiments, Form A of the tosylate salt of the compound of formula (I) is given here (I) .
[0363] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has a powder X-ray diffraction pattern (XRPD) comprising a peak at about 5.1° 2θ.
[0364] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 6.1°, about 6.6°, about 7.3°, about 8.9°, about 10.2°, about 11.2°, about 11.8°, about 12.0°, about 12.6°, about 13.1° and about 13.8° 2θ.
[0365] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.6°, about 16.3°, about 17.1°, about 17.3°, about 17.6°, about 20.5°, about 21.0° and about 21.8° 2θ.
[0366] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.4°, about 26.8° and about 32.0° 2θ.
[0367] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.1°, about 6.1°, about 6.6°, about 7.3°, about 8.9°, about 10.2°, about 11.2°, about 11.8°, about 12.0°, about 12.6°, about 13.1°, about 13.8°, about 15.6°, about 16.3°, about 17.1°, Petition 870260106343, dated 10 / 15 / 2026, page 66 / 289 61 / 280 approximately 17.3°, approximately 17.6°, approximately 20.5°, approximately 21.0°, approximately 21.8°, approximately 25.4°, approximately 26.8° and approximately 32.0° 2θ.
[0368] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has an XRPD pattern comprising peaks at about 5.1°, about 6.1°, about 6.6°, about 7.3°, about 8.9°, about 10.2°, about 11.2°, about 11.8°, about 12.0°, about 12.6°, about 13.1°, about 13.8°, about 15.6°, about 16.3°, about 17.1°, about 17.3°, about 17.6°, about 20.5°, about 21.0°, about 21.8°, about 25.4°, about 26.8° and about 32.0° 2θ.
[0369] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has an XRPD pattern comprising a peak at 5.1° ± 0.3° 2θ.
[0370] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 6.1° ± 0.3°, 6.6° ± 0.3°, 7.3° ± 0.3°, 8.9° ± 0.3°, 10.2° ± 0.3°, 11.2° ± 0.3°, 11.8° ± 0.3°, 12.0° ± 0.3°, 12.6° ± 0.3°, 13.1° ± 0.3° and 13.8° ± 0.3° 2θ.
[0371] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.3°, 16.3° ± 0.3°, 17.1° ± 0.3°, 17.3° ± 0.3°, 17.6° ± 0.3°, 20.5° ± 0.3°, 21.0° ± 0.3° and 21.8° ± 0.3° 2θ.
[0372] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.4° ± 0.3°, 26.8° ± 0.3° and 32.0° ± 0.3° 2θ.
[0373] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.1° ± 0.3°, 6.1° ± 0.3°, 6.6° ± 0.3°, 7.3° ± 0.3°, 8.9° ± 0.3°, 10.2° ± 0.3°, 11.2° ± 0.3°, 11.8° ± 0.3°, 12.0° ± 0.3°, 12.6° ± 0.3°, 13.1° ± 0.3°, 13.8° ± 0.3°, 15.6° ± 0.3°, 16.3° ± 0.3°, 17.1° ± 0.3°, 17.3° ± 0.3°, 17.6° ± 0.3°, 20.5° ± 0.3°, 21.0° ± 0.3°, 21.8° ± 0.3°, 25.4° ± 0.3°, 26.8° ± 0.3° and Petition 870260106343, dated 10 / 15 / 2026, page 67 / 289 62 / 280 32.0° ± 0.3° 2θ.
[0374] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.1° ± 0.3°, 6.1° ± 0.3°, 6.6° ± 0.3°, 7.3° ± 0.3°, 8.9° ± 0.3°, 10.2° ± 0.3°, 11.2° ± 0.3°, 11.8° ± 0.3°, 12.0° ± 0.3°, 12.6° ± 0.3°, 13.1° ± 0.3°, 13.8° ± 0.3°, 15.6° ± 0.3°, 16.3° ± 0.3°, 17.1° ± 0.3°, 17.3° ± 0.3°, 17.6° ± 0.3°, 20.5° ± 0.3°, 21.0° ± 0.3°, 21.8° ± 0.3°, 25.4° ± 0.3°, 26.8° ± 0.3° and 32.0° ± 0.3° 2θ.
[0375] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has an XRPD pattern comprising a peak at 5.1° ± 0.2° 2θ.
[0376] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 6.1° ± 0.2°, 6.6° ± 0.2°, 7.3° ± 0.2°, 8.9° ± 0.2°, 10.2° ± 0.2°, 11.2° ± 0.2°, 11.8° ± 0.2°, 12.0° ± 0.2°, 12.6° ± 0.2°, 13.1° ± 0.2° and 13.8° ± 0.2° 2θ.
[0377] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.2°, 16.3° ± 0.2°, 17.1° ± 0.2°, 17.3° ± 0.2°, 17.6° ± 0.2°, 20.5° ± 0.2°, 21.0° ± 0.2° and 21.8° ± 0.2° 2θ.
[0378] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.4° ± 0.2°, 26.8° ± 0.2° and 32.0° ± 0.2° 2θ.
[0379] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.1° ± 0.2°, 6.1° ± 0.2°, 6.6° ± 0.2°, 7.3° ± 0.2°, 8.9° ± 0.2°, 10.2° ± 0.2°, 11.2° ± 0.2°, 11.8° ± 0.2°, 12.0° ± 0.2°, 12.6° ± 0.2°, 13.1° ± 0.2°, 13.8° ± 0.2°, 15.6° ± 0.2°, 16.3° ± 0.2°, 17.1° ± 0.2°, 17.3° ± 0.2°, 17.6° ± 0.2°, 20.5° ± 0.2°, 21.0° ± 0.2°, 21.8° ± 0.2°, 25.4° ± 0.2°, 26.8° ± 0.2° and 32.0° ± 0.2° 2θ.
[0380] In certain embodiments, Form A of the tosylate salt of Petition 870260106343, dated 10 / 15 / 2026, page 68 / 289 63 / 280 compound of formula (I) has an XRPD pattern comprising peaks at 5.1° ± 0.2°, 6.1° ± 0.2°, 6.6° ± 0.2°, 7.3° ± 0.2°, 8.9° ± 0.2°, 10.2° ± 0.2°, 11.2° ± 0.2°, 11.8° ± 0.2°, 12.0° ± 0.2°, 12.6° ± 0.2°, 13.1° ± 0.2°, 13.8° ± 0.2°, 15.6° ± 0.2°, 16.3° ± 0.2°, 17.1° ± 0.2°, 17.3° ± 0.2°, 17.6° ± 0.2°, 20.5° ± 0.2°, 21.0° ± 0.2°, 21.8° ± 0.2°, 25.4° ± 0.2°, 26.8° ± 0.2° and 32.0° ± 0.2° 2θ.
[0381] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 18. In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 26.
[0382] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak beginning at about 126°C. In certain embodiments, Form A of the tosylate salt of the compound of formula (I) has a DSC thermogram substantially the same as that shown in Figure 19.
[0383] In certain embodiments, Form A of the tosylate salt of the compound of formula (I) exhibits a weight loss of less than or equal to about 5.1% by weight when heated from about 25°C to about 170°C. The weight loss exhibited by a crystalline form (e.g., Form A of the tosylate salt of the compound of formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, Form A of the tosylate salt of the compound of formula (I) exhibits a TGA thermogram substantially the same as that shown in Figure 19. (4) Succinate Salt Forms
[0384] In several embodiments, a succinate salt of the compound of formula (I) is provided here Petition 870260106343, dated 10 / 15 / 2026, p. 69 / 289 64 / 280 (I) .
[0385] In certain embodiments, the succinate salt of the compound of formula (I) is a crystalline salt form.
[0386] In several embodiments, a crystalline succinate salt of the compound of formula (I) is provided here H2N N θχΤχΧ aJÔl IHOH (I).
[0387] In certain embodiments, the crystalline succinate salt of the compound of formula (I) is Form A of the succinate salt of the compound of formula (I).
[0388] In certain embodiments, the crystalline succinate salt has a substantially the same XRPD pattern as shown in Figure 22. In certain embodiments, the crystalline tosylate salt has an XRPD pattern substantially the same as shown in Figure 24. In certain embodiments, the crystalline tosylate salt has an XRPD pattern substantially the same as that shown in Figure 25.
[0389] In certain embodiments, the crystalline fumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 29. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 30. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 31. (A) Form A
[0390] In several forms, Form A is provided here. Petition 870260106343, dated 10 / 15 / 2026, page 70 / 289 65 / 280 succinate salt of the compound of formula (I) (I) .
[0391] In certain embodiments, Form A of the succinate salt of the compound of formula (I) has a powder X-ray diffraction pattern (XRPD) comprising a peak at about 7.6° 2θ.
[0392] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 5.6°, about 8.9°, about 10.0°, about 11.0°, about 12.7° and about 13.1° 2θ.
[0393] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.4°, about 16.2°, about 16.4°, about 17.2°, about 17.6°, about 18.3°, about 19.1°, about 21.2°, about 21.8°, about 22.1°, about 22.3°, about 22.6°, about 22.9°, about 23.4°, about 24.2°, about 24.5° and about 24.8° 2θ.
[0394] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.8°, about 26.3°, about 26.5°, about 27.0°, about 27.6°, about 27.7°, about 28.6°, about 29.8°, about 30.2°, about 31.0°, about 32.2°, about 32.5°, about 33.3° and about 34.9° 2θ.
[0395] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 35.8°, about 36.5°, about 37.1°, about 37.9°, about 38.8° and about 39.5° 2θ.
[0396] In certain embodiments, Form A of the succinate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.6°, about 7.6°, about 8.9°, about 10.0°, about 11.0°, about 12.7°, about 13.1°, about 15.4°, about 16.2°, about 16.4°, about 17.2°, Petition 870260106343, dated 10 / 15 / 2026, p. 71 / 289 66 / 280 about about 17, 21, 6 8°, °, about about 18.3°, , about about 19.1° 22.3°, about 24.5°, about 24.8°, about 25.8°, about 26.3°, about 26.5°, about 27.0°, about 27.6°, about 27.7°, about 28.6°, about 29.8°, about 30.2° , about 31.0° , approximately 32.2°, approximately 32.5°, approximately 33.3°, approximately 34.9°, approximately 35.8°, approximately 36.5°, approximately 39.5°, approximately 2°, approximately 37.1°, approximately 37.9°, approximately 38.8° A of succinate salt
[0397] In certain embodiments, the Formula compound of formula (I) has an XRPD pattern comprising peaks at about 5.6°, about 7.6°, about 8.9°, about 10.0°, approximately 15.4°, approximately 17.6°, approximately 21.8°, approximately 22.9°, approximately 24.8°, approximately 27.0°, approximately 29.8°, approximately 32.5°, approximately 36.5°, approximately 11.0°, approximately 16.2°, approximately 18.3°, approximately 22.1°, approximately 23.4°, approximately 25.8°, approximately 27.6°, approximately 30.2°, approximately 33.3°, approximately 37.1°, approximately 12.7°, approximately 16.4°, approximately 19.1°, circa 22.3°, approximately 24.2°, approximately 26.3°, approximately 27.7°, approximately 31.0°, approximately 34.9°, approximately 37.9°, approximately 13.1°, circa 17.2°, approximately 21.2°, approximately 22.6°, approximately 24.5°, approximately 26.5°, approximately 28.6°, approximately 32.2°, approximately 35.8°, approximately ,8° and approximately 39.5° 2θ.
[0398] In certain embodiments, Form A of the succinate salt of the compound of formula (I) has an XRPD pattern comprising a peak at 7.6° ± 0.3° 2θ.
[0399] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 5.6° ± 0.3°, 8.9° ± 0.3°, 10.0° ± 0.3°, 11.0° ± 0.3°, 12.7° ± 0.3° and 13.1° ± 0.3° 2θ.
[0400] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.4° ± 0.3°, 16.2° ± 0.3°, 16.4° ± 0.3°, 17.2° ± 0.3°, 17.6° ± 0.3°, 18.3° ± 0.3°, 19.1° ± 0.3°, 21.2° ± 0.3°, 21.8° ± 0.3°, 22.1° ± 0.3°, 22.3° ± 0.3°, Petition 870260106343, dated 10 / 15 / 2026, page 72 / 289 67 / 280 22.6° ± 0.3°, 22.9° ± 0.3°, 23.4° ± 0.3°, 24.2° ± 0.3°, 24.5° ± 0.3° and 24.8° ± 0.3° 2θ.
[0401] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.8° ± 0.3°, 26.3° ± 0.3°, 26.5° ± 0.3°, 27.0° ± 0.3°, 27.6° ± 0.3°, 27.7° ± 0.3°, 28.6° ± 0.3°, 29.8° ± 0.3°, 30.2° ± 0.3°, 31.0° ± 0.3°, 32.2° ± 0.3°, 32.5° ± 0.3°, 33.3° ± 0.3° and 34.9° ± 0.3° 2θ.
[0402] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 35.8° ± 0.3°, 36.5°, 37.1° ± 0.3°, 37.9° ± 0.3°, 38.8° ± 0.3° and 39.5° ± 0.3°. 2θ.
[0403] In certain embodiments, Form A of the succinate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.6° ± 0.3°, 7.6° ± 0.3°, 8.9° ± 0.3°, 10.0° ± 0.3°, 11.0° ± 0.3°, 12.7° ± 0.3°, 13.1° ± 0.3°, 15.4° ± 0.3°, 16.2° ± 0.3°, 16.4° ± 0.3°, 17.2° ± 0.3°, 17.6° ± 0.3°, 18.3° ± 0.3°, 19.1° ± 0.3°, 21.2° ± 0.3°, 21.8° ± 0.3°, 22.1° ± 0.3°, 22.3° ± 0.3°, 22.6° ± 0.3°, 22.9° ± 0.3°, 23.4° ± 0.3°, 24.2° ± 0.3°, 24.5° ± 0.3°, 24.8° ± 0.3°, 25.8° ± 0.3°, 26.3° ± 0.3°, 26.5° ± 0.3°, 27.0° ± 0.3°, 27.6° ± 0.3°, 27.7° ± 0.3°, 28.6° ± 0.3°, 29.8° ± 0.3°, 30.2° ± 0.3°, 31.0° ± 0.3°, 32.2° ± 0.3°, 32.5° ± 0.3°, 33.3° ± 0.3°, 34.9° ± 0.3°, 35.8° ± 0.3°, 36.5° ± 0.3°, 37.1° ± 0.3°, 37.9° ± 0.3°, 38.8° ± 0.3° and 39.5° ± 0.3° 2θ.
[0404] In certain embodiments, Form A of the succinate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.6° ± 0.3°, 7.6° ± 0.3°, 8.9° ± 0.3°, 10.0° ± 0.3°, 11.0° ± 0.3°, 12.7° ± 0.3°, 13.1° ± 0.3°, 15.4° ± 0.3°, 16.2° ± 0.3°, 16.4° ± 0.3°, 17.2° ± 0.3°, 17.6° ± 0.3°, 18.3° ± 0.3°, 19.1° ± 0.3°, 21.2° ± 0.3°, 21.8° ± 0.3°, 22.1° ± 0.3°, 22.3° ± 0.3°, 22.6° ± 0.3°, 22.9° ± 0.3°, 23.4° ± 0.3°, 24.2° ± 0.3°, 24.5° ± 0.3°, 24.8° ± 0.3°, 25.8° ± 0.3°, 26.3° ± 0.3°, 26.5° ± 0.3°, 27.0° ± 0.3°, 27.6° ± 0.3°, 27.7° ± 0.3°, 28.6° ± 0.3°, 29.8° ± 0.3°, 30.2° ± 0.3°, 31.0° ± 0.3°, 32.2° ± 0.3°, 32.5° ± Petition 870260106343, dated 10 / 15 / 2026, page 73 / 289 68 / 280 0.3°, 33.3° ± 0.3°, 34.9° ± 0.3°, 35.8° ± 0.3°, 36.5° ± 0.3°, 37.1° ± 0.3°, 37.9° ± 0.3°, 38.8° ± 0.3° and 39.5° ± 0.3°2θ.
[0405] In certain embodiments, Form A of the succinate salt of the compound of formula (I) has an XRPD pattern comprising a peak at 7.6° ± 0.2°2θ.
[0406] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 5.6° ± 0.2°, 8.9° ±0.2°, 10.0° ± 0.2°, 11.0° ± 0.2°, 12.7° ± 0.2° and 13.1° ± 0.2°2θ.
[0407] In certain forms, the XRPD standard comprises 15.4° ± 0.2°, 16.2° ± 0.2°, 0.2°, 18.3° ± 0.2°, 19.1° ± 22.1° ± 0.2°, 22.3° ± 0.2°, 0.2°, 24.2° ± 0.2°, 24.5° ± additionally one or more peaks at 16.4° ± 0.2°, 17.2° ± 0.2°, 17.6° ± 0.2°, 21.2° ± 0.2°, 21.8° ± 0.2°, 22.6° ± 0.2°, 22.9° ± 0.2°, 23.4° ± 0.2° and 24.8° ± 0.2°2θ.
[0408] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.8° ± 0.2°, 26.3° ± 0.2°, 26.5° ± 0.2°, 27.0° ± 0.2°, 27.6° ± 0.2°, 27.7° ± 0.2°, 28.6° ± 0.2°, 29.8° ± 0.2°, 30.2° ± 0.2°, 31.0° ± 0.2°, 32.2° ± 0.2°, 32.5° ± 0.2°, 33.3° ± 0.2° and 34.9° ± 0.2° 2θ.
[0409] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 35.8° ± 0.2°, 36.5° ± 0.2°, 37.1° ± 0.2°, 37.9° ± 0.2°, 38.8° ± 0.2° and 39.5° ± 0.2°. 2θ.
[0410] In certain embodiments, Form A of the succinate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.6° ± 0.2°, 7.6° ± 0.2°, 8.9° ± 0.2°, 10.0° ± 0.2°, 11.0° ± 0.2°, 12.7° ± 0.2°, 13.1° ± 0.2°, 15.4° ± 0.2°, 16.2° ± 0.2°, 16.4° ± 0.2°, 17.2° ± 0.2°, 17.6° ± 0.2°, 18.3° ± 0.2°, 19.1° ± 0.2°, 21.2° ± 0.2°, 21.8° ± 0.2°, 22.1° ± 0.2°, 22.3° ± 0.2°, 22.6° ± 0.2°, 22.9° ± 0.2°, 23.4° ± 0.2°, 24.2° ± 0.2°, 24.5° ± 0.2°, 24.8° ± 0.2°, 25.8° ± 0.2°, 26.3° ± 0.2°, 26.5° ± 0.2°, 27.0° ± 0.2°, 27.6° ± 0.2°, 27.7° ± 0.2°, 28.6° ± 0.2°, 29.8° ± 0.2°, 30.2° ± 0.2°, 31.0° ± 0.2°, 32.2° ± 0.2°, 32.5° ± 0.2°, 33.3° ± 0.2°, 34.9° ± 0.2°, 35.8° ± 0.2°, 36.5° ± Petition 870260106343, dated 10 / 15 / 2026, p. 74 / 289 69 / 280 0.2°, 37.1° ± 0.2°, 37.9° ± 0.2°, 38.8° ± 0.2° and 39.5° ± 0.2° 2θ.
[0411] In certain embodiments, Form A of the succinate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.6° ± 0.2°, 7.6° ± 0.2°, 8.9° ± 0.2°, 10.0° ± 0.2°, 11.0° ± 0.2°, 12.7° ± 0.2°, 13.1° ± 0.2°, 15.4° ± 0.2°, 16.2° ± 0.2°, 16.4° ± 0.2°, 17.2° ± 0.2°, 17.6° ± 0.2°, 18.3° ± 0.2°, 19.1° ± 0.2°, 21.2° ± 0.2°, 21.8° ± 0.2°, 22.1° ± 0.2°, 22.3° ± 0.2°, 22.6° ± 0.2°, 22.9° ± 0.2°, 23.4° ± 0.2°, 24.2° ± 0.2°, 24.5° ± 0.2°, 24.8° ± 0.2°, 25.8° ± 0.2°, 26.3° ± 0.2°, 26.5° ± 0.2°, 27.0° ± 0.2°, 27.6° ± 0.2°, 27.7° ± 0.2°, 28.6° ± 0.2°, 29.8° ± 0.2°, 30.2° ± 0.2°, 31.0° ± 0.2°, 32.2° ± 0.2°, 32.5° ± 0.2°, 33.3° ± 0.2°, 34.9° ± 0.2°, 35.8° ± 0.2°, 36.5° ± 0.2°, 37.1° ± 0.2°, 37.9° ± 0.2°, 38.8° ± 0.2° and 39.5° ± 0.2° 2θ.
[0412] In certain embodiments, Form A of the succinate salt of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 22. In certain embodiments, Form A of the succinate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 29.
[0413] In certain embodiments, Form A of the succinate salt of compound formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak beginning at about 87°C. In certain embodiments, Form A of the succinate salt of compound formula (I) has a DSC thermogram substantially the same as that shown in Figure 23.
[0414] In certain embodiments, Form A of the succinate salt of the compound of formula (I) exhibits a weight loss of less than or equal to about 0.8% by weight when heated to Form A from about 25°C to about 80°C. The weight loss exhibited by a crystalline form (e.g., Form A of the succinate salt of the compound of formula (I)) can be determined, for example, Petition 870260106343, dated 10 / 15 / 2026, p. 75 / 289 70 / 280 using thermogravimetric analysis (TGA). In certain embodiments, Form A of the succinate salt of the compound of formula (I) has a TGA thermogram substantially the same as that shown in Figure 23. (5) Camsilate Salt Form
[0415] In one aspect, a crystalline camsylate salt of the compound of formula (I) is provided here H2N N 'HOH (I).
[0416] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at about 5.2° 2θ. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at about 13.2° 2θ. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at about 14.7° 2θ. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at about 5.2°, about 13.2° and about 14.7° 2θ.
[0417] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.7°, about 17.8°, about 18.2°, about 19.3° and about 21.8° 2θ.
[0418] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.2°, about 13.2°, about 14.7°, about 15.7°, about 17.8°, about 18.2°, about 19.3° and about 21.8° 2θ.
[0419] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising peaks at about 5.2°, about 13.2°, about 14.7°, about Petition 870260106343, dated 10 / 15 / 2026, p. 76 / 289 71 / 280 15.7°, approximately 17.8°, approximately 18.2°, approximately 19.3°, and approximately 21.8° 2θ.
[0420] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.2°, about 13.2° and about 14.7° 2θ.
[0421] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 6.9°, about 8.5°, about 8.9°, about 10.5°, about 10.8°, about 12.3°, about 12.6°, about 13.4°, about 14.0°, about 14.1° and about 14.7° 2θ.
[0422] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 17.8°, about 18.2°, about 21.8° and about 21.9° 2θ.
[0423] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.1°, about 15.7°, about 17.0°, about 17.2°, about 17.6°, about 18.1°, about 19.3°, about 19.8°, about 20.2°, about 20.6°, about 20.9°, about 21.1°, about 21.6°, about 22.5°, about 22.9°, about 23.9° and about 24.9° 2θ.
[0424] In certain modes, the XRPD pattern additionally comprises peaks at about 25.4°, about 25.6° and about 25.9° 2θ.
[0425] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 26.3°, about 26.6°, about 27.1°, about 27.5°, about 28.5°, about 28.9°, about 29.4° and about 30.1° 2θ.
[0426] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.2°, about 6.9°, about 8.5°, about 8.9°, about 10.5°, about 10.8°, about 12.3°, about 12.6°, about 13.2°, about 13.4°, about 14.0°, about 14.1°, about 14.7°, about 15.1°, about 15.7°, Petition 870260106343, dated 10 / 15 / 2026, page 77 / 289 72 / 280 about 17.0°, about 17.2°, about 17.6°, about 17.8° about 18.1°, about 18.2°, about 19.3°, about 19.8° about 20.2°, about 20.6°, about 20.9°, about 21.1° about 21.6°, about 21.8°, about 22.5°, about 22.9° about 23.9°, about 24.9°, about 25.4°, about 25.6° about 25.9°, about 26.3°, about 26.6°, about 27.1° about 27.5°, about 28.5°, about of 28.9°, approximately 29.4 and approximately 30.1° 2θ.
[0427] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising peaks at about 5.2°, about 6.9°, about 8.5°, about 8.9°, approximately 12.6°, approximately 14.1°, circa 17.0°, approximately 18.1°, circa 20.2°, approximately 21.6°, approximately 23.9°, approximately 25.9°, approximately 27.5°, approximately 10.5°, approximately 13.2°, approximately 14.7°, approximately 17.2°, approximately 18.2°, approximately 20.6°, approximately 21.8°, approximately 24.9°, approximately 26.3°, approximately 28.5°, approximately 10.8°, approximately 13.4°, approximately 15.1°, approximately 17.6°, approximately 19.3°, approximately 20.9°, approximately 22.5°, approximately 25.4°, approximately 26.6°, approximately 28.9°, approximately 12.3°, approximately 14.0°, approximately 15.7°, approximately 17.8°, approximately 19.8°, approximately 21.1°, approximately 22.9°, approximately 25.6°, approximately 27.1°, approximately 29.4° and approximately 30.1° 2θ.
[0428] In certain embodiments, the crystalline camsylate salt of the compound peaks at about 8.9°, about 12.6°, approximately 14.1°, circa 17.0°, approximately 18.1°, circa 20.2°, approximately 21.6°, approximately 23.9°, about formula (I) has an XRPD pattern comprising 5.2°, about 6.9°, about 8.5°, about 10.5°, about 10.8°, about 12.3°, about 13.2°, about 13.4°, about 14.0°, about 14.7°, approximately 17.2°, approximately 18.2°, approximately 20.6°, approximately 21.8°, approximately 24.9°, approximately 15.1°, approximately 17.6°, approximately 19.3°, approximately 20.9°, approximately 22.5°, approximately 25.4°, approximately 15.7°, approximately 17.8°, approximately 19.8°, approximately 21.1°, approximately 22.9°, approximately 25.6°, approximately Petition 870260106343, dated 10 / 15 / 2026, page 78 / 289 73 / 280 25.9°, about 26.3°, about 26.6°, about 27.1°, about 27.5°, about 28.5°, about 28.9°, about 29.4° and about 30.1° 2Θ may be referred to herein as “Form A of crystalline camsylate salt.
[0429] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 5.2° ± 0.3° 2θ. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 13.2° ± 0.3° 2θ. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 14.7° ± 0.3° 2θ. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at 5.2° ± 0.3°, 13.2° ± 0.3° and 14.7° ± 0.3° 2θ.
[0430] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.7° ± 0.3°, 17.8° ± 0.3°, 18.2° ± 0.3°, 19.3° ± 0.3° and 21.8° ± 0.3° 2θ.
[0431] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.2° ± 0.3°, 13.2° ± 0.3°, 14.7° ± 0.3°, 15.7° ± 0.3°, 17.8° ± 0.3°, 18.2° ± 0.3°, 19.3° ± 0.3° and 21.8° ± 0.3° 2θ.
[0432] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.2° ± 0.3°, 13.2° ± 0.3° and 14.7° ± 0.3° 2θ.
[0433] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 6.9° ± 0.3°, 8.5° ± 0.3°, 8.9° ± 0.3°, 10.5° ± 0.3°, 10.8° ± 0.3°, 12.3° ± 0.3°, 12.6° ± 0.3°, 13.4° ± 0.3°, 14.0° ± 0.3°, 14.1° ± 0.3° and 14.7° ± 0.3° 2θ.
[0434] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 17.8° ± 0.3°, 18.2° ± 0.3°, Petition 870260106343, dated 10 / 15 / 2026, page 79 / 289 74 / 280 21.8° ± 0.3° and 21.9° ± 0.3° 2θ.
[0435] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.3°, 15.7° ± 0.3°, 17.0° ± 0.3°, 17.2° ± 0.3°, 17.6° ± 0.3°, 18.1° ± 0.3°, 19.3° ± 0.3°, 19.8° ± 0.3°, 20.2° ± 0.3°, 20.6° ± 0.3°, 20.9° ± 0.3°, 21.1° ± 0.3°, 21.6° ± 0.3°, 22.5° ± 0.3°, 22.9° ± 0.3°, 23.9° ± 0.3° and 24.9° ± 0.3° 2θ.
[0436] In certain modalities, the XRPD pattern additionally comprises peaks at 25.4° ± 0.3°, 25.6° ± 0.3° and 25.9° ± 0.3° 2θ.
[0437] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.3° ± 0.3°, 26.6° ± 0.3°, 27.1° ± 0.3°, 27.5° ± 0.3°, 28.5° ± 0.3°, 28.9° ± 0.3°, 29.4° ± 0.3° and 30.1° ± 0.3° 2θ.
[0438] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.2° ± 0.3°, 6.9° ± 0.3°, 8.5° ± 0.3°, 8.9° ± 0.3°, 10.5° ± 0.3°, 10.8° ± 0.3°, 12.3° ± 0.3°, 12.6° ± 0.3°, 13.2° ± 0.3°, 13.4° ± 0.3°, 14.0° ± 0.3°, 14.1° ± 0.3°, 14.7° ± 0.3°, 15.1° ± 0.3°, 15.7° ± 0.3°, 17.0° ± 0.3°, 17.2° ± 0.3°, 17.6° ± 0.3°, 17.8° ± 0.3°, 18.1° ± 0.3°, 18.2° ± 0.3°, 19.3° ± 0.3°, 19.8° ± 0.3°, 20.2° ± 0.3°, 20.6° ± 0.3°, 20.9° ± 0.3°, 21.1° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 22.5° ± 0.3°, 22.9° ± 0.3°, 23.9° ± 0.3°, 24.9° ± 0.3°, 25.4° ± 0.3°, 25.6° ± 0.3°, 25.9° ± 0.3°, 26.3° ± 0.3°, 26.6° ± 0.3°, 27.1° ± 0.3°, 27.5° ± 0.3°, 28.5° ± 0.3°, 28.9° ± 0.3°, 29.4° ± 0.3° and 30.1° ± 0.3° 2θ.
[0439] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.2° ± 0.3°, 6.9° ± 0.3°, 8.5° ± 0.3°, 8.9° ± 0.3°, 10.5° ± 0.3°, 10.8° ± 0.3°, 12.3° ± 0.3°, 12.6° ± 0.3°, 13.2° ± 0.3°, 13.4° ± 0.3°, 14.0° ± 0.3°, 14.1° ± 0.3°, 14.7° ± 0.3°, 15.1° ± 0.3°, 15.7° ± 0.3°, 17.0° ± 0.3°, 17.2° ± 0.3°, 17.6° ± Petition 870260106343, dated 10 / 15 / 2026, page 80 / 289 75 / 280 0.3°, 17.8° ± 0.3°, 18.1° ± 0.3°, 18.2° ± 0.3°, 19.3° ± 0.3°, 19.8° ± 0.3°, 20.2° ± 0.3°, 20.6° ± 0.3°, 20.9° ± 0.3°, 21.1° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 22.5° ± 0.3°, 22.9° ± 0.3°, 23.9° ± 0.3°, 24.9° ± 0.3°, 25.4° ± 0.3°, 25.6° ± 0.3°, 25.9° ± 0.3°, 26.3° ± 0.3°, 26.6° ± 0.3°, 27.1° ± 0.3°, 27.5° ± 0.3°, 28.5° ± 0.3°, 28.9° ± 0.3°, 29.4° ± 0.3° and 30.1° ± 0.3° 2θ may be referred to herein as “Form A of the crystalline camsylate salt.
[0440] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 5.2° ± 0.2° 2θ. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 13.2° ± 0.2° 2θ. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 14.7° ± 0.2° 2θ. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at 5.2° ± 0.2°, 13.2° ± 0.2° and 14.7° ± 0.2° 2θ.
[0441] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.7° ± 0.2°, 17.8° ± 0.2°, 18.2° ± 0.2°, 19.3° ± 0.2° and 21.8° ± 0.2° 2θ.
[0442] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.2° ± 0.2°, 13.2° ± 0.2°, 14.7° ± 0.2°, 15.7° ± 0.2°, 17.8° ± 0.2°, 18.2° ± 0.2°, 19.3° ± 0.2° and 21.8° ± 0.2° 2θ.
[0443] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.2° ± 0.2°, 13.2° ± 0.2°, 14.7° ± 0.2°, 15.7° ± 0.2°, 17.8° ± 0.2°, 18.2° ± 0.2°, 19.3° ± 0.2° and 21.8° ± 0.2° 2θ.
[0444] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.2° ± 0.2°, 13.2° ± 0.2° and 14.7° ± 0.2° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 81 / 289 76 / 280
[0445] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 6.9° ± 0.2°, 8.5° ± 0.2°, 8.9° ± 0.2°, 10.5° ± 0.2°, 10.8° ± 0.2°, 12.3° ± 0.2°, 12.6° ± 0.2°, 13.4° ± 0.2°, 14.0° ± 0.2°, 14.1° ± 0.2° and 14.7° ± 0.2° 2θ.
[0446] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 17.8° ± 0.2°, 18.2° ± 0.2°, 21.8° ± 0.2° and 21.9° ± 0.2° 2θ.
[0447] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.2°, 15.7° ± 0.2°, 17.0° ± 0.2°, 17.2° ± 0.2°, 17.6° ± 0.2°, 18.1° ± 0.2°, 19.3° ± 0.2°, 19.8° ± 0.2°, 20.2° ± 0.2°, 20.6° ± 0.2°, 20.9° ± 0.2°, 21.1° ± 0.2°, 21.6° ± 0.2°, 22.5° ± 0.2°, 22.9° ± 0.2°, 23.9° ± 0.2° and 24.9° ± 0.2° 2θ.
[0448] In certain modalities, the XRPD pattern additionally comprises peaks at 25.4° ± 0.2°, 25.6° ± 0.2° and 25.9° ± 0.2° 2θ.
[0449] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.3° ± 0.2°, 26.6° ± 0.2°, 27.1° ± 0.2°, 27.5° ± 0.2°, 28.5° ± 0.2°, 28.9° ± 0.2°, 29.4° ± 0.2° and 30.1° ± 0.2° 2θ.
[0450] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.2° ± 0.2°, 6.9° ± 0.2°, 8.5° ± 0.2°, 8.9° ± 0.2°, 10.5° ± 0.2°, 10.8° ± 0.2°, 12.3° ± 0.2°, 12.6° ± 0.2°, 13.2° ± 0.2°, 13.4° ± 0.2°, 14.0° ± 0.2°, 14.1° ± 0.2°, 14.7° ± 0.2°, 15.1° ± 0.2°, 15.7° ± 0.2°, 17.0° ± 0.2°, 17.2° ± 0.2°, 17.6° ± 0.2°, 17.8° ± 0.2°, 18.1° ± 0.2°, 18.2° ± 0.2°, 19.3° ± 0.2°, 19.8° ± 0.2°, 20.2° ± 0.2°, 20.6° ± 0.2°, 20.9° ± 0.2°, 21.1° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 22.5° ± 0.2°, 22.9° ± 0.2°, 23.9° ± 0.2°, 24.9° ± 0.2°, 25.4° ± 0.2°, 25.6° ± 0.2°, 25.9° ± 0.2°, 26.3° ± 0.2°, 26.6° ± 0.2°, 27.1° ± 0.2°, 27.5° ± 0.2°, 28.5° ± 0.2°, 28.9° ± 0.2°, 29.4° ± 0.2° and 30.1° ± 0.2° Petition 870260106343, dated 10 / 15 / 2026, page 82 / 289 77 / 280 2Θ.
[0451] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 5.2° ± 0.2°, 6.9° ± 0.2°, 8.5° ± 0.2°, 8.9° ± 0.2°, 10.5° ± 0.2°, 10.8° ± 0.2°, 12.3° ± 0.2°, 12.6° ± 0.2°, 13.2° ± 0.2°, 13.4° ± 0.2°, 14.0° ± 0.2°, 14.1° ± 0.2°, 14.7° ± 0.2°, 15.1° ± 0.2°, 15.7° ± 0.2°, 17.0° ± 0.2°, 17.2° ± 0.2°, 17.6° ± 0.2°, 17.8° ± 0.2°, 18.1° ± 0.2°, 18.2° ± 0.2°, 19.3° ± 0.2°, 19.8° ± 0.2°, 20.2° ± 0.2°, 20.6° ± 0.2°, 20.9° ± 0.2°, 21.1° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 22.5° ± 0.2°, 22.9° ± 0.2°, 23.9° ± 0.2°, 24.9° ± 0.2°, 25.4° ± 0.2°, 25.6° ± 0.2°, 25.9° ± 0.2°, 26.3° ± 0.2°, 26.6° ± 0.2°, 27.1° ± 0.2°, 27.5° ± 0.2°, 28.5° ± 0.2°, 28.9° ± 0.2°, 29.4° ± 0.2° and 30.1° ± 0.2° 2Θ may be referred to herein as Form A of the crystalline camsylate salt.
[0452] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) (e.g., Form A of the crystalline camsylate salt) has an XRPD pattern substantially the same as that shown in Figure 58. In certain embodiments, the crystalline camsylate salt of the compound of formula (I) (e.g., Form A of the crystalline camsylate salt) has an XRPD pattern comprising one or more diffraction peaks (2Θ) revealed in Table 47.
[0453] In certain embodiments, Form A of the crystalline camsylate salt of the compound of formula (I) has a DSC thermogram comprising an endotherm with a maximum peak at about 54°C. In certain embodiments, Form A of the crystalline camsylate salt of the compound of formula (I) has a DSC thermogram comprising an endotherm with a maximum peak at about 133°C. In certain embodiments, Form A of the crystalline camsylate salt of the compound of formula (I) has a DSC thermogram comprising an endotherm with a maximum peak at about 174°C. In certain embodiments, Form A of the crystalline camsylate salt of the compound of formula (I) has a DSC thermogram comprising an or Petition 870260106343, dated 10 / 15 / 2026, page 83 / 289 78 / 280 more endotherms with peaks starting at about 54°C, about 133°C and about 174°C. In certain embodiments, Form A of the crystalline camsylate salt of compound formula (I) has a DSC thermogram substantially the same as that shown in Figure 59.
[0454] In certain embodiments, Form A of the crystalline camsylate salt of compound formula (I) exhibits a weight loss of less than or equal to about 2.8% by weight when heated Form A of the crystalline camsylate salt of compound formula (I) from about 36°C to about 189°C. The weight loss exhibited by a crystalline form (e.g., Form A of the crystalline camsylate salt of compound formula (I)) can be determined, for example, using TGA. In certain embodiments, the crystalline camsylate salt of compound formula (I) (e.g., Form A of the crystalline camsylate salt of compound formula (I)) has a TGA thermogram substantially the same as that shown in Figure 60.
[0455] In certain embodiments, Form A of the crystalline camsylate salt of the compound of formula (I) is a crystalline hydrate. (6) Phosphate Salt Forms
[0456] In one aspect, a phosphate salt of a compound of formula (I) is provided here. (I).
[0457] In certain embodiments, the phosphate salt of the compound of formula (I) is a crystalline phosphate salt. In certain embodiments, a material (e.g., a pharmaceutical material) comprising a crystalline phosphate salt of the compound of formula (I) is provided herein. (A) Material A of the Phosphate Salt
[0458] In certain embodiments, the crystalline phosphate salt of Petition 870260106343, dated 10 / 15 / 2026, page 84 / 289 79 / 280 compound of formula (I) exhibits an XRPD pattern comprising a peak at about 3.9° 2Θ. In certain embodiments, the crystalline phosphate salt of compound of formula (I) exhibits an XRPD pattern comprising a peak at about 7.7° 2Θ. In certain embodiments, the crystalline phosphate salt of compound of formula (I) exhibits an XRPD pattern comprising a peak at about 13.7° 2Θ. In certain embodiments, the crystalline phosphate salt of compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at about 3.9°, about 7.7° and about 13.7° 2Θ.
[0459] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks at about 3.9°, about 7.7° and about 13.7° 2θ.
[0460] In certain embodiments, the material comprising a crystalline phosphate salt comprising XRPD peaks at about 3.9°, about 7.7° and about 13.7° 2Θ may be referred to herein as “Phosphate salt Material A.
[0461] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 3.9° 2θ.
[0462] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 5.5°, about 7.0°, about 7.7°, about 13.7° and about 14.0° 2Θ.
[0463] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.0°, about 16.3°, about 17.2° and about 24.2° 2Θ.
[0464] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 3.9°, about 5.5°, about 7.0°, about 7.7°, about 13.7°, about 14.0°, about 16.0°, about 16.3°, about 17.2° and about 24.2° 2θ.
[0465] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks Petition 870260106343, dated 10 / 15 / 2026, page 85 / 289 80 / 280 at approximately 3.9°, approximately 5.5°, approximately 7.0°, approximately 7.7°, approximately 13.7°, approximately 14.0°, approximately 16.0°, approximately 16.3°, approximately 17.2°, and approximately 24.2° 2Θ.
[0466] In certain embodiments, the material comprising a crystalline phosphate salt comprising XRPD peaks at about 3.9°, about 5.5°, about 7.0°, about 7.7°, about 13.7°, about 14.0°, about 16.0°, about 16.3°, about 17.2° and about 24.2° 2Θ may be referred to herein as “Phosphate salt Material A.
[0467] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 3.9° ± 0.3° 2Θ. In certain embodiments, the crystalline phosphate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 7.7° ± 0.3° 2θ. In certain embodiments, the crystalline phosphate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 13.7° ± 0.3° 2θ. In certain embodiments, the crystalline phosphate salt of the compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at 3.9° ± 0.3°, 7.7° ± 0.3° and 13.7° ± 0.3° 2θ.
[0468] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 3.9° ± 0.3°, 7.7° ± 0.3° and 13.7° ± 0.3° 2Θ.
[0469] In certain embodiments, the material comprising a crystalline phosphate salt comprising XRPD peaks at 3.9° ± 0.3°, 7.7° ± 0.3° and 13.7° ± 0.3° 2Θ may be referred to herein as “Phosphate salt Material A.
[0470] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 3.9° ± 0.3° 2Θ.
[0471] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 5.5° ± 0.3°, 7.0° ± 0.3°, 7.7° ± 0.3°, 13.7° ± 0.3° and 14.0° ± 0.3° 2Θ.
[0472] In certain forms, the XRPD standard comprises Petition 870260106343, dated 10 / 15 / 2026, page 86 / 289 81 / 280 additionally one or more peaks at 16.0° ± 0.3°, 16.3° ± 0.3°, 17.2° ± 0.3° and 24.2° ± 0.3° 2Θ.
[0473] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 3.9° ± 0.3°, 5.5° ± 0.3°, 7.0° ± 0.3°, 7.7° ± 0.3°, 13.7° ± 0.3°, 14.0° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 17.2° ± 0.3° and 24.2° ± 0.3° 2Θ.
[0474] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 3.9° ± 0.3°, 5.5° ± 0.3°, 7.0° ± 0.3°, 7.7° ± 0.3°, 13.7° ± 0.3°, 14.0° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 17.2° ± 0.3° and 24.2° ± 0.3° 2θ.
[0475] In certain embodiments, the material comprising a crystalline phosphate salt comprising XRPD peaks at 3.9° ± 0.3°, 5.5° ± 0.3°, 7.0° ± 0.3°, 7.7° ± 0.3°, 13.7° ± 0.3°, 14.0° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 17.2° ± 0.3° and 24.2° ± 0.3° 2Θ can be referred to here as “Material A of the phosphate salt.
[0476] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 3.9° ± 0.2° 2Θ. In certain embodiments, the crystalline phosphate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 7.7° ± 0.2° 2θ. In certain embodiments, the crystalline phosphate salt of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 13.7° ± 0.2° 2θ. In certain embodiments, the crystalline phosphate salt of the compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at 3.9° ± 0.2°, 7.7° ± 0.2° and 13.7° ± 0.2° 2θ.
[0477] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 3.9° ± 0.2°, 7.7° ± 0.2° and 13.7° ± 0.2° 2Θ.
[0478] In certain embodiments, the material comprising a crystalline phosphate salt comprising XRPD peaks at 3.9° ± 0.2°, 7.7° ± 0.2° and 13.7° ± 0.2° 2θ may be referred to here Petition 870260106343, dated 10 / 15 / 2026, page 87 / 289 82 / 280 as "Material A of the phosphate salt".
[0479] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 3.9° ± 0.2° 2θ.
[0480] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 5.5° ± 0.2°, 7.0° ± 0.2°, 7.7° ± 0.2°, 13.7° ± 0.2° and 14.0° ± 0.2° 2θ.
[0481] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.0° ± 0.2°, 16.3° ± 0.2°, 17.2° ± 0.2° and 24.2° ± 0.2° 2θ.
[0482] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 3.9° ± 0.2°, 5.5° ± 0.2°, 7.0° ± 0.2°, 7.7° ± 0.2°, 13.7° ± 0.2°, 14.0° ± 0.2°, 16.0° ± 0.2°, 16.3° ± 0.2°, 17.2° ± 0.2° and 24.2° ± 0.2° 2θ.
[0483] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 3.9° ± 0.2°, 5.5° ± 0.2°, 7.0° ± 0.2°, 7.7° ± 0.2°, 13.7° ± 0.2°, 14.0° ± 0.2°, 16.0° ± 0.2°, 16.3° ± 0.2°, 17.2° ± 0.2° and 24.2° ± 0.2° 2θ.
[0484] In certain embodiments, the material comprising a crystalline phosphate salt comprising XRPD peaks at 3.9° ± 0.2°, 5.5° ± 0.2°, 7.0° ± 0.2°, 7.7° ± 0.2°, 13.7° ± 0.2°, 14.0° ± 0.2°, 16.0° ± 0.2°, 16.3° ± 0.2°, 17.2° ± 0.2° and 24.2° ± 0.2° 2θ may be referred to herein as “Phosphate salt Material A”.
[0485] In certain embodiments, Material A of the phosphate salt of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 61. In certain embodiments, Material A of the phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 48. (B) Phosphate Salt Material B
[0486] In certain embodiments, the crystalline phosphate salt of Petition 870260106343, dated 10 / 15 / 2026, pp. 88 / 289 83 / 280 compound of formula (I) has an XRPD pattern comprising peaks at about 4.1°, about 6.9°, about 10.8° and about 11.4° 2θ.
[0487] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 7.8°, about 8.3°, about 8.5°, about 9.1°, about 9.3°, about 10.6°, about 12.3°, about 13.4° and about 14.6° 2θ.
[0488] In certain embodiments, the XRPD pattern additionally comprises peaks at about 18.0°, about 20.0°, about 21.4° and about 21.7° 2θ.
[0489] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.8°, about 16.2°, about 16.4°, about 16.6°, about 16.7°, about 17.1°, about 18.4°, about 18.8°, about 19.8°, about 20.8°, about 22.0°, about 22.5°, about 22.9°, about 23.2° and about 24.0° 2θ.
[0490] In certain modes, additionally peaks at around 28.0° 2θ.
[0491] In certain modes, in addition to one or more peaks, the XRPD pattern comprises 25.1°, approximately 26.1°, and the XRPD standard comprises approximately 26.7°, approximately 27.3, approximately 28.5 and approximately 28.7 2θ.
[0492] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 4.1°, about 6.9°, about 7.8°, about 8.3°, about 8.5°, about 9.1°, about 9.3°, about 10.6°, about 13.4°, about 16.4°, about 18.0°, about 20.0°, about 22.0°, about 24.0°, about 10.8°, about 14.6°, about 16.6°, about 18.4°, about 20.8°, about 22.5°, about 25.1°, about 11.4°, about 15.8°, about 16.7°, about 18.8°, about 21.4°, about 22.9°, about 26.1°, about 12.3°, about 16.2°, about 17.1°, about 19.8°, about 21.7°, about 23.2°, about 26.7°, about Petition 870260106343, dated 10 / 15 / 2026, page 89 / 289 84 / 280 of 27.3°, approximately 28.0°, approximately 28.5° and approximately 28.7° 2θ.
[0493] In certain embodiments, the crystalline phosphate salt of the formula XRPD comprising peaks (I) has a composite pattern approximately 4.1°, approximately 6.9°, approximately 7.8°, approximately 8.3°, approximately 8.5°, approximately 9.1°, approximately 9.3°, approximately 10.6°, approximately 10.8°, approximately 11.4°, approximately 12.3°, approximately 13.4°, approximately 14.6°, approximately 15.8°, approximately 16.2°, approximately 16.4°, approximately 16.6°, approximately 16.7°, approximately 17.1°, approximately 18.0°, approximately 18.4°, approximately 18.8°, approximately 19.8°, approximately 20.0°, approximately 20.8°, approximately 21.4°, approximately 21.7°, approximately 22.0°, approximately 22.5°, approximately 22.9°, approximately 23.2°, approximately 24.0°, approximately 25.1°, approximately 26.1°, approximately 26.7°, approximately 27.3°, approximately 28.0°, approximately 28.5° and approximately 28.7° 2θ.
[0494] In certain embodiments, the material comprising a crystalline phosphate salt comprising XRPD peaks at about 4.1°, about 6.9°, about 7.8°, about 8.3°, about 8.5°, about 9.1°, about 9.3°, about 10.6°, about 10.8°, about 11.4°, about 12.3°, about 13.4°, about 14.6°, about 15.8°, about 16.2°, about 16.4°, about 16.6°, about 16.7°, about 17.1°, about 18.0°, about 18.4°, about 18.8°, about 19.8°, about 20.0°, about 20.8°, about 21.4°, about 21.7°, about 22.0°, about 22.5°, about 22.9°, about 23.2°, about 24.0°, about 25.1°, about 26.1°, about 26.7°, about 27.3°, about 28.0°, about 28.5° and about 28.7° 2θ can be referred to here. "phosphate salt". such as “Material B of
[0495] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 4.1° ± 0.3°, 6.9° ± 0.3°, 10.8° ± 0.3° and 11.4° ± 0.3° 2θ.
[0496] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.8° ± 0.3°, 8.3° ± 0.3°, 8.5° ± 0.3°, 9.1° ± 0.3°, 9.3° ± 0.3°, 10.6° ± 0.3°, 12.3° ± 0.3°, 13.4° ± 0.3° and 14.6° ± 0.3° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 90 / 289 85 / 280
[0497] In certain embodiments, the XRPD pattern additionally comprises peaks at 18.0° ± 0.3°, 20.0° ± 0.3°, 21.4° ± 0.3° and 21.7° ± 0.3° 2θ.
[0498] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.8° ± 0.3°, 16.2° ± 0.3°, 16.4° ± 0.3°, 16.6° ± 0.3°, 16.7° ± 0.3°, 17.1° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.8° ± 0.3°, 20.8° ± 0.3°, 22.0° ± 0.3°, 22.5° ± 0.3°, 22.9° ± 0.3°, 23.2° ± 0.3° and 24.0° ± 0.3° 2θ.
[0499] In certain embodiments, the XRPD pattern additionally comprises peaks at 25.1° ± 0.3°, 26.1° ± 0.3° and 28.0° ± 0.3° 2θ.
[0500] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.7° ± 0.3°, 27.3° ± 0.3°, 28.5° ± 0.3° and 28.7° ± 0.3° 2θ.
[0501] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.1° ± 0.3°, 6.9° ± 0.3°, 7.8° ± 0.3°, 8.3° ± 0.3°, 8.5° ± 0.3°, 9.1° ± 0.3°, 9.3° ± 0.3°, 10.6° ± 0.3°, 10.8° ± 0.3°, 11.4° ± 0.3°, 12.3° ± 0.3°, 13.4° ± 0.3°, 14.6° ± 0.3°, 15.8° ± 0.3°, 16.2° ± 0.3°, 16.4° ± 0.3°, 16.6° ± 0.3°, 16.7° ± 0.3°, 17.1° ± 0.3°, 18.0° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.8° ± 0.3°, 20.0° ± 0.3°, 20.8° ± 0.3°, 21.4° ± 0.3°, 21.7° ± 0.3°, 22.0° ± 0.3°, 22.5° ± 0.3°, 22.9° ± 0.3°, 23.2° ± 0.3°, 24.0° ± 0.3°, 25.1° ± 0.3°, 26.1° ± 0.3°, 26.7° ± 0.3°, 27.3° ± 0.3°, 28.0° ± 0.3°, 28.5° ± 0.3° and 28.7° ± 0.3° 2θ.
[0502] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 4.1° ± 0.3°, 6.9° ± 0.3°, 7.8° ± 0.3°, 8.3° ± 0.3°, 8.5° ± 0.3°, 9.1° ± 0.3°, 9.3° ± 0.3°, 10.6° ± 0.3°, 10.8° ± 0.3°, 11.4° ± 0.3°, 12.3° ± 0.3°, 13.4° ± 0.3°, 14.6° ± 0.3°, 15.8° ± 0.3°, 16.2° ± 0.3°, 16.4° ± 0.3°, 16.6° ± 0.3°, 16.7° ± 0.3°, 17.1° ± 0.3°, 18.0° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.8° ± 0.3°, 20.0° ± 0.3°, 20.8° ± 0.3°, 21.4° ± 0.3°, 21.7° ± 0.3°, 22.0° ± Petition 870260106343, dated 10 / 15 / 2026, page 91 / 289 86 / 280 0.3°, 22.5° ± 0.3°, 22.9° ± 0.3°, 23.2° ± 0.3°, 24.0° ± 0.3°, 25.1° ± 0.3°, 26.1° ± 0.3°, 26.7° ± 0.3°, 27.3° ± 0.3°, 28.0° ± 0.3°, 28.5° ± 0.3° and 28.7° ± 0.3°2Θ
[0503] In certain embodiments, the material comprising a crystalline phosphate salt comprising XRPD peaks at 4.1°± 0.3°, 6.9° ± 0.3°, 7.8° ± 0.3°, 8.3° ± 0.3°, 8.5° ± 0.3°, 9.1° ± 0.3°, 9.3° ± 0.3°, 10.6° ± 0.3°, 10.8° ± 0.3°, 11.4° ± 0.3°, 12.3° ± 0.3°, 13.4° ± 0.3°, 14.6° ± 0.3°, 15.8° ± 0.3°, 16.2° ± 0.3°, 16.4° ± 0.3°, 16.6° ± 0.3°, 16.7° ± 0.3°, 17.1° ± 0.3°, 18.0° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.8° ± 0.3°, 20.0° ± 0.3°, 20.8° ± 0.3°, 21.4° ± 0.3°, 21.7° ± 0.3°, 22.0° ± 0.3°, 22.5° ± 0.3°, 22.9° ± 0.3°, 23.2° ± 0.3°, 24.0° ± 0.3°, 25.1° ± 0.3°, 26.1° ± 0.3°, 26.7° ± 0.3°, 27.3° ± 0.3°, 28.0° ± 0.3°, 28.5° ± 0.3° and 28.7° ± 0.3° 2Θ can be referred to here as “Material B of the phosphate salt”.
[0504] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 4.1° ± 0.2°, 6.9° ± 0.2°, 10.8° ± 0.2° and 11.4° ± 0.2°2θ.
[0505] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.8° ± 0.2°, 8.3° ±0.2°, 8.5° ± 0.2°, 9.1° ± 0.2°, 9.3° ± 0.2°, 10.6° ± 0.2°, 12.3° ± 0.2°, 13.4° ± 0.2° and 14.6° ± 0.2°2θ.
[0506] In certain embodiments, the XRPD pattern additionally comprises peaks at 18.0° ± 0.2°, 20.0° ± 0.2°, 21.4° ± 0.2° and 21.7° ± 0.2°2θ.
[0507] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.8° ± 0.2°, 16.2° ±0.2°, 16.4° ± 0.2°, 16.6° ± 0.2°, 16.7° ± 0.2°, 17.1° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.8° ± 0.2°, 20.8° ± 0.2°, 22.0° ± 0.2°, 22.5° ± 0.2°, 22.9° ± 0.2°, 23.2° ± 0.2° and 24.0° ± 0.2°2θ.
[0508] In certain modalities, the XRPD pattern additionally comprises peaks at 25.1° ± 0.2°, 26.1° ± 0.2° and 28.0° ± 0.2°2θ. Petition 870260106343, dated 10 / 15 / 2026, page 92 / 289 87 / 280
[0509] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.7° ± 0.2°, 27.3° ± 0.2°, 28.5° ± 0.2° and 28.7° ± 0.2° 2θ.
[0510] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.1° ± 0.2°, 6.9° ± 0.2°, 7.8° ± 0.2°, 8.3° ± 0.2°, 8.5° ± 0.2°, 9.1° ± 0.2°, 9.3° ± 0.2°, 10.6° ± 0.2°, 10.8° ± 0.2°, 11.4° ± 0.2°, 12.3° ± 0.2°, 13.4° ± 0.2°, 14.6° ± 0.2°, 15.8° ± 0.2°, 16.2° ± 0.2°, 16.4° ± 0.2°, 16.6° ± 0.2°, 16.7° ± 0.2°, 17.1° ± 0.2°, 18.0° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.8° ± 0.2°, 20.0° ± 0.2°, 20.8° ± 0.2°, 21.4° ± 0.2°, 21.7° ± 0.2°, 22.0° ± 0.2°, 22.5° ± 0.2°, 22.9° ± 0.2°, 23.2° ± 0.2°, 24.0° ± 0.2°, 25.1° ± 0.2°, 26.1° ± 0.2°, 26.7° ± 0.2°, 27.3° ± 0.2°, 28.0° ± 0.2°, 28.5° ± 0.2° and 28.7° ± 0.2° 2θ.
[0511] In certain embodiments, the crystalline phosphate salt of the compound of formula (I) has an XRPD pattern comprising peaks at 4.1° ± 0.2°, 6.9° ± 0.2°, 7.8° ± 0.2°, 8.3° ± 0.2°, 8.5° ± 0.2°, 9.1° ± 0.2°, 9.3° ± 0.2°, 10.6° ± 0.2°, 10.8° ± 0.2°, 11.4° ± 0.2°, 12.3° ± 0.2°, 13.4° ± 0.2°, 14.6° ± 0.2°, 15.8° ± 0.2°, 16.2° ± 0.2°, 16.4° ± 0.2°, 16.6° ± 0.2°, 16.7° ± 0.2°, 17.1° ± 0.2°, 18.0° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.8° ± 0.2°, 20.0° ± 0.2°, 20.8° ± 0.2°, 21.4° ± 0.2°, 21.7° ± 0.2°, 22.0° ± 0.2°, 22.5° ± 0.2°, 22.9° ± 0.2°, 23.2° ± 0.2°, 24.0° ± 0.2°, 25.1° ± 0.2°, 26.1° ± 0.2°, 26.7° ± 0.2°, 27.3° ± 0.2°, 28.0° ± 0.2°, 28.5° ± 0.2° and 28.7° ± 0.2° 2θ.
[0512] In certain embodiments, the material comprising a crystalline phosphate salt comprising XRPD peaks at 4.1° ± 0.2°, 6.9° ± 0.2°, 7.8° ± 0.2°, 8.3° ± 0.2°, 8.5° ± 0.2°, 9.1° ± 0.2°, 9.3° ± 0.2°, 10.6° ± 0.2°, 10.8° ± 0.2°, 11.4° ± 0.2°, 12.3° ± 0.2°, 13.4° ± 0.2°, 14.6° ± 0.2°, 15.8° ± 0.2°, 16.2° ± 0.2°, 16.4° ± 0.2°, 16.6° ± 0.2°, 16.7° ± 0.2°, 17.1° ± 0.2°, 18.0° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.8° ± 0.2°, 20.0° ± 0.2°, 20.8° ± 0.2°, 21.4° ± 0.2°, 21.7° ± 0.2°, 22.0° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, page 93 / 289 88 / 280 22.5° ± 0.2°, 22.9° ± 0.2°, 23.2° ± 0.2°, 24.0° ± 0.2°, 25.1° ± 0.2°, 26.1° ± 0.2°, 26.7° ± 0.2°, 27.3° ± 0.2°, 28.0° ± 0.2°, 28.5° ± 0.2° and 28.7° ± 0.2° 2Θ can be referred to here as “Material B of the phosphate salt”.
[0513] In certain embodiments, Material B of the phosphate salt of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 62. In certain embodiments, Material B of the phosphate salt of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 49.
[0514] In certain embodiments, Material B of the phosphate salt of the compound of formula (I) has a DSC thermogram comprising an endotherm with a maximum peak at about 54°C. In certain embodiments, Material B of the phosphate salt of the compound of formula (I) has a DSC thermogram comprising an endotherm with a maximum peak at about 90°C. In certain embodiments, the Material B of the phosphate salt of compound formula (I) has a DSC thermogram comprising one or more endotherms with maximum peaks at about 54°C and about 90°C. In certain embodiments, Material B of the phosphate salt of compound formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 176°C. In certain embodiments, Material B of the phosphate salt of compound formula (I) has a DSC thermogram substantially the same as that shown in Figure 63.
[0515] In certain embodiments, Material B of the phosphate salt of compound formula (I) exhibits a weight loss of less than or equal to about 3.3% by weight when heated Material B of the phosphate salt of compound formula (I) from about 36°C to about 149°C. The weight loss exhibited by a crystalline form (e.g., Material B of the phosphate salt of compound formula (I)) can be determined, for example, using TGA. In certain embodiments, Material B of the phosphate salt of compound formula (I) has a TGA thermogram substantially the same Petition 870260106343, dated 10 / 15 / 2026, page 94 / 289 89 / 280 as shown in Figure 64. Crystalline Free Base Forms of a Compound of Formula (I)
[0516] In one aspect, crystalline forms of the compound of formula (I) are given here. H2N N xXxi jjbi 'HOH (I).
[0517] In certain embodiments, the crystalline form of the compound of formula (I) is a free base crystalline form. In certain embodiments, the crystalline form of the compound of formula (I) is an anhydrous crystalline form.
[0518] In certain embodiments, the crystalline form of the compound of formula (I) is Form A of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form B of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form C of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form D of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form E of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form H of the compound of formula (I).
[0519] In certain embodiments, the crystalline form of the compound of formula (I) is a crystalline solvate. In certain embodiments, the crystalline solvate is a crystalline solvate of acetonitrile. In certain embodiments, the crystalline solvate is a crystalline solvate of acetone. In certain embodiments, the crystalline solvate is a crystalline solvate of ethyl acetate.
[0520] In certain embodiments, the crystalline form of the compound of formula (I) is a crystalline hydrate. Crystalline Free Base Forms Petition 870260106343, dated 10 / 15 / 2026, p. 95 / 289 90 / 280 (1) Form A
[0521] In several embodiments, Form A of a compound of formula (I) is given here H2N N IHOH (I).
[0522] In certain embodiments, Form A of the compound of formula (I) shows an X-ray powder diffraction (XRPD) pattern comprising a peak at about 8.1° 2θ. In certain embodiments, Form A of the compound of formula (I) shows an XRPD pattern comprising a peak at about 9.4° 2θ. In certain embodiments, Form A of the compound of formula (I) shows an XRPD pattern comprising a peak at about 9.8° 2θ. In certain embodiments, Form A of the compound of formula (I) shows an XRPD pattern comprising one or more peaks at about 8.1°, about 9.4° and about 9.8° 2θ.
[0523] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.6°, about 16.0°, about 16.3°, about 16.9°, about 17.1°, about 18.4°, about 18.8°, about 20.0°, about 20.1°, about 20.3°, about 20.6°, about 21.4°, about 21.6° and about 24.5° 2θ.
[0524] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 8.1°, about 9.4°, about 9.8°, about 15.6°, about 16.0°, about 16.3°, about 16.9°, about 17.1°, about 18.4°, about 18.8°, about 20.0°, about 20.1°, about 20.3°, about 20.6°, about 21.4°, about 21.6° and about 24.5° 2θ.
[0525] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising peaks at about 8.1°, about 9.4°, about 9.8°, about 15.6°, about 16.0°, Petition 870260106343, dated 10 / 15 / 2026, page 96 / 289 91 / 280 approximately 16.3°, approximately 16.9°, approximately 17.1°, approximately 18.4°, approximately 18.8°, approximately 20.0°, approximately 20.1°, approximately 20.3°, approximately 20.6°, approximately 21.4°, approximately 21.6° and approximately 24.5° 2θ.
[0526] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 8.1° and about 9.4° 2θ.
[0527] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 5.3°, about 6.9°, about 9.8°, about 10.6°, about 10.7°, about 11.9°, about 12.2°, about 12.7°, about 12.9°, about 13.1°, about 13.6°, about 13.9°, about 14.5° and about 14.8° 2θ.
[0528] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.3°, about 17.1°, about 18.8°, about 20.0°, about 20.1°, about 20.6° and about 24.5 2θ.
[0529] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.6°, about 16.0°, about 16.9°, about 17.6°, about 18.4°, about 19.1°, about 19.3°, about 19.6°, about 20.3°, about 20.8°, about 21.0°, about 21.1°, about 21.4°, about 21.6°, about 21.8°, about 22.0°, about 22.3°, about 22.7°, about 22.9°, about 23.3°, about 23.8°, about 24.1° and about 24.9° 2θ.
[0530] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.5°, about 26.1°, about 26.3°, about 26.4°, about 26.9°, about 27.1° and about 29.1° 2θ.
[0531] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at approximately 26.6°, approximately 27.7°, approximately 27.8°, approximately 28.3°, approximately 28.8°, approximately 29.8°, approximately 30.8°, approximately 31.2°, approximately 31.5°, approximately Petition 870260106343, dated 10 / 15 / 2026, page 97 / 289 92 / 280 31.7°, approximately 32.3°, approximately 33.1°, approximately 33.6° and approximately 34.5° 2θ.
[0532] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.3°, about 9.8°, approximately 12.2°, approximately 13.6°, approximately 15.6°, approximately 17.1°, circa 19.1°, circa 20.1°, approximately 21.0°, approximately 21.8°, approximately 22.9°, approximately 24.5°, approximately 26.3°, approximately 27.1°, approximately 28.8°, approximately 31.2°, approximately 33.1°, approximately 6.9°, approximately 10.6°, approximately 12.7°, approximately 13.9°, approximately 16.0°, approximately 17.6°, approximately 19.3°, approximately 20.3°, approximately 21.1°, approximately 22.0°, approximately 23.3°, approximately 24.9°, approximately 26.4°, approximately 27.7°, approximately 29.1°, approximately 31.5°, approximately 33.6° and approximately 8.1°, approximately 10.7°, approximately 12.9°, approximately 14.5°, approximately 16.3°, approximately 18.5°, approximately 19.6°, approximately 20.6°, approximately 21.4°, approximately 22.3°, approximately 23.8°, approximately 25.5°, approximately 26.6°, approximately 27.8°, approximately 29.8°, approximately 31.7°, approximately 34.5°2θ. 9.4°, approximately 11.9°, approximately 13.1°, circa 14.8°, approximately 16.9°, approximately 18.8°, approximately 20.0°, approximately 20.8°, approximately 21.6°, approximately 22.7°, approximately 24.1°, approximately 26.1°, approximately 26.9°, approximately 28.3°, approximately 30.8°, approximately 32.3°, approximately
[0533] In certain embodiments, Form A of the compound with formula (I) has an XRPD pattern comprising peaks at approximately 5.3°, approximately 6.9°, approximately 8.1°, approximately 9.4°, approximately 9.8°, approximately 10.6°, approximately 10.7°, approximately 11.9°, approximately 12.2°, approximately 12.7°, approximately 12.9°, approximately 13.1°, approximately 13.6°, approximately 13.9°, approximately 14.5°, approximately 14.8°, approximately 15.6°, approximately 16.0°, approximately 16.3°, approximately 16.9°, approximately 17.1°, approximately 17.6°, approximately 18.5°, approximately 18.8°, approximately 19.1°, approximately 19.3°, about 19.6°, about 20.0°, about 20.1°, about 20.3°, about 20.6°, about 20.8°, about 21.0°, about 21.1°, about 21.4°, about 21.6°, about 21.8°, about 22.0°, about 22.3°, about 22.7°, about 22.9°, about Petition 870260106343, dated 10 / 15 / 2026, page 98 / 289 93 / 280 of 23.3°, about 23.8°, about 24.1°, about 24.5°, about 24.9°, about 25.5°, about 26.1°, about 26.3°, about 26.4°, about 26.6°, about 26.9°, about 27.1 °, about 27.7°, about 27.8°, about 28.3°, about 28.8°, about 29.1°, about 29.8°, about 30.8°, about 31.2°, about 31.5°, about 31.7°, about 32.3°, about 33, 1st, about 33.6° and approximately 34.5° 2θ.
[0534] In certain embodiments, Form A of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 8.1° ± 0.3° 2θ. In certain embodiments, Form A of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 9.4° ± 0.3° 2θ. In certain embodiments, Form A of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 9.8° ± 0.3° 2θ. In certain embodiments, Form A of the compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at 8.1° ± 0.3°, 9.4° ± 0.3° and 9.8° ± 0.3° 2θ.
[0535] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.1° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 20.0° ± 0.3°, 20.1° ± 0.3°, 20.3° ± 0.3°, 20.6° ± 0.3°, 21.4° ± 0.3°, 21.6° ± 0.3° and 24.5° ± 0.3° 2θ.
[0536] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.1° ± 0.3°, 9.4° ± 0.3°, 9.8° ± 0.3°, 15.6° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.1° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 20.0° ± 0.3°, 20.1° ± 0.3°, 20.3° ± 0.3°, 20.6° ± 0.3°, 21.4° ± 0.3°, 21.6° ± 0.3° and 24.5° ± 0.3° 2θ.
[0537] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising peaks at 8.1° ± 0.3°, 9.4° ± 0.3°, 9.8° ± 0.3°, 15.6° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.1° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 20.0° ± 0.3°, 20.1° ± 0.3°, 20.3° ± 0.3°, 20.6° ± 0.3°, 21.4° ± 0.3°, 21.6° ± 0.3° and 24.5° ± 0.3° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 99 / 289 94 / 280
[0538] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.1° ± 0.3° and 9.4° ± 0.3° 2θ.
[0539] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 5.3° ± 0.3°, 6.9° ± 0.3°, 9.8° ± 0.3°, 10.6° ± 0.3°, 10.7° ± 0.3°, 11.9° ± 0.3°, 12.2° ± 0.3°, 12.7° ± 0.3°, 12.9° ± 0.3°, 13.1° ± 0.3°, 13.6° ± 0.3°, 13.9° ± 0.3°, 14.5° ± 0.3° and 14.8° ± 0.3° 2θ.
[0540] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.3° ± 0.3°, 17.1° ± 0.3°, 18.8° ± 0.3°, 20.0° ± 0.3°, 20.1° ± 0.3°, 20.6° ± 0.3° and 24.5° ± 0.3° 2θ.
[0541] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.3°, 16.0° ±0.3°, 16.9° ± 0.3°, 17.6° ± 0.3°, 18.4° ± 0.3°, 19.1° ± 0.3°, 19.3° ± 0.3°, 19.6° ± 0.3°, 20.3° ± 0.3°, 20.8° ± 0.3°, 21.0° ± 0.3°, 21.1° ± 0.3°, 21.4° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 22.0° ± 0.3°, 22.3° ± 0.3°, 22.7° ± 0.3°, 22.9° ± 0.3°, 23.3° ± 0.3°, 23.8° ± 0.3°, 24.1° ± 0.3° and 24.9° ± 0.3°2θ.
[0542] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.5° ± 0.3°, 26.1° ±0.3°, 26.3° ± 0.3°, 26.4° ± 0.3°, 26.9° ± 0.3°, 27.1° ± 0.3° and 29.1° ± 0.3°2θ.
[0543] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.6° ± 0.3°, 27.7° ± 0.3°, 27.8° ± 0.3°, 28.3° ± 0.3°, 28.8° ± 0.3°, 29.8° ± 0.3°, 30.8° ± 0.3°, 31.2° ± 0.3°, 31.5° ± 0.3°, 31.7° ± 0.3°, 32.3° ± 0.3°, 33.1° ± 0.3°, 33.6° ± 0.3° and 34.5° ± 0.3° 2θ.
[0544] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.3° ± 0.3°, 6.9° ± 0.3°, 8.1° ± 0.3°, 9.4° ± 0.3°, 9.8° ± 0.3°, 10.6° ± 0.3°, 10.7° ± 0.3°, 11.9° ± 0.3°, 12.2° ± 0.3°, 12.7° ± 0.3°, 12.9° ± 0.3°, 13.1° ± 0.3°, 13.6° ± 0.3°, 13.9° ± 0.3°, 14.5° ± Petition 870260106343, dated 10 / 15 / 2026, page 100 / 289 95 / 280 0.3°, 14.8° ± 0.3°, 15.6° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.1° ± 0.3°, 17.6° ± 0.3°, 18.5° ± 0.3°, 18.8° ± 0.3°, 19.1° ± 0.3°, 19.3° ± 0.3°, 19.6° ± 0.3°, 20.0° ± 0.3°, 20.1° ± 0.3°, 20.3° ± 0.3°, 20.6° ± 0.3°, 20.8° ± 0.3°, 21.0° ± 0.3°, 21.1° ± 0.3°, 21.4° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 22.0° ± 0.3°, 22.3° ± 0.3°, 22.7° ± 0.3°, 22.9° ± 0.3°, 23.3° ± 0.3°, 23.8° ± 0.3°, 24.1° ± 0.3°, 24.5° ± 0.3°, 24.9° ± 0.3°, 25.5° ± 0.3°, 26.1° ± 0.3°, 26.3° ± 0.3°, 26.4° ± 0.3°, 26.6° ± 0.3°, 26.9° ± 0.3°, 27.1° ± 0.3°, 27.7° ± 0.3°, 27.8° ± 0.3°, 28.3° ± 0.3°, 28.8° ± 0.3°, 29.1° ± 0.3°, 29.8° ± 0.3°, 30.8° ± 0.3°, 31.2° ± 0.3°, 31.5° ± 0.3°, 31.7° ± 0.3°, 32.3° ± 0.3°, 33.1° ± 0.3°, 33.6° ± 0.3° and 34.5° ± 0.3° 2θ.
[0545] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising peaks at 5.3° ± 0.3°, 6.9° ± 0.3°, 8.1° ± 0.3°, 9.4° ± 0.3°, 9.8° ± 0.3°, 10.6° ± 0.3°, 10.7° ± 0.3°, 11.9° ± 0.3°, 12.2° ± 0.3°, 12.7° ± 0.3°, 12.9° ± 0.3°, 13.1° ± 0.3°, 13.6° ± 0.3°, 13.9° ± 0.3°, 14.5° ± 0.3°, 14.8° ± 0.3°, 15.6° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.1° ± 0.3°, 17.6° ± 0.3°, 18.5° ± 0.3°, 18.8° ± 0.3°, 19.1° ± 0.3°, 19.3° ± 0.3°, 19.6° ± 0.3°, 20.0° ± 0.3°, 20.1° ± 0.3°, 20.3° ± 0.3°, 20.6° ± 0.3°, 20.8° ± 0.3°, 21.0° ± 0.3°, 21.1° ± 0.3°, 21.4° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 22.0° ± 0.3°, 22.3° ± 0.3°, 22.7° ± 0.3°, 22.9° ± 0.3°, 23.3° ± 0.3°, 23.8° ± 0.3°, 24.1° ± 0.3°, 24.5° ± 0.3°, 24.9° ± 0.3°, 25.5° ± 0.3°, 26.1° ± 0.3°, 26.3° ± 0.3°, 26.4° ± 0.3°, 26.6° ± 0.3°, 26.9° ± 0.3°, 27.1° ± 0.3°, 27.7° ± 0.3°, 27.8° ± 0.3°, 28.3° ± 0.3°, 28.8° ± 0.3°, 29.1° ± 0.3°, 29.8° ± 0.3°, 30.8° ± 0.3°, 31.2° ± 0.3°, 31.5° ± 0.3°, 31.7° ± 0.3°, 32.3° ± 0.3°,33.1° ± 0.3°, 33.6° ± 0.3° and 34.5° ± 0.3° 2θ.,
[0546] In certain embodiments, Form A of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 8.1° ± 0.2° 2θ. In certain embodiments, Form A of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 9.4° ± Petition 870260106343, dated 10 / 15 / 2026, page 101 / 289 96 / 280 0.2° 2θ. In certain embodiments, Form A of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 9.8° ± 0.2° 2θ. In certain embodiments, Form A of the compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at 8.1° ± 0.2°, 9.4° ± 0.2° and 9.8° ± 0.2° 2θ.
[0547] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.2°, 16.0° ± 0.2°, 16.3° ± 0.2°, 16.9° ± 0.2°, 17.1° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 20.0° ± 0.2°, 20.1° ± 0.2°, 20.3° ± 0.2°, 20.6° ± 0.2°, 21.4° ± 0.2°, 21.6° ± 0.2° and 24.5° ± 0.2° 2θ.
[0548] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.1° ± 0.2°, 9.4° ± 0.2°, 9.8° ± 0.2°, 15.6° ± 0.2°, 16.0° ± 0.2°, 16.3° ± 0.2°, 16.9° ± 0.2°, 17.1° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 20.0° ± 0.2°, 20.1° ± 0.2°, 20.3° ± 0.2°, 20.6° ± 0.2°, 21.4° ± 0.2°, 21.6° ± 0.2° and 24.5° ± 0.2° 2θ.
[0549] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising peaks at 8.1° ± 0.2°, 9.4° ± 0.2°, 9.8° ± 0.2°, 15.6° ± 0.2°, 16.0° ± 0.2°, 16.3° ± 0.2°, 16.9° ± 0.2°, 17.1° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 20.0° ± 0.2°, 20.1° ± 0.2°, 20.3° ± 0.2°, 20.6° ± 0.2°, 21.4° ± 0.2°, 21.6° ± 0.2° and 24.5° ± 0.2° 2θ.
[0550] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.1° ± 0.2° and 9.4° ± 0.2° 2θ.
[0551] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 5.3° ± 0.2°, 6.9° ± 0.2°, 9.8° ± 0.2°, 10.6° ± 0.2°, 10.7° ± 0.2°, 11.9° ± 0.2°, 12.2° ± 0.2°, 12.7° ± 0.2°, 12.9° ± 0.2°, 13.1° ± 0.2°, 13.6° ± 0.2°, 13.9° ± 0.2°, 14.5° ± 0.2° and 14.8° ± 0.2° 2θ.
[0552] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.3° ± 0.2°, 17.1° ± 0.2°, 18.8° ± 0.2°, 20.0° ± 0.2°, 20.1° ± 0.2°, 20.6° ± 0.2° and 24.5° Petition 870260106343, dated 10 / 15 / 2026, page 102 / 289 97 / 280 ± 0.2° 2θ.
[0553] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.2°, 16.0° ± 0.2°, 16.9° ± 0.2°, 17.6° ± 0.2°, 18.4° ± 0.2°, 19.1° ± 0.2°, 19.3° ± 0.2°, 19.6° ± 0.2°, 20.3° ± 0.2°, 20.8° ± 0.2°, 21.0° ± 0.2°, 21.1° ± 0.2°, 21.4° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 22.0° ± 0.2°, 22.3° ± 0.2°, 22.7° ± 0.2°, 22.9° ± 0.2°, 23.3° ± 0.2°, 23.8° ± 0.2°, 24.1° ± 0.2° and 24.9° ± 0.2° 2θ.
[0554] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.5° ± 0.2°, 26.1° ± 0.2°, 26.3° ± 0.2°, 26.4° ± 0.2°, 26.9° ± 0.2°, 27.1° ± 0.2° and 29.1° ± 0.2° 2θ.
[0555] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.6° ± 0.2°, 27.7° ± 0.2°, 27.8° ± 0.2°, 28.3° ± 0.2°, 28.8° ± 0.2°, 29.8° ± 0.2°, 30.8° ± 0.2°, 31.2° ± 0.2°, 31.5° ± 0.2°, 31.7° ± 0.2°, 32.3° ± 0.2°, 33.1° ± 0.2°, 33.6° ± 0.2° and 34.5° ± 0.2° 2θ.
[0556] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.3° ± 0.2°, 6.9° ± 0.2°, 8.1° ± 0.2°, 9.4° ± 0.2°, 9.8° ± 0.2°, 10.6° ± 0.2°, 10.7° ± 0.2°, 11.9° ± 0.2°, 12.2° ± 0.2°, 12.7° ± 0.2°, 12.9° ± 0.2°, 13.1° ± 0.2°, 13.6° ± 0.2°, 13.9° ± 0.2°, 14.5° ± 0.2°, 14.8° ± 0.2°, 15.6° ± 0.2°, 16.0° ± 0.2°, 16.3° ± 0.2°, 16.9° ± 0.2°, 17.1° ± 0.2°, 17.6° ± 0.2°, 18.5° ± 0.2°, 18.8° ± 0.2°, 19.1° ± 0.2°, 19.3° ± 0.2°, 19.6° ± 0.2°, 20.0° ± 0.2°, 20.1° ± 0.2°, 20.3° ± 0.2°, 20.6° ± 0.2°, 20.8° ± 0.2°, 21.0° ± 0.2°, 21.1° ± 0.2°, 21.4° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 22.0° ± 0.2°, 22.3° ± 0.2°, 22.7° ± 0.2°, 22.9° ± 0.2°, 23.3° ± 0.2°, 23.8° ± 0.2°, 24.1° ± 0.2°, 24.5° ± 0.2°, 24.9° ± 0.2°, 25.5° ± 0.2°, 26.1° ± 0.2°, 26.3° ± 0.2°, 26.4° ± 0.2°, 26.6° ± 0.2°, 26.9° ± 0.2°, 27.1° ± 0.2°, 27.7° ± 0.2°, 27.8° ± 0.2°, 28.3° ± 0.2°, 28.8° ± 0.2°, 29.1° ± 0.2°, 29.8° ± 0.2°, 30.8° ± 0.2°, 31.2° ± 0.2°, 31.5° ± 0.2°, 31.7° ± 0.2°,32.3° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, page 103 / 289 98 / 280 33.1° ± 0.2°, 33.6° ± 0.2° and 34.5° ± 0.2° 2θ.
[0557] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising peaks at 5.3° ± 0.2°, 6.9° ± 0.2°, 8.1° ± 0.2°, 9.4° ± 0.2°, 9.8° ± 0.2°, 10.6° ± 0.2°, 10.7° ± 0.2°, 11.9° ± 0.2°, 12.2° 0.2°, 13.1° ± 0.2°, 13.6° ± 0.2°, 14.8° ± 0.2°, 15.6° ± 0.2°, 16.0° 0.2°, 17.1° ± 0.2°, 17.6° ± 0.2°, 19.1° ± 0.2°, 19.3° ± 0.2°, 19.6° 0.2°, 20.3° ± 0.2°, 20.6° ± 0.2°, 21.1° ± 0.2°, 21.4° ± 0.2°, 21.6° 0.2°, 22.3° ± 0.2°, 22.7° ± 0.2°, 23.8° ± 0.2°, 24.1° ± 0.2°, 24.5° 0.2°, 26.1° ± 0.2°, 26.3° ± 0.2°, 26.9° ± 0.2°, 27.1° ± 0.2°, 27.7° 0.2°, 28.8° ± 0.2°, 29.1° ± 0.2°, 31.2° ± 0.2°, 31.5° ± 0.2°, 31.7° 0.2°, 33.6° ± 0.2° and 34.5° ± 0.2°
[0558] In certain modalities, ± 0.2°, 12.7° ± 0.2°, 12.9°± 13.9° ± 0.2°, 14.5° ± 0.2°, ± 0.2°, 16.3° ± 0.2°, 16.9° ± 18.5° ± 0.2°, 18.8° ± 0.2°, ± 0.2°, 20.0° ± 0.2°, 20.1° ± 20.8° ± 0.2°, 21.0° ± 0.2°, ± 0.2°, 21.8° ± 0.2°, 22.0° ± 22.9° ± 0.2°, 23.3° ± 0.2°, ± 0.2°, 24.9° ± 0.2°, 25.5° ± 26.4° ± 0.2°, 26.6° ± 0.2°, ± 0.2°, 27.8° ± 0.2°, 28.3° ± 29.8° ± 0.2°, 30.8° ± 0.2°, ± 0.2°, 32.3° ± 0.2°, 33.1° ± 2θ. Form A of the compound of formula (I) exists in a triclinic crystal system and has a P1 space group. In certain embodiments, Form A of the compound of formula (I) is characterized by the crystallographic unit cell parameters as set forth below. Table 1. Unit Cell Parameters of Form A of Formula I compound Dimensions of the unit cell a = 10.80853(12) Â α = 79.7155(11)° b = 13.1889(2) Â β = 80.3819(9)° c = 16.99402(19) Â γ = 77.3515(11)° Volume of the unit cell (Â3) 2305.02(5) Cell formula units, Z 4 Calculated density (g^cm-3) 1.310 Petition 870260106343, dated 10 / 15 / 2026, p. 104 / 289 99 / 280
[0559] In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 26A. In certain embodiments, Form A of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 32.
[0560] In certain embodiments, Form A of the compound of formula (I) has a differential scanning calorimetry (DSC) thermogram comprising an endotherm with a peak starting at about 205°C. In certain embodiments, Form A of the compound of formula (I) has a DSC thermogram substantially the same as that shown in Figure 27.
[0561] In certain embodiments, Form A of the compound of formula (I) is an anhydrous crystalline form. (2) Form B
[0562] In several embodiments, Form B of a compound of formula (I) is given here H2N N OH (I) .
[0563] In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 4.0°, about 11.1° and about 12.9° 2θ.
[0564] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 7.9°, about 9.1°, about 10.4° and about 11.9° 2θ.
[0565] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.9°, about 18.8°, about 22.4°, about 23.1° and about 23.8° 2θ.
[0566] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 18.2°, about 18.5°, about 19.4°, about 19.9°, about 20.2°, about 21.4°, about 24.4° and about 24.7° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 105 / 289 100 / 280
[0567] In certain modes, the XRPD pattern additionally comprises one or more peaks at approximately 28.8° and approximately 31.5°2θ.
[0568] In certain modes, additionally one or more peaks of 26.3°, approximately 26.6°, approximately 30.1°, approximately 32.1°, approximately 33.0°, approximately 33.4°, approximately
[0569] In certain embodiments, the XRPD pattern comprises approximately 26.0°, approximately 27.5°, approximately 29.7°, approximately 32.3°, approximately 32.7°, approximately 33.9° and approximately 33.4°2θ. Form B of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 4.0°, about 7.9°, about 9.1°, about 10.4°, about 11.1°, circa 18.2°, approximately 19.9°, approximately 23.1°, approximately 26.0°, approximately 28.8°, approximately 32.1°, approximately 11.9°, approximately 18.5°, approximately 20.2°, approximately 23.8°, approximately 26.3°, approximately 29.7°, approximately 32.3°, approximately 12.9°, approximately 18.8°, approximately 21.4°, approximately 24.4°, approximately 26.6°, approximately 30.1°, approximately 32.7°, approximately 15.9°, approximately 19.4°, approximately 22.4°, approximately 24.7°, approximately 27.5°, approximately 31.5°, approximately 33.0°, approximately 33.4°, approximately 33.9° and approximately 33.4° 2θ.
[0570] In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern comprising peaks at about 4.0°, about 7.9°, about 9.1°, about 10.4°, about 11.1°, about 11.9°, about 12.9°, about 15.9°, about 18.2°, about 18.5°, about 18.8°, about 19.4°, about 19.9°, about 20.2°, about 21.4°, about 22.4°, about 23.1°, about 23.8°, about 24.4°, about 24.7°, about 26.0°, about 26.3°, about 26.6°, about 27.5°, about of 28.8°, about 29.7°, about 30.1°, about 31.5°, about 32.1°, about about 32 33.3°, 9°, about and about 32.7°, 33.4° about 2θ. of 33.0°, about 33.4°,
[0571] In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.0 ± 0.3°, 11.1° ± 0.3° and 12.9° ± 0.3° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 106 / 289 101 / 280
[0572] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.9° ± 0.3°, 9.1° ± 0.3°, 10.4° ± 0.3° and 11.9° ± 0.3° 2θ.
[0573] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.9° ± 0.3°, 18.8° ± 0.3°, 22.4° ± 0.3°, 23.1° ± 0.3° and 23.8° ± 0.3° 2θ.
[0574] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 18.2° ± 0.3°, 18.5° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 21.4° ± 0.3°, 24.4° ± 0.3° and 24.7° ± 0.3° 2θ.
[0575] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 28.8° ± 0.3° and 31.5° ± 0.3° 2θ.
[0576] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.0° ± 0.3°, 26.3° ± 0.3°, 26.6° ± 0.3°, 27.5° ± 0.3°, 29.7° ± 0.3°, 30.1° ± 0.3°, 32.1° ± 0.3°, 32.3° ± 0.3°, 32.7° ± 0.3°, 33.0° ± 0.3°, 33.4° ± 0.3°, 33.9° ± 0.3° and 33.4° ± 0.3° 2θ.
[0577] In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.0° ± 0.3°, 7.9° ± 0.3°, 9.1° ± 0.3°, 10.4° ± 0.3°, 11.1° ± 0.3°, 11.9° ± 0.3°, 12.9° ± 0.3°, 15.9° ± 0.3°, 18.2° ± 0.3°, 18.5° ± 0.3°, 18.8° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 21.4° ± 0.3°, 22.4° ± 0.3°, 23.1° ± 0.3°, 23.8° ± 0.3°, 24.4° ± 0.3°, 24.7° ± 0.3°, 26.0° ± 0.3°, 26.3° ± 0.3°, 26.6° ± 0.3°, 27.5° ± 0.3°, 28.8° ± 0.3°, 29.7° ± 0.3°, 30.1° ± 0.3°, 31.5° ± 0.3°, 32.1° ± 0.3°, 32.3° ± 0.3°, 32.7° ± 0.3°, 33.0° ± 0.3°, 33.4° ± 0.3°, 33.9° ± 0.3° and 33.4° ± 0.3° 2θ.
[0578] In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern comprising peaks at 4.0° ± 0.3°, 7.9° ± 0.3°, 9.1° ± 0.3°, 10.4° ± 0.3°, 11.1° ± 0.3°, 11.9° ± 0.3°, 12.9° ± 0.3°, 15.9° ± 0.3°, 18.2° ± 0.3°, 18.5° ± 0.3°, 18.8° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 21.4° ± Petition 870260106343, dated 10 / 15 / 2026, page 107 / 289 102 / 280 0.3°, 22.4° ± 0.3°, 23.1° ± 0.3°, 23.8° ± 0.3°, 24.4° ± 0.3°, 24.7° ± 0.3°, 26.0° ± 0.3°, 26.3° ± 0.3°, 26.6° ± 0.3°, 27.5° ± 0.3°, 28.8° ± 0.3°, 29.7° ± 0.3°, 30.1° ± 0.3°, 31.5° ± 0.3°, 32.1° ± 0.3°, 32.3° ± 0.3°, 32.7° ± 0.3°, 33.0° ± 0.3°, 33.4° ± 0.3°, 33.9° ± 0.3° and 33.4° ± 0.3° 2θ.
[0579] In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.0° ± 0.2°, 11.1° ± 0.2° and 12.9° ± 0.2° 2θ.
[0580] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.9° ± 0.2°, 9.1° ± 0.2°, 10.4° ± 0.2° and 11.9° ± 0.2° 2θ.
[0581] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.9° ± 0.2°, 18.8° ± 0.2°, 22.4° ± 0.2°, 23.1° ± 0.2° and 23.8° ± 0.2° 2θ.
[0582] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 18.2° ± 0.2°, 18.5° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 21.4° ± 0.2°, 24.4° ± 0.2° and 24.7° ± 0.2° 2θ.
[0583] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 28.8° ± 0.2° and 31.5° ± 0.2° 2θ.
[0584] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.0° ± 0.2°, 26.3° ± 0.2°, 26.6° ± 0.2°, 27.5° ± 0.2°, 29.7° ± 0.2°, 30.1° ± 0.2°, 32.1° ± 0.2°, 32.3° ± 0.2°, 32.7° ± 0.2°, 33.0° ± 0.2°, 33.4° ± 0.2°, 33.9° ± 0.2° and 33.4° ± 0.2° 2θ.
[0585] In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.0° ± 0.2°, 7.9° ± 0.2°, 9.1° ± 0.2°, 10.4° ± 0.2°, 11.1° ± 0.2°, 11.9° ± 0.2°, 12.9° ± 0.2°, 15.9° ± 0.2°, 18.2° ± 0.2°, 18.5° ± 0.2°, 18.8° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 21.4° ± 0.2°, 22.4° ± 0.2°, 23.1° ± 0.2°, 23.8° ± 0.2°, 24.4° ± 0.2°, 24.7° ± 0.2°, 26.0° ± 0.2°, 26.3° ± 0.2°, 26.6° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, page 108 / 289 103 / 280 27.5° ± 0.2°, 28.8° ± 0.2°, 29.7° ± 0.2°, 30.1° ± 0.2°, 31.5° ± 0.2°, 32.1° ± 0.2°, 32.3° ± 0.2°, 32.7° ± 0.2°, 33.0° ± 0.2°, 33.4° ± 0.2°, 33.9° ± 0.2° and 33.4° ± 0.2°2θ.
[0586] In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern comprising peaks at 4.0° ±0.2°, 7.9° ± 0.2°, 9.1° ± 0.2°, 10.4° ± 0.2°, 11.1° ± 0.2°, 11.9° ± 0.2°, 12.9° ± 0.2°, 15.9° ± 0.2°, 18.2° ± 0.2°, 18.5° ± 0.2°, 18.8° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 21.4° ± 0.2°, 22.4° ± 0.2°, 23.1° ± 0.2°, 23.8° ± 0.2°, 24.4° ± 0.2°, 24.7° ± 0.2°, 26.0° ± 0.2°, 26.3° ± 0.2°, 26.6° ± 0.2°, 27.5° ± 0.2°, 28.8° ± 0.2°, 29.7° ± 0.2°, 30.1° ± 0.2°, 31.5° ± 0.2°, 32.1° ± 0.2°, 32.3° ± 0.2°, 32.7° ± 0.2°, 33.0° ± 0.2°, 33.4° ± 0.2°, 33.9° ± 0.2° and 33.4° ± 0.2°2θ.
[0587] In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 30. In certain embodiments, Form B of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 36.
[0588] In certain embodiments, Form B of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 89°C. In certain embodiments, Form B of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 136°C. In certain embodiments, Form B of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 197°C. In certain embodiments, Form B of the compound of formula (I) has a DSC thermogram comprising one or more endotherms with peaks starting at about 89°C, about 136°C, and about 197°C. In certain embodiments, Form B of the compound of formula (I) has a DSC thermogram comprising an exotherm with a peak starting at about 164°C. In certain embodiments, Form B of the compound of formula (I) has a DSC thermogram substantially the same Petition 870260106343, dated 10 / 15 / 2026, p. 109 / 289 104 / 280 as shown in Figure 31.
[0589] In certain embodiments, Form B of the compound of formula (I) exhibits a weight loss of less than or equal to about 0.8% by weight when Form B is heated from about 25°C to about 194°C. The weight loss exhibited by a crystalline form (e.g., Form B of the compound of formula (I)) can be determined, for example, using thermogravimetric analysis (TGA). In certain embodiments, Form B of the compound of formula (I) exhibits a TGA thermogram substantially the same as that shown in Figure 32.
[0590] In certain embodiments, Form B of the compound of formula (I) is an anhydrous crystalline form. (3) Form C
[0591] In several embodiments, Form C of a compound of formula (I) is given here H2N N OH
[0592] In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 6.7° and about 12.0° 2θ.
[0593] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 3.4°, about 9.3°, about 9.6°, about 10.2°, about 11.0°, about 13.1°, about 13.5° and about 14.4° 2θ.
[0594] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 18.9°, about 19.3°, about 22.6°, about 22.8° and about 23.6° 2θ.
[0595] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at approximately 15.7°, approximately 16.9°, approximately 17.1°, approximately 18.4°, approximately 18.7°, approximately 19.1°, approximately 20.1°, approximately 20.4°, approximately 21.6°, approximately Petition 870260106343, dated 10 / 15 / 2026, p. 110 / 289 105 / 280 24.2°, approximately 24.7° and approximately the XRPD standard comprises approximately 25.9° and approximately the XRPD standard comprises approximately 26.2°, approximately 28.5°, about 29.1°, about 30.7° 2θ. Form C of the compound with the formula 22.1°, about 23.2°, about 25.0° 2θ.
[0596] In certain modes, additionally one or more 30.1° 2θ peaks.
[0597] In certain modes, additionally one or more peaks 26.6°, approximately 28.1°, approximately 29.4°, approximately 29.6° and approximately
[0598] In certain embodiments, (I) has an XRPD pattern comprising one or more peaks at about 3.4°, about 6.7°, about 9.3°, about 9.6°, about 10.2°, approximately 13.5°, approximately 17.1°, circa 19.1°, circa 21.6°, approximately 23.2°, approximately 25.0°, approximately 28.1°, approximately 29.6°, approximately 11.0°, approximately 14.4°, approximately 18.4°, approximately 19.3°, approximately 22.1°, approximately 23.6°, approximately 25.9°, approximately 28.5°, approximately 30.1° and about 12.0°, approximately 15.7°, approximately 18.7°, approximately 20.1°, approximately 22.6°, approximately 24.2°, approximately 26.2°, approximately 29.1°, approximately 30.7°2θ. 13.1°, circa 16.9°, approximately 18.9°, approximately 20.4°, approximately 22.8°, approximately 24.7°, approximately 26.6°, approximately 29.4°, approximately
[0599] In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern comprising peaks at about 3.4°, about 6.7°, about 9.3°, about 9.6°, about 10.2 about 11.0°, about 12.0° about 13.1°, about 13.5 about 14.4°, about 15.7° about 16.9°, about 17.1 about 18.4°, about 18.7° about 18, 9°, about 19, 1 about 19.3°, about 20.1° about 20, 4°, about 21, 6 about 22.1°, about 22.6° about 22, 8°, about 23. 7°, about 25, 0 about 25.9°, approximately 26.2°, approximately 26.6°, approximately 28.1°, approximately 28.5°, approximately 29.1°, approximately 29.4°, approximately 29.6°, approximately 30.1°, and approximately 30.7° 2θ. ° ° ° °, °, °, ° ° ° Petition 870260106343, dated 10 / 15 / 2026, page 111 / 289 106 / 280
[0600] In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.7° ± 0.3° and 12.0° ± 0.3° 2θ.
[0601] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 3.4° ± 0.3°, 9.3° ± 0.3°, 9.6° ± 0.3°, 10.2° ± 0.3°, 11.0° ± 0.3°, 13.1° ± 0.3°, 13.5° ± 0.3° and 14.4° ± 0.3° 2θ.
[0602] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 18.9° ± 0.3°, 19.3° ± 0.3°, 22.6° ± 0.3°, 22.8° ± 0.3° and 23.6° ± 0.3° 2θ.
[0603] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.7° ± 0.3°, 16.9° ± 0.3°, 17.1° ± 0.3°, 18.4° ± 0.3°, 18.7° ± 0.3°, 19.1° ± 0.3°, 20.1° ± 0.3°, 20.4° ± 0.3°, 21.6° ± 0.3°, 22.1° ± 0.3°, 23.2° ± 0.3°, 24.2° ± 0.3°, 24.7° ± 0.3° and 25.0° ± 0.3° 2θ.
[0604] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.9° ± 0.3° and 30.1° ± 0.3° 2θ.
[0605] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.2° ± 0.3°, 26.6° ± 0.3°, 28.1° ± 0.3°, 28.5° ± 0.3°, 29.1° ± 0.3°, 29.4° ± 0.3°, 29.6° ± 0.3° and 30.7° ± 0.3° 2θ.
[0606] In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 3.4° ± 0.3°, 6.7° ± 0.3°, 9.3° ± 0.3°, 9.6° ± 0.3°, 10.2° ± 0.3°, 11.0° ± 0.3°, 12.0° ± 0.3°, 13.1° ± 0.3°, 13.5° ± 0.3°, 14.4° ± 0.3°, 15.7° ± 0.3°, 16.9° ± 0.3°, 17.1° ± 0.3°, 18.4° ± 0.3°, 18.7° ± 0.3°, 18.9° ± 0.3°, 19.1° ± 0.3°, 19.3° ± 0.3°, 20.1° ± 0.3°, 20.4° ± 0.3°, 21.6° ± 0.3°, 22.1° ± 0.3°, 22.6° ± 0.3°, 22.8° ± 0.3°, 23.2° ± 0.3°, 23.6° ± 0.3°, 24.2° ± 0.3°, 24.7° ± 0.3°, 25.0° ± 0.3°, 25.9° ± 0.3°, 26.2° ± 0.3°, 26.6° ± 0.3°, 28.1° ± 0.3°, 28.5° ± 0.3°, 29.1° ± 0.3°, 29.4° ± 0.3°, 29.6° ± 0.3°, 30.1° ± 0.3° and 30.7° ± 0.3° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 112 / 289 107 / 280
[0607] In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern comprising peaks at 3.4° ± 0.3°, 6.7° ± 0.3°, 9.3° ± 0.3°, 9.6° ± 0.3°, 10.2° ± 0.3°, 11.0° ± 0.3°, 12.0° ± 0.3°, 13.1° ± 0.3°, 13.5° ± 0.3°, 14.4° ± 0.3°, 15.7° ± 0.3°, 16.9° ± 0.3°, 17.1° ± 0.3°, 18.4° ± 0.3°, 18.7° ± 0.3°, 18.9° ± 0.3°, 19.1° ± 0.3°, 19.3° ± 0.3°, 20.1° ± 0.3°, 20.4° ± 0.3°, 21.6° ± 0.3°, 22.1° ± 0.3°, 22.6° ± 0.3°, 22.8° ± 0.3°, 23.2° ± 0.3°, 23.6° ± 0.3°, 24.2° ± 0.3°, 24.7° ± 0.3°, 25.0° ± 0.3°, 25.9° ± 0.3°, 26.2° ± 0.3°, 26.6° ± 0.3°, 28.1° ± 0.3°, 28.5° ± 0.3°, 29.1° ± 0.3°, 29.4° ± 0.3°, 29.6° ± 0.3°, 30.1° ± 0.3° and 30.7° ± 0.3° 2θ.
[0608] In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.7° ± 0.2° and 12.0° ± 0.2° 2θ.
[0609] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 3.4° ± 0.2°, 9.3° ± 0.2°, 9.6° ± 0.2°, 10.2° ± 0.2°, 11.0° ± 0.2°, 13.1° ± 0.2°, 13.5° ± 0.2° and 14.4° ± 0.2° 2θ.
[0610] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 18.9° ± 0.2°, 19.3° ± 0.2°, 22.6° ± 0.2°, 22.8° ± 0.2° and 23.6° ± 0.2° 2θ.
[0611] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.7° ± 0.2°, 16.9° ± 0.2°, 17.1° ± 0.2°, 18.4° ± 0.2°, 18.7° ± 0.2°, 19.1° ± 0.2°, 20.1° ± 0.2°, 20.4° ± 0.2°, 21.6° ± 0.2°, 22.1° ± 0.2°, 23.2° ± 0.2°, 24.2° ± 0.2°, 24.7° ± 0.2° and 25.0° ± 0.2° 2θ.
[0612] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.9° ± 0.2° and 30.1° ± 0.2° 2θ.
[0613] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.2° ± 0.2°, 26.6° ± 0.2°, 28.1° ± 0.2°, 28.5° ± 0.2°, 29.1° ± 0.2°, 29.4° ± 0.2°, 29.6° ± 0.2° and 30.7° ± 0.2° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 113 / 289 108 / 280
[0614] In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 3.4° ± 0.2°, 6.7° ± 0.2°, 9.3° ± 0.2°, 9.6° ± 0.2°, 10.2° ± 0.2°, 11.0° ± 0.2°, 12.0° ± 0.2°, 13.1° ± 0.2°, 13.5° ± 0.2°, 14.4° ± 0.2°, 15.7° ± 0.2°, 16.9° ± 0.2°, 17.1° ± 0.2°, 18.4° ± 0.2°, 18.7° ± 0.2°, 18.9° ± 0.2°, 19.1° ± 0.2°, 19.3° ± 0.2°, 20.1° ± 0.2°, 20.4° ± 0.2°, 21.6° ± 0.2°, 22.1° ± 0.2°, 22.6° ± 0.2°, 22.8° ± 0.2°, 23.2° ± 0.2°, 23.6° ± 0.2°, 24.2° ± 0.2°, 24.7° ± 0.2°, 25.0° ± 0.2°, 25.9° ± 0.2°, 26.2° ± 0.2°, 26.6° ± 0.2°, 28.1° ± 0.2°, 28.5° ± 0.2°, 29.1° ± 0.2°, 29.4° ± 0.2°, 29.6° ± 0.2°, 30.1° ± 0.2° and 30.7° ± 0.2°2θ.
[0615] In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern comprising peaks at 3.4° ±0.2°, 6.7° ± 0.2°, 9.3° ± 0.2°, 9.6° ± 0.2°, 10.2° ± 0.2°, 11.0° ± 0.2°, 12.0° ± 0.2°, 13.1° ± 0.2°, 13.5° ± 0.2°, 14.4° ± 0.2°, 15.7° ± 0.2°, 16.9° ± 0.2°, 17.1° ± 0.2°, 18.4° ± 0.2°, 18.7° ± 0.2°, 18.9° ± 0.2°, 19.1° ± 0.2°, 19.3° ± 0.2°, 20.1° ± 0.2°, 20.4° ± 0.2°, 21.6° ± 0.2°, 22.1° ± 0.2°, 22.6° ± 0.2°, 22.8° ± 0.2°, 23.2° ± 0.2°, 23.6° ± 0.2°, 24.2° ± 0.2°, 24.7° ± 0.2°, 25.0° ± 0.2°, 25.9° ± 0.2°, 26.2° ± 0.2°, 26.6° ± 0.2°, 28.1° ± 0.2°, 28.5° ± 0.2°, 29.1° ± 0.2°, 29.4° ± 0.2°, 29.6° ± 0.2°, 30.1° ± 0.2° and 30.7° ± 0.2°2θ.
[0616] In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 35. In certain embodiments, Form C of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 38.
[0617] In certain embodiments, Form C of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 91°C. In certain embodiments, Form C of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 132°C. In certain forms, the C form of the compound with the formula Petition 870260106343, dated 10 / 15 / 2026, p. 114 / 289 109 / 280 (I) has a DSC thermogram comprising an endotherm with a peak starting at about 203°C. In certain embodiments, Form C of the compound of formula (I) has a DSC thermogram comprising one or more endotherms with peaks starting at about 91°C, about 132°C, and about 203°C. In certain embodiments, Form C of the compound of formula (I) has a DSC thermogram comprising an endotherm with a maximum peak at about 65°C. In certain embodiments, Form C of the compound of formula (I) has a DSC thermogram comprising an exotherm with a peak starting at about 157°C. In certain embodiments, Form C of the compound of formula (I) has a DSC thermogram substantially the same as shown in Figure 36.
[0618] In certain embodiments, Form C of the compound of formula (I) shows a weight loss of less than or equal to about 2.7% by weight when heated to Form C from about 25°C to about 199°C. The weight loss exhibited by a crystalline form (e.g., Form C of compound formula (I)) can be determined, for example, using TGA. In certain embodiments, Form C of compound formula (I) has a TGA thermogram substantially the same as that shown in Figure 37.
[0619] In certain embodiments, Form C of the compound of formula (I) is a crystalline solvate. In certain embodiments, Form C of the compound of formula (I) is a crystalline acetonitrile solvate. In certain embodiments, Form C of the compound of formula (I) is a crystalline ethyl acetate solvate. (4) Form D
[0620] In several embodiments, Form D of a compound of formula (I) (I) is given here Petition 870260106343, dated 10 / 15 / 2026, p. 115 / 289 110 / 280
[0621] In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 9.2°, about 10.3° and about 10.6° 2θ.
[0622] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 7.4°, about 7.6°, about 11.0°, about 12.0°, about 12.2°, about 12.8°, about 13.0° and about 14.8° 2θ.
[0623] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.4°, about 17.3°, about 21.3° and about 22.6° 2θ.
[0624] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.1°, about 16.0°, about 16.9°, about 17.6°, about 18.1°, about 18.5°, about 19.0°, about 19.5°, about 19.7°, about 20.3°, about 21.8°, about 22.0°, about 22.2°, about 22.9°, about 23.3°, about 23.6°, about 24.0°, about 24.4°, about 24.6° and about 24.9° 2θ.
[0625] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 26.6°, about 27.8°, about 28.7° and about 32.2° 2θ.
[0626] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.1°, about 25.8°, about 26.2°, about 26.7°, about 27.0°, about 27.6°, about 28.2°, about 29.0°, about 29.2°, about 30.2°, about 30.9°, about 31.5° and about 32.6° 2θ.
[0627] In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 7.4°, about 7.6°, about 9.2°, about 10.3°, about 10.6°, about 11.0°, about 12.0°, about 12.2°, about 12.8°, about 13.0°, about 14.8°, about 15.1°, about 16.0°, about 16.4°, about 16.9°, about 17.3°, about 17.6°, about 18.1°, about 18.5°, about 19.0°, about 19.5°, about 19.7°, about 20.3°, about 21.3°, approximately Petition 870260106343, dated 10 / 15 / 2026, page 116 / 289 111 / 280 21.8°, approximately 22.9°, approximately 24.4°, approximately 25.8°, approximately 27.0°, approximately 28.7°, approximately 30.9°, approximately
[0628] In 22.0°, approximately 23.3°, approximately 24.6°, approximately 26.2°, approximately 27.6°, approximately 29.0°, approximately 31.5°, around certain modalities, 22.2°, approximately 23.6°, approximately 24.9°, approximately 26.6°, approximately 27.8°, approximately 29.2°, approximately 32.2° and the Shape 22.6°, approximately 24.0°, approximately 25.1°, approximately 26.7°, approximately 28.2°, approximately 30.2°, approximately 32.6°2θ. about D of the compound of formula (I) has an XRPD pattern comprising peaks at approximately 7.4°, about 7.6°, about 9.2°, about 10.3°, about 10.6°, about 11.0°, about 12.0°, about 12.2°, about 12.8°, about 13.0°, about 14.8°, about 15.1°, about 16.0°, about 16.4°, about 16.9°, about 17.3°, about 17.6°, about 18.1°, about 18.5°, about 19.0°, about 19.5°, about 19.7°, about 20.3°, about 21.3°, about 21.8°, about 22.0°, about 22.2°, approximately 22.6°, approximately 22.9°, approximately 23.3°, approximately 23.6°, approximately 24.0°, approximately 24.4°, approximately 24.6°, approximately 24.9°, approximately 25.1°, approximately 25.8°, approximately 26.2°, approximately 26.6°, approximately 26.7°, approximately 27.0°, approximately 27.6°, approximately 27.8°, approximately 28.2°, approximately 28.7°, approximately 29.0°, approximately 29.2°, approximately 30.2°, approximately 30.9°, approximately 31.5°, approximately 32.2° and approximately 32. ,6° 2θ.
[0629] In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 9.2° ± 0.3°, 10.3° ± 0.3° and 10.6° ± 0.3°2θ.
[0630] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.4° ± 0.3°, 7.6° ±0.3°, 11.0° ± 0.3°, 12.0° ± 0.3°, 12.2° ± 0.3°, 12.8° ± 0.3°, 13.0° ± 0.3° and 14.8° ± 0.3°2θ.
[0631] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.4° ± 0.3°, 17.3° ±0.3°, 21.3° ± 0.3° and 22.6° ± 0.3°2θ.
[0632] In certain forms, the XRPD standard comprises Petition 870260106343, dated 10 / 15 / 2026, page 117 / 289 112 / 280 additionally one or more peaks at 15.1° ± 0.3°, 16.0° ± 0.3°, 16.9° ± 0.3°, 17.6° ± 0.3°, 18.1° ± 0.3°, 18.5° ± 0.3°, 19.0° ± 0.3°, 19.5° ± 0.3°, 19.7° ± 0.3°, 20.3° ± 0.3°, 21.8° ± 0.3°, 22.0° ± 0.3°, 22.2° ± 0.3°, 22.9° ± 0.3°, 23.3° ± 0.3°, 23.6° ± 0.3°, 24.0° ± 0.3°, 24.4° ± 0.3°, 24.6° ± 0.3° and 24.9° ± 0.3° 2θ.
[0633] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.6° ± 0.3°, 27.8° ± 0.3°, 28.7° ± 0.3° and 32.2° ± 0.3° 2θ.
[0634] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.1° ± 0.3°, 25.8° ± 0.3°, 26.2° ± 0.3°, 26.7° ± 0.3°, 27.0° ± 0.3°, 27.6° ± 0.3°, 28.2° ± 0.3°, 29.0° ± 0.3°, 29.2° ± 0.3°, 30.2° ± 0.3°, 30.9° ± 0.3°, 31.5° ± 0.3° and 32.6° ± 0.3° 2θ.
[0635] In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 7.4° ± 0.3°, 7.6° ± 0.3°, 9.2° ± 0.3°, 10.3° ± 0.3°, 10.6° ± 0.3°, 11.0° ± 0.3°, 12.0° ± 0.3°, 12.2° ± 0.3°, 12.8° ± 0.3°, 13.0° ± 0.3°, 14.8° ± 0.3°, 15.1° ± 0.3°, 16.0° ± 0.3°, 16.4° ± 0.3°, 16.9° ± 0.3°, 17.3° ± 0.3°, 17.6° ± 0.3°, 18.1° ± 0.3°, 18.5° ± 0.3°, 19.0° ± 0.3°, 19.5° ± 0.3°, 19.7° ± 0.3°, 20.3° ± 0.3°, 21.3° ± 0.3°, 21.8° ± 0.3°, 22.0° ± 0.3°, 22.2° ± 0.3°, 22.6° ± 0.3°, 22.9° ± 0.3°, 23.3° ± 0.3°, 23.6° ± 0.3°, 24.0° ± 0.3°, 24.4° ± 0.3°, 24.6° ± 0.3°, 24.9° ± 0.3°, 25.1° ± 0.3°, 25.8° ± 0.3°, 26.2° ± 0.3°, 26.6° ± 0.3°, 26.7° ± 0.3°, 27.0° ± 0.3°, 27.6° ± 0.3°, 27.8° ± 0.3°, 28.2° ± 0.3°, 28.7° ± 0.3°, 29.0° ± 0.3°, 29.2° ± 0.3°, 30.2° ± 0.3°, 30.9° ± 0.3°, 31.5° ± 0.3°, 32.2° ± 0.3° and 32.6° ± 0.3° 2θ.
[0636] In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern comprising peaks at 7.4° ± 0.3°, 7.6° ± 0.3°, 9.2° ± 0.3°, 10.3° ± 0.3°, 10.6° ± 0.3°, 11.0° ± 0.3°, 12.0° ± 0.3°, 12.2° ± 0.3°, 12.8° ± 0.3°, 13.0° ± 0.3°, 14.8° ± 0.3°, 15.1° ± 0.3°, 16.0° ± 0.3°, 16.4° ± 0.3°, 16.9° ± Petition 870260106343, dated 10 / 15 / 2026, p. 118 / 289 113 / 280 0.3°, 17.3° ± 0.3°, 17.6° ± 0.3°, 18.1° ± 0.3°, 18.5° ± 0.3°, 19.0° ± 0.3°, 19.5° ± 0.3°, 19.7° ± 0.3°, 20.3° ± 0.3°, 21.3° ± 0.3°, 21.8° ± 0.3°, 22.0° ± 0.3°, 22.2° ± 0.3°, 22.6° ± 0.3°, 22.9° ± 0.3°, 23.3° ± 0.3°, 23.6° ± 0.3°, 24.0° ± 0.3°, 24.4° ± 0.3°, 24.6° ± 0.3°, 24.9° ± 0.3°, 25.1° ± 0.3°, 25.8° ± 0.3°, 26.2° ± 0.3°, 26.6° ± 0.3°, 26.7° ± 0.3°, 27.0° ± 0.3°, 27.6° ± 0.3°, 27.8° ± 0.3°, 28.2° ± 0.3°, 28.7° ± 0.3°, 29.0° ± 0.3°, 29.2° ± 0.3°, 30.2° ± 0.3°, 30.9° ± 0.3°, 31.5° ± 0.3°, 32.2° ± 0.3° and 32.6° ± 0.3° 2θ.
[0637] In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 9.2° ± 0.2°, 10.3° ± 0.2° and 10.6° ± 0.2° 2θ.
[0638] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.4° ± 0.2°, 7.6° ± 0.2°, 11.0° ± 0.2°, 12.0° ± 0.2°, 12.2° ± 0.2°, 12.8° ± 0.2°, 13.0° ± 0.2° and 14.8° ± 0.2° 2θ.
[0639] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.4° ± 0.2°, 17.3° ± 0.2°, 21.3° ± 0.2° and 22.6° ± 0.2° 2θ.
[0640] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.2°, 16.0° ± 0.2°, 16.9° ± 0.2°, 17.6° ± 0.2°, 18.1° ± 0.2°, 18.5° ± 0.2°, 19.0° ± 0.2°, 19.5° ± 0.2°, 19.7° ± 0.2°, 20.3° ± 0.2°, 21.8° ± 0.2°, 22.0° ± 0.2°, 22.2° ± 0.2°, 22.9° ± 0.2°, 23.3° ± 0.2°, 23.6° ± 0.2°, 24.0° ± 0.2°, 24.4° ± 0.2°, 24.6° ± 0.2° and 24.9° ± 0.2° 2θ.
[0641] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.6° ± 0.2°, 27.8° ± 0.2°, 28.7° ± 0.2° and 32.2° ± 0.2° 2θ.
[0642] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.1° ± 0.2°, 25.8° ± 0.2°, 26.2° ± 0.2°, 26.7° ± 0.2°, 27.0° ± 0.2°, 27.6° ± 0.2°, 28.2° ± 0.2°, 29.0° ± 0.2°, 29.2° ± 0.2°, 30.2° ± 0.2°, 30.9° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, page 119 / 289 114 / 280 31.5° ± 0.2° and 32.6° ± 0.2° 2θ.
[0643] In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 7.4° ± 0.2°, 7.6° ± 0.2°, 9.2° ± 0.2°, 10.3° ± 0.2°, 10.6° ± 0.2°, 11.0° ± 0.2°, 12.0° ± 0.2°, 12.2° ± 0.2°, 12.8° ± 0.2°, 13.0° ± 0.2°, 14.8° ± 0.2°, 15.1° ± 0.2°, 16.0° ± 0.2°, 16.4° ± 0.2°, 16.9° ± 0.2°, 17.3° ± 0.2°, 17.6° ± 0.2°, 18.1° ± 0.2°, 18.5° ± 0.2°, 19.0° ± 0.2°, 19.5° ± 0.2°, 19.7° ± 0.2°, 20.3° ± 0.2°, 21.3° ± 0.2°, 21.8° ± 0.2°, 22.0° ± 0.2°, 22.2° ± 0.2°, 22.6° ± 0.2°, 22.9° ± 0.2°, 23.3° ± 0.2°, 23.6° ± 0.2°, 24.0° ± 0.2°, 24.4° ± 0.2°, 24.6° ± 0.2°, 24.9° ± 0.2°, 25.1° ± 0.2°, 25.8° ± 0.2°, 26.2° ± 0.2°, 26.6° ± 0.2°, 26.7° ± 0.2°, 27.0° ± 0.2°, 27.6° ± 0.2°, 27.8° ± 0.2°, 28.2° ± 0.2°, 28.7° ± 0.2°, 29.0° ± 0.2°, 29.2° ± 0.2°, 30.2° ± 0.2°, 30.9° ± 0.2°, 31.5° ± 0.2°, 32.2° ± 0.2° and 32.6° ± 0.2° 2θ.
[0644] In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern comprising peaks at 7.4° ± 0.2°, 7.6° ± 0.2°, 9.2° ± 0.2°, 10.3° ± 0.2°, 10.6° ± 0.2°, 11.0° ± 0.2°, 12.0° ± 0.2°, 12.2° ± 0.2°, 12.8° ± 0.2°, 13.0° ± 0.2°, 14.8° ± 0.2°, 15.1° ± 0.2°, 16.0° ± 0.2°, 16.4° ± 0.2°, 16.9° ± 0.2°, 17.3° ± 0.2°, 17.6° ± 0.2°, 18.1° ± 0.2°, 18.5° ± 0.2°, 19.0° ± 0.2°, 19.5° ± 0.2°, 19.7° ± 0.2°, 20.3° ± 0.2°, 21.3° ± 0.2°, 21.8° ± 0.2°, 22.0° ± 0.2°, 22.2° ± 0.2°, 22.6° ± 0.2°, 22.9° ± 0.2°, 23.3° ± 0.2°, 23.6° ± 0.2°, 24.0° ± 0.2°, 24.4° ± 0.2°, 24.6° ± 0.2°, 24.9° ± 0.2°, 25.1° ± 0.2°, 25.8° ± 0.2°, 26.2° ± 0.2°, 26.6° ± 0.2°, 26.7° ± 0.2°, 27.0° ± 0.2°, 27.6° ± 0.2°, 27.8° ± 0.2°, 28.2° ± 0.2°, 28.7° ± 0.2°, 29.0° ± 0.2°, 29.2° ± 0.2°, 30.2° ± 0.2°, 30.9° ± 0.2°, 31.5° ± 0.2°, 32.2° ± 0.2° and 32.6° ± 0.2° 2θ.
[0645] In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 39. In certain embodiments, Form D of the compound of formula (I) has an XRPD pattern comprising one or more peaks Petition 870260106343, dated 10 / 15 / 2026, pp. 120 / 289 115 / 280 diffraction (2θ) values revealed in Table 40.
[0646] In certain embodiments, Form D of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak maximum at about 66°C. In certain embodiments, Form D of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak maximum at about 138°C. In certain embodiments, Form D of the compound of formula (I) has a DSC thermogram comprising one or more endotherms with peak maximums at about 66°C and about 138°C. In certain embodiments, Form D of the compound of formula (I) has a DSC thermogram comprising an exotherm with a peak maximum at about 157°C. In certain embodiments, Form D of the compound of formula (I) has a DSC thermogram substantially the same as shown in Figure 40.
[0647] In certain embodiments, Form D of the compound of formula (I) shows a weight loss of less than or equal to about 1.0% by weight when heated to Form D from about 25°C to about 108°C. The weight loss exhibited by a crystalline form (e.g., Form D of compound formula (I)) can be determined, for example, using TGA. In certain embodiments, Form D of compound formula (I) has a TGA thermogram substantially the same as that shown in Figure 41.
[0648] In certain embodiments, Form D of the compound of formula (I) is an anhydrous crystalline form.
[0649] In certain embodiments, Form D of the compound of formula (I) exhibits a mass change less than or equal to about 1.9% by weight when the relative humidity varies between about 5% and about 95%, measured at room temperature. The mass change exhibited by a crystalline form (e.g., Form D of the compound of formula (I)) can be determined, for example, using dynamic vapor sorption / desorption (DVS). In certain embodiments, Form D of the compound of formula (I) has a water sorption isotherm substantially equal to that shown in Petition 870260106343, dated 10 / 15 / 2026, pp. 121 / 289 116 / 280 Figure 42. (5) Form E
[0650] In several embodiments, Form E of a compound of formula (I) is given here H2N N XçaA sóf IHOH (I).
[0651] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 6.7°, about 8.5°, about 8.8° and about 10.2° 2θ.
[0652] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 7.2°, about 11.1°, about 11.4°, about 12.2°, about 13.5°, about 14.2° and about 14.5° 2θ.
[0653] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.1°, about 18.5°, about 19.0°, about 21.1°, about 22.8° and about 23.4° 2θ.
[0654] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.1°, about 16.0°, about 16.8°, about 17.0°, about 17.6°, about 17.7°, about 19.2°, about 19.7°, about 20.5°, about 21.0°, about 21.7°, about 22.2°, about 24.1° and about 24.6° 2θ.
[0655] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.7°, about 26.1° and about 27.2° 2θ.
[0656] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.1°, about 26.6°, about 27.7°, about 28.2°, about 29.2°, about 29.5°, about 30.1°, about 30.4°, about 30.9° and about 31.4° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 122 / 289 117 / 280
[0657] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 6.7°, about 7.2°, about 8.5°, about 8.8°, about 10.2°, approximately 13.5°, approximately 16.0°, approximately 17.6°, approximately 19.2°, approximately 21.1°, approximately 23.4°, approximately 25.7°, approximately 27.7°, approximately 30.1°, approximately 11.1°, circa 14.2°, approximately 16.1°, circa 17.7°, approximately 19.7°, approximately 21.7°, approximately 24.1°, approximately 26.1°, approximately 28.2°, approximately 30.4°, approximately 11.4°, approximately 14.5°, approximately 16.8°, approximately 18.5°, approximately 20.5°, approximately 22.2°, approximately 24.6°, approximately 26.6°, approximately 29.2°, approximately 30.9° and about 12.2°, approximately 15.1°, approximately 17.0°, approximately 19.0°, approximately 21.0°, approximately 22.8°, approximately 25.1°, approximately 27.2°, approximately 29.5°, approximately 31.4°2θ.
[0658] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising peaks at about 6.7°, about about 7.2° 11.1°, about about 8.5° 11.4°, about about about 8.8°, about 16.8° about 17.0° about 17.6° about 17.7° about 18.5° about 19.0° about 19.2° about 19.7° about 20.5° about 21.0° about 21.1° about 21.7° about 22.2° about 22.8 ° about 23.4 ° about from 24.1° approximately 24.6° approximately 25.1° approximately 25.7° approximately 26.1° approximately 26.6° approximately 27.2° approximately 27.7° approximately approximately 28.2° 30.4° approximately approximately 29.2° 30.9° approximately and approximately 29.31° 5.4° approximately 2θ. from 30.1°
[0659] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.7° ± 0.3°, 8.5° ± 0.3°, 8.8° ± 0.3° and 10.2° ± 0.3° 2θ.
[0660] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.2° ± 0.3°, 11.1° ± 0.3°, 11.4° ± 0.3°, 12.2° ± 0.3°, 13.5° ± 0.3°, 14.2° ± 0.3° and 14.5° ± 0.3° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 123 / 289 118 / 280
[0661] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.1° ± 0.3°, 18.5° ± 0.3°, 19.0° ± 0.3°, 21.1° ± 0.3°, 22.8° ± 0.3° and 23.4° ± 0.3° 2θ.
[0662] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.3°, 16.0° ± 0.3°, 16.8° ± 0.3°, 17.0° ± 0.3°, 17.6° ± 0.3°, 17.7° ± 0.3°, 19.2° ± 0.3°, 19.7° ± 0.3°, 20.5° ± 0.3°, 21.0° ± 0.3°, 21.7° ± 0.3°, 22.2° ± 0.3°, 24.1° ± 0.3° and 24.6° ± 0.3° 2θ.
[0663] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.7° ± 0.3°, 26.1° ± 0.3° and 27.2° ± 0.3° 2θ.
[0664] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.1° ± 0.3°, 26.6° ± 0.3°, 27.7° ± 0.3°, 28.2° ± 0.3°, 29.2° ± 0.3°, 29.5° ± 0.3°, 30.1° ± 0.3°, 30.4° ± 0.3°, 30.9° ± 0.3° and 31.4° ± 0.3° 2θ.
[0665] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.7° ± 0.3°, 7.2° ± 0.3°, 8.5° ± 0.3°, 8.8° ± 0.3°, 10.2° ± 0.3°, 11.1° ± 0.3°, 11.4° ± 0.3°, 12.2° ± 0.3°, 13.5° ± 0.3°, 14.2° ± 0.3°, 14.5° ± 0.3°, 15.1° ± 0.3°, 16.0° ± 0.3°, 16.1° ± 0.3°, 16.8° ± 0.3°, 17.0° ± 0.3°, 17.6° ± 0.3°, 17.7° ± 0.3°, 18.5° ± 0.3°, 19.0° ± 0.3°, 19.2° ± 0.3°, 19.7° ± 0.3°, 20.5° ± 0.3°, 21.0° ± 0.3°, 21.1° ± 0.3°, 21.7° ± 0.3°, 22.2° ± 0.3°, 22.8° ± 0.3°, 23.4° ± 0.3°, 24.1° ± 0.3°, 24.6° ± 0.3°, 25.1° ± 0.3°, 25.7° ± 0.3°, 26.1° ± 0.3°, 26.6° ± 0.3°, 27.2° ± 0.3°, 27.7° ± 0.3°, 28.2° ± 0.3°, 29.2° ± 0.3°, 29.5° ± 0.3°, 30.1° ± 0.3°, 30.4° ± 0.3°, 30.9° ± 0.3° and 31.4° ± 0.3° 2θ.
[0666] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising peaks at 6.7° ± 0.3°, 7.2° ± 0.3°, 8.5° ± 0.3°, 8.8° ± 0.3°, 10.2° ± 0.3°, 11.1° ± 0.3°, 11.4° ± 0.3°, 12.2° ± 0.3°, 13.5° ± 0.3°, 14.2° ± 0.3°, 14.5° ± 0.3°, 15.1° ± 0.3°, 16.0° ± 0.3°, 16.1° ± 0.3°, 16.8° ± 0.3°, 17.0° ± 0.3°, 17.6° ± 0.3°, 17.7° ± 0.3°, 18.5° ± 0.3°, Petition 870260106343, dated 10 / 15 / 2026, pp. 124 / 289 119 / 280 19.0° ± 0.3°, 19.2° ± 0.3°, 19.7° ± 0.3°, 20.5° ± 0.3°, 21.0° ± 0.3°, 21.1° ± 0.3°, 21.7° ± 0.3°, 22.2° ± 0.3°, 22.8° ± 0.3°, 23.4° ± 0.3°, 24.1° ± 0.3°, 24.6° ± 0.3°, 25.1° ± 0.3°, 25.7° ± 0.3°, 26.1° ± 0.3°, 26.6° ± 0.3°, 27.2° ± 0.3°, 27.7° ± 0.3°, 28.2° ± 0.3°, 29.2° ± 0.3°, 29.5° ± 0.3°, 30.1° ± 0.3°, 30.4° ± 0.3°, 30.9° ± 0.3° and 31.4° ± 0.3° 2θ.
[0667] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.7° ± 0.2°, 8.5° ± 0.2°, 8.8° ± 0.2° and 10.2° ± 0.2° 2θ.
[0668] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 7.2° ± 0.2°, 11.1° ± 0.2°, 11.4° ± 0.2°, 12.2° ± 0.2°, 13.5° ± 0.2°, 14.2° ± 0.2° and 14.5° ± 0.2° 2θ.
[0669] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.1° ± 0.2°, 18.5° ± 0.2°, 19.0° ± 0.2°, 21.1° ± 0.2°, 22.8° ± 0.2° and 23.4° ± 0.2° 2θ.
[0670] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.1° ± 0.2°, 16.0° ± 0.2°, 16.8° ± 0.2°, 17.0° ± 0.2°, 17.6° ± 0.2°, 17.7° ± 0.2°, 19.2° ± 0.2°, 19.7° ± 0.2°, 20.5° ± 0.2°, 21.0° ± 0.2°, 21.7° ± 0.2°, 22.2° ± 0.2°, 24.1° ± 0.2° and 24.6° ± 0.2° 2θ.
[0671] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.7° ± 0.2°, 26.1° ± 0.2° and 27.2° ± 0.2° 2θ.
[0672] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.1° ± 0.2°, 26.6° ± 0.2°, 27.7° ± 0.2°, 28.2° ± 0.2°, 29.2° ± 0.2°, 29.5° ± 0.2°, 30.1° ± 0.2°, 30.4° ± 0.2°, 30.9° ± 0.2° and 31.4° ± 0.2° 2θ.
[0673] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.7° ± 0.2°, 7.2° ± 0.2°, 8.5° ± 0.2°, 8.8° ± 0.2°, 10.2° ± 0.2°, 11.1° ± 0.2°, 11.4° ± 0.2°, 12.2° ± 0.2°, 13.5° ± 0.2°, 14.2° ± 0.2°, 14.5° ± 0.2°, 15.1° ± 0.2°, 16.0° ± 0.2°, 16.1° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, page 125 / 289 120 / 280 16.8° ± 0.2°, 17.0° ± 0.2°, 17.6° ± 0.2°, 17.7° ± 0.2°, 18.5° ± 0.2°, 19.0° ± 0.2°, 19.2° ± 0.2°, 19.7° ± 0.2°, 20.5° ± 0.2°, 21.0° ± 0.2°, 21.1° ± 0.2°, 21.7° ± 0.2°, 22.2° ± 0.2°, 22.8° ± 0.2°, 23.4° ± 0.2°, 24.1° ± 0.2°, 24.6° ± 0.2°, 25.1° ± 0.2°, 25.7° ± 0.2°, 26.1° ± 0.2°, 26.6° ± 0.2°, 27.2° ± 0.2°, 27.7° ± 0.2°, 28.2° ± 0.2°, 29.2° ± 0.2°, 29.5° ± 0.2°, 30.1° ± 0.2°, 30.4° ± 0.2°, 30.9° ± 0.2° and 31.4° ± 0.2° 2θ.
[0674] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising peaks at 6.7° ±0.2°, 7.2° ± 0.2°, 8.5° ± 0.2°, 8.8° ± 0.2°, 10.2° ± 0.2°, 11.4° ± 0.2°, 12.2° ± 0.2°, 13.5° ± 0.2°, 14.5° ± 0.2°, 15.1° ± 0.2°, 16.0° ± 0.2°, 16.1° ± 0.2°, 17.0° ± 0.2°, 17.6° ± 0.2°, 17.7° ± 0.2°, 19.0° ± 0.2°, 19.2° ± 0.2°, 19.7° ± 0.2°, 20.5° ± 0.2°, 21.1° ± 0.2°, 21.7° ± 0.2°, 22.2° ± 0.2°, 23.4° ± 0.2°, 24.1° ± 0.2°, 24.6° ± 0.2°, 25.1° ± 0.2°, 26.1° ± 0.2°, 26.6° ± 0.2°, 27.2° ± 0.2°, 28.2° ± 0.2°, 29.2° ± 0.2°, 29.5° ± 0.2°, 30.1° ± 0.2°, 30.9° ± 0.2° and 31.4° ± 0.2°2θ. 0.2°, 14.2° 0.2°, 18.5° 0.2°, 22.8° 0.2°, 27.7° 0.2°, 11.1° ± 0.2° 16.8° ± 0.2° 21.0° ± 0.2° 25.7° ± 0.2° 30.4°±
[0675] In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 43. In certain embodiments, Form E of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 42.
[0676] In certain embodiments, Form E of the compound of formula (I) has a DSC thermogram comprising an endotherm with a maximum peak at about 40°C. In certain embodiments, Form E of the compound of formula (I) has a DSC thermogram comprising an endotherm with a maximum peak at about 92°C. In certain embodiments, Form E of the compound of formula (I) has a DSC thermogram comprising an endotherm with a maximum peak at about 137°C. In certain embodiments, Form E of the compound of formula (I) has a DSC thermogram comprising an or Petition 870260106343, dated 10 / 15 / 2026, p. 126 / 289 121 / 280 more endothermic with maximum peaks at about 40°C, about 92°C and about 137°C. In certain embodiments, Form E of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 202°C. In certain embodiments, Form E of the compound of formula (I) has a DSC thermogram comprising an exotherm with a maximum peak at about 161°C. In certain embodiments, Form E of the compound of formula (I) has a DSC thermogram substantially the same as shown in Figure 44.
[0677] In certain embodiments, Form E of the compound of formula (I) shows a weight loss of less than or equal to about 9.0% by weight when heated Form E from about 25°C to about 219°C. The weight loss exhibited by a crystalline form (e.g., Form E of the compound of formula (I)) can be determined, for example, using TGA. In certain embodiments, Form E of the compound of formula (I) has a TGA thermogram substantially the same as that shown in Figure 45.
[0678] In certain embodiments, Form E of the compound of formula (I) is a crystalline solvate. In certain embodiments, Form E of the compound of formula (I) is a crystalline ethyl acetate solvate. (6) H-shape
[0679] In several embodiments, the H form of a compound of formula (I) is given here (I).
[0680] In certain embodiments, the H form of the compound of formula (I) shows an XRPD pattern comprising a peak at about 8.1° 2θ. In certain embodiments, the H form of a compound of formula (I) shows an XRPD pattern comprising a peak at about 9.4° 2θ. In certain embodiments, the H form of the compound Petition 870260106343, dated 10 / 15 / 2026, pp. 127 / 289 Formula 122 / 280 (I) shows an XRPD pattern comprising one or more peaks at about 8.1° and about 9.4° 2θ.
[0681] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.6°, about 16.3°, about 16.9°, about 17.0°, about 18.4°, about 18.8°, about 19.9°, about 20.2°, about 20.5°, about 21.5°, about 21.6°, about 21.8°, about 24.5° and about 26.3° 2θ.
[0682] In certain embodiments, the H Form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 8.1°, about 9.4°, about 15.6°, about 16.3°, about 16.9°, about 17.0°, about 18.4°, about 18.8°, about 19.9°, about 20.2°, about 20.5°, about 21.5°, about 21.6°, about 21.8°, about 24.5° and about 26.3° 2θ.
[0683] In certain embodiments, the H Form of the compound of formula (I) has an XRPD pattern comprising peaks at about 8.1°, about 9.4°, about 15.6°, about 16.3°, about 16.9°, about 17.0°, about 18.4°, about 18.8°, about 19.9°, about 20.2°, about 20.5°, about 21.5°, about 21.6°, about 21.8°, about 24.5° and about 26.3° 2θ.
[0684] In certain embodiments, the H form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 8.1° and about 9.4° 2θ.
[0685] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 5.3°, about 6.9°, about 8.1°, about 9.4°, about 9.7°, about 10.7°, about 11.6°, about 12.3°, about 12.4°, about 13.5°, about 13.8° and about 14.7° 2θ.
[0686] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 16.3°, about 16.9°, about 17.0°, about 18.4°, about 18.8°, about 19.9°, about 20.2°, about 20.5°, about 21.6° and 24.5° 2θ. Petition 870260106343, dated 10 / 15 / 2026, pp. 128 / 289 123 / 280
[0687] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at approximately 15.6°, approximately 17.7°, approximately 19.4°, approximately 20.8°, approximately 21.2°, approximately 21.5°, about 21.8°, about 22.4°, about 22.8°, about 23.1°, approximately 24.3° and approximately 24.9°2θ.
[0688] In certain modes, the XRPD pattern additionally comprises one or more peaks at approximately 26.3°2θ.
[0689] In certain embodiments, the H form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 5.3°, about 9.7°, approximately 12.4°, approximately 15.6°, approximately 17.0°, approximately 19.4°, approximately 20.8°, approximately 21.8°, approximately 24.3°, approximately 26.3°, approximately 29.3 of about 6.9°, about 10.7°, approximately 13.5°, approximately 16.0°, approximately 17.7°, approximately 19.9°, approximately 21.2°, approximately 22.4°, approximately 24.5°, approximately 26.9°, approximately 30.0°2θ. of 8.1°, approximately 11.6°, approximately 13.8°, approximately 16.3°, approximately 18.4°, approximately 20.2°, approximately 21.5°, approximately 22.8°, approximately 24.9°, approximately 28.2°, approximately 9.4°, approximately 12.3°, approximately 14.7°, approximately 16.9°, approximately 18.8°, approximately 20.5°, approximately 21.6°, approximately 23.1°, approximately 25.6°, approximately 29.0°, approximately
[0690] In certain embodiments, Form H of the compound of formula (I) has an XRPD pattern comprising peaks at about 5.3°, about 6.9°, about 8.1°, about 9.4°, about 9.7°, about 10.7°, about 13.5°, about 16.0°, about 17.7°, about 19.9°, about 21.2°, about 22.4°, about 24.5°, about 26.9°, about 11.6°, about 13.8°, about 16.3°, about 18.4°, about 20.2°, about 21.5°, about 22.8°, about 24.9°, about 28.2°, about 12.3°, about 14.7°, about of 16.9°, approximately 18.8°, approximately 20.5°, approximately 21.6°, approximately 23.1°, approximately 25.6°, approximately 29.0°, approximately 12.4°, approximately 15.6°, approximately 17.0°, approximately 19.4°, approximately 20.8°, approximately 21.8°, approximately 24.3°, approximately 26.3°, approximately 29.3° and approximately approximately approximately approximately approximately approximately approximately approximately approximately 30.0° 2θ. Petition 870260106343, dated 10 / 15 / 2026, pp. 129 / 289 124 / 280
[0691] In certain embodiments, the H Form of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 8.1° ± 0.3° 2θ. In certain embodiments, the H Form of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 9.4° ± 0.3° 2θ. In certain embodiments, the H Form of the compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at 8.1° ± 0.3° and 9.4° ± 0.3° 2θ.
[0692] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.0° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 20.5° ± 0.3°, 21.5° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 24.5° ± 0.3° and 26.3° ± 0.3° 2θ.
[0693] In certain embodiments, the H Form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.1° ± 0.3°, 9.4° ± 0.3°, 15.6° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.0° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 20.5° ± 0.3°, 21.5° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 24.5° ± 0.3° and 26.3° ± 0.3° 2θ.
[0694] In certain embodiments, Form H of the compound of formula (I) has an XRPD pattern comprising peaks at 8.1° ± 0.3°, 9.4° ± 0.3°, 15.6° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.0° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 20.5° ± 0.3°, 21.5° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 24.5° ± 0.3° and 26.3° ± 0.3° 2θ.
[0695] In certain embodiments, the H form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.1° ± 0.3° and 9.4° ± 0.3° 2θ.
[0696] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 5.3° ± 0.3°, 6.9° ± 0.3°, 8.1° ± 0.3°, 9.4° ± 0.3°, 9.7° ± 0.3°, 10.7° ± 0.3°, 11.6° ± 0.3°, 12.3° ± 0.3°, 12.4° ± 0.3°, 13.5° ± 0.3°, 13.8° ± 0.3° and 14.7° ± 0.3° 2θ.
[0697] In certain forms, the XRPD standard comprises Petition 870260106343, dated 10 / 15 / 2026, page 130 / 289 125 / 280 additionally one or more peaks at 16.3° ± 0.3°, 16.9° ± 0.3°, 17.0° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 20.5° ± 0.3°, 21.6° ± 0.3° and 24.5° ± 0.3° 2θ.
[0698] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.3°, 17.7° ± 0.3°, 19.4° ± 0.3°, 20.8° ± 0.3°, 21.2° ± 0.3°, 21.5° ± 0.3°, 21.8° ± 0.3°, 22.4° ± 0.3°, 22.8° ± 0.3°, 23.1° ± 0.3°, 24.3° ± 0.3° and 24.9° ± 0.3° 2θ.
[0699] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.3° ± 0.3° 2θ.
[0700] In certain embodiments, Form H of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.3° ± 0.3°, 6.9° ± 0.3°, 8.1° ± 0.3°, 9.4° ± 0.3°, 9.7° ± 0.3°, 10.7° ± 0.3°, 11.6° ± 0.3°, 12.3° ± 0.3°, 12.4° ± 0.3°, 13.5° ± 0.3°, 13.8° ± 0.3°, 14.7° ± 0.3°, 15.6° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.0° ± 0.3°, 17.7° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 20.5° ± 0.3°, 20.8° ± 0.3°, 21.2° ± 0.3°, 21.5° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 22.4° ± 0.3°, 22.8° ± 0.3°, 23.1° ± 0.3°, 24.3° ± 0.3°, 24.5° ± 0.3°, 24.9° ± 0.3°, 25.6° ± 0.3°, 26.3° ± 0.3°, 26.9° ± 0.3°, 28.2° ± 0.3°, 29.0° ± 0.3°, 29.3° ± 0.3° and 30.0° ± 0.3° 2θ.
[0701] In certain embodiments, Form H of the compound of formula (I) has an XRPD pattern comprising peaks at 5.3° ± 0.3°, 6.9° ± 0.3°, 8.1° ± 0.3°, 9.4° ± 0.3°, 9.7° ± 0.3°, 10.7° ± 0.3°, 11.6° ± 0.3°, 12.3° ± 0.3°, 12.4° ± 0.3°, 13.5° ± 0.3°, 13.8° ± 0.3°, 14.7° ± 0.3°, 15.6° ± 0.3°, 16.0° ± 0.3°, 16.3° ± 0.3°, 16.9° ± 0.3°, 17.0° ± 0.3°, 17.7° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 20.5° ± 0.3°, 20.8° ± 0.3°, 21.2° ± 0.3°, 21.5° ± 0.3°, 21.6° ± 0.3°, 21.8° ± 0.3°, 22.4° ± 0.3°, 22.8° ± 0.3°, 23.1° ± 0.3°, 24.3° ± 0.3°, 24.5° ± 0.3°, 24.9° ± 0.3°, 25.6° ± 0.3°, 26.3° ± 0.3°, 26.9° ± 0.3°, 28.2° ± 0.3°, 29.0° ± 0.3°, 29.3° ± 0.3° and 30.0° ± 0.3° Petition 870260106343, dated 10 / 15 / 2026, page 131 / 289 126 / 280 2θ.
[0702] In certain embodiments, the H Form of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 8.1° ± 0.2° 2θ. In certain embodiments, the H Form of the compound of formula (I) exhibits an XRPD pattern comprising a peak at 9.4° ± 0.2° 2θ. In certain embodiments, the H Form of the compound of formula (I) exhibits an XRPD pattern comprising one or more peaks at 8.1° ± 0.2° and 9.4° ± 0.2° 2θ.
[0703] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.2°, 16.3° ± 0.2°, 16.9° ± 0.2°, 17.0° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 20.5° ± 0.2°, 21.5° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 24.5° ± 0.2° and 26.3° ± 0.2° 2θ.
[0704] In certain embodiments, the H Form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.1° ± 0.2°, 9.4° ± 0.2°, 15.6° ± 0.2°, 16.3° ± 0.2°, 16.9° ± 0.2°, 17.0° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 20.5° ± 0.2°, 21.5° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 24.5° ± 0.2° and 26.3° ± 0.2° 2θ.
[0705] In certain embodiments, Form H of the compound of formula (I) has an XRPD pattern comprising peaks at 8.1° ± 0.2°, 9.4° ± 0.2°, 15.6° ± 0.2°, 16.3° ± 0.2°, 16.9° ± 0.2°, 17.0° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 20.5° ± 0.2°, 21.5° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 24.5° ± 0.2° and 26.3° ± 0.2° 2θ.
[0706] In certain embodiments, the H form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.1° ± 0.2° and 9.4° ± 0.2° 2θ.
[0707] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 5.3° ± 0.2°, 6.9° ± 0.2°, 8.1° ± 0.2°, 9.4° ± 0.2°, 9.7° ± 0.2°, 10.7° ± 0.2°, 11.6° ± 0.2°, 12.3° ± 0.2°, 12.4° ± 0.2°, 13.5° ± 0.2°, 13.8° ± 0.2° and 14.7° ± 0.2° 2θ. Petition 870260106343, dated 10 / 15 / 2026, page 132 / 289 127 / 280
[0708] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.3° ± 0.2°, 16.9° ± 0.2°, 17.0° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 20.5° ± 0.2°, 21.6° ± 0.2° and 24.5° ± 0.2° 2θ.
[0709] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.6° ± 0.2°, 17.7° ± 0.2°, 19.4° ± 0.2°, 20.8° ± 0.2°, 21.2° ± 0.2°, 21.5° ± 0.2°, 21.8° ± 0.2°, 22.4° ± 0.2°, 22.8° ± 0.2°, 23.1° ± 0.2°, 24.3° ± 0.2° and 24.9° ± 0.2° 2θ.
[0710] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.3° ± 0.2° 2θ.
[0711] In certain embodiments, the H Form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 5.3° ± 0.2°, 6.9° ± 0.2°, 8.1° ± 0.2°, 9.4° ± 0.2°, 9.7° ± 0.2°, 10.7° ± 0.2°, 11.6° ± 0.2°, 12.3° ± 0.2°, 12.4° ± 0.2°, 13.5° ± 0.2°, 13.8° ± 0.2°, 14.7° ± 0.2°, 15.6° ± 0.2°, 16.0° ± 0.2°, 16.3° ± 0.2°, 16.9° ± 0.2°, 17.0° ± 0.2°, 17.7° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 20.5° ± 0.2°, 20.8° ± 0.2°, 21.2° ± 0.2°, 21.5° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 22.4° ± 0.2°, 22.8° ± 0.2°, 23.1° ± 0.2°, 24.3° ± 0.2°, 24.5° ± 0.2°, 24.9° ± 0.2°, 25.6° ± 0.2°, 26.3° ± 0.2°, 26.9° ± 0.2°, 28.2° ± 0.2°, 29.0° ± 0.2°, 29.3° ± 0.2° and 30.0° ± 0.2° 2θ.
[0712] In certain embodiments, Form H of the compound of formula (I) has an XRPD pattern comprising peaks at 5.3° ± 0.2°, 6.9° ± 0.2°, 8.1° ± 0.2°, 9.4° ± 0.2°, 9.7° ± 0.2°, 10.7° ± 0.2°, 11.6° ± 0.2°, 12.3° ± 0.2°, 12.4° ± 0.2°, 13.5° ± 0.2°, 13.8° ± 0.2°, 14.7° ± 0.2°, 15.6° ± 0.2°, 16.0° ± 0.2°, 16.3° ± 0.2°, 16.9° ± 0.2°, 17.0° ± 0.2°, 17.7° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 20.5° ± 0.2°, 20.8° ± 0.2°, 21.2° ± 0.2°, 21.5° ± 0.2°, 21.6° ± 0.2°, 21.8° ± 0.2°, 22.4° ± 0.2°, 22.8° ± 0.2°, 23.1° ± 0.2°, 24.3° ± 0.2°, 24.5° ± 0.2°, 24.9° ± 0.2°, 25.6° ± 0.2°, 26.3° ± 0.2°, 26.9° ± Petition 870260106343, dated 10 / 15 / 2026, page 133 / 289 128 / 280 0.2°, 28.2° ± 0.2°, 29.0° ± 0.2°, 29.3° ± 0.2° and 30.0° ± 0.2° 2θ.
[0713] In certain embodiments, the H Form of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 46. In certain embodiments, the H Form of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 43.
[0714] In certain embodiments, Form H of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 205°C. In certain embodiments, Form H of the compound of formula (I) has a DSC thermogram substantially the same as that shown in Figure 47.
[0715] In certain embodiments, Form H of the compound of formula (I) is an anhydrous crystalline form. (7) Material F
[0716] In various embodiments, a material (for example, a pharmaceutical material) comprising a crystalline form of a compound of formula (I) is provided here (I).
[0717] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 12.9° and about 13.6° 2θ.
[0718] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 4.0°, about 7.7°, about 9.1°, about 9.4°, about 10.5°, about 11.1° and about 11.9° 2θ.
[0719] In certain modes, the XRPD pattern additionally comprises one or more peaks at approximately 15.4°, approximately 15.8°, about 18.4°, about 18.8°, about 22.4°, about 23.1° and approximately 23.8° 2θ. Petition 870260106343, dated 10 / 15 / 2026, p. 134 / 289 129 / 280
[0720] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at approximately 16.7°, approximately 19.4°, approximately 19.9°, approximately 20.2°, approximately 21.0°, approximately 21.4°, approximately 22.7° and approximately 24.7°2θ.
[0721] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.8° and about 28.8°2θ.
[0722] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.3°, about 26.5°, about 27.6° and about 29.6°2θ.
[0723] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 4.0°, about 7.7°, about 9.1°, about 9.4°, about 10.5°, about 11.1°, about 11.9°, about 12.9°, about 13.6°, about 15.4°, about 15.8°, about 16.7°, about 18.4°, about 18.8°, about 19.4°, about 19.9°, about 20.2°, about 21.0°, about 21.4°, about 22.4°, about 22.7°, about 23.1°, about 23.8°, about 24.7°, approximately 25.3°, approximately 25.8°, approximately 26.5°, approximately 27.6°, approximately 28.8°, and approximately 29.6° 2θ.
[0724] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising peaks at about 4.0°, about 7.7°, 10.5°, about 11.1°, 13.6°, approximately 15.4°, 18.4°, approximately 18.8°, 20.2°, approximately 21.0°, 22.7°, approximately 23.1°, 25.3°, approximately 25.8°, 28.8° and about 29.6° 2θ. modalities of 9.4°, 12.9°, 16.7°, 19.9°, 22.4°, 24.7°, 27.6°, about about about about about about about about comprising a crystalline form of the compound of formula (I) comprising XRPD peaks at about 4.0°, about 7.7°, about 9.1°, about Petition 870260106343, dated 10 / 15 / 2026, page 135 / 289 130 / 280 9.4°, approximately 10.5°, approximately 11.1°, approximately 11.9°, approximately 12.9°, approximately 13.6°, approximately 15.4°, approximately 15.8°, approximately 16.7°, approximately 18.4°, approximately 18.8°, approximately 19.4°, approximately 19.9°, approximately 20.2°, approximately 21.0°, approximately 21.4°, approximately 22.4°, approximately 22.7°, approximately 23.1°, approximately 23.8°, approximately 24.7°, approximately 25.3°, approximately 25.8°, approximately 26.5°, approximately 27.6°, approximately 28.8° and approximately 29.6° 2Θ can be referred here as “Material F.
[0726] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 12.9° ± 0.3° and 13.6° ± 0.3° 2θ.
[0727] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 4.0° ± 0.3°, 7.7° ± 0.3°, 9.1° ± 0.3°, 9.4° ± 0.3°, 10.5° ± 0.3°, 11.1° ± 0.3° and 11.9° ± 0.3° 2θ.
[0728] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.4° ± 0.3°, 15.8° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 22.4° ± 0.3°, 23.1° ± 0.3° and 23.8° ± 0.3° 2θ.
[0729] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.7° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 21.0° ± 0.3°, 21.4° ± 0.3°, 22.7° ± 0.3° and 24.7° ± 0.3° 2θ.
[0730] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.8° ± 0.3° and 28.8° ± 0.3° 2θ.
[0731] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.3° ± 0.3°, 26.5° ± 0.3°, 27.6° ± 0.3° and 29.6° ± 0.3° 2θ.
[0732] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.0° ± 0.3°, 7.7° ± 0.3°, 9.1° ± 0.3°, 9.4° ± 0.3°, 10.5° ± 0.3°, 11.1° ± 0.3°, 11.9° ± 0.3°, 12.9° ± 0.3°, 13.6° ± Petition 870260106343, dated 10 / 15 / 2026, page 136 / 289 131 / 280 0.3°, 15.4° ± 0.3°, 15.8° ± 0.3°, 16.7° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 21.0° ± 0.3°, 21.4° ± 0.3°, 22.4° ± 0.3°, 22.7° ± 0.3°, 23.1° ± 0.3°, 23.8° ± 0.3°, 24.7° ± 0.3°, 25.3° ± 0.3°, 25.8° ± 0.3°, 26.5° ± 0.3°, 27.6° ± 0.3°, 28.8° ± 0.3° and 29.6° ± 0.3° 2θ.
[0733] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising peaks at 4.0° ± 0.3°, 7.7° ± 0.3°, 9.1° ± 0.3°, 9.4° ± 0.3°, 10.5° ± 0.3°, 11.1° ± 0.3°, 11.9° ± 0.3°, 12.9° ± 0.3°, 13.6° ± 0.3°, 15.4° ± 0.3°, 15.8° ± 0.3°, 16.7° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 21.0° ± 0.3°, 21.4° ± 0.3°, 22.4° ± 0.3°, 22.7° ± 0.3°, 23.1° ± 0.3°, 23.8° ± 0.3°, 24.7° ± 0.3°, 25.3° ± 0.3°, 25.8° ± 0.3°, 26.5° ± 0.3°, 27.6° ± 0.3°, 28.8° ± 0.3° and 29.6° ± 0.3° 2θ.
[0734] In certain embodiments, the material comprising a crystalline form of the compound of formula (I) comprising XRPD peaks at 4.0° ± 0.3°, 7.7° ± 0.3°, 9.1° ± 0.3°, 9.4° ± 0.3°, 10.5° ± 0.3°, 11.1° ± 0.3°, 11.9° ± 0.3°, 12.9° ± 0.3°, 13.6° ± 0.3°, 15.4° ± 0.3°, 15.8° ± 0.3°, 16.7° ± 0.3°, 18.4° ± 0.3°, 18.8° ± 0.3°, 19.4° ± 0.3°, 19.9° ± 0.3°, 20.2° ± 0.3°, 21.0° ± 0.3°, 21.4° ± 0.3°, 22.4° ± 0.3°, 22.7° ± 0.3°, 23.1° ± 0.3°, 23.8° ± 0.3°, 24.7° ± 0.3°, 25.3° ± 0.3°, 25.8° ± 0.3°, 26.5° ± 0.3°, 27.6° ± 0.3°, 28.8° ± 0.3° and 29.6° ± 0.3° 2Θ can be referred to Here as Material F.
[0735] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 12.9° ± 0.2° and 13.6° ± 0.2° 2θ.
[0736] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 4.0° ± 0.2°, 7.7° ± 0.2°, 9.1° ± 0.2°, 9.4° ± 0.2°, 10.5° ± 0.2°, 11.1° ± 0.2° and 11.9° ± 0.2° 2θ.
[0737] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.4° ± 0.2°, 15.8° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, page 137 / 289 132 / 280 18.4° ± 0.2°, 18.8° ± 0.2°, 22.4° ± 0.2°, 23.1° ± 0.2° and 23.8 ± 0.2° 2θ.
[0738] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 16.7° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 21.0° ± 0.2°, 21.4° ± 0.2°, 22.7° ± 0.2° and 24.7° ± 0.2° 2θ.
[0739] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.8° ± 0.2° and 28.8° ± 0.2° 2θ.
[0740] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.3° ± 0.2°, 26.5° ± 0.2°, 27.6° ± 0.2° and 29.6° ± 0.2° 2θ.
[0741] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 4.0° ± 0.2°, 7.7° ± 0.2°, 9.1° ± 0.2°, 9.4° ± 0.2°, 10.5° ± 0.2°, 11.1° ± 0.2°, 11.9° ± 0.2°, 12.9° ± 0.2°, 13.6° ± 0.2°, 15.4° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 21.0° ± 0.2°, 21.4° ± 0.2°, 22.4° ± 0.2°, 22.7° ± 0.2°, 23.1° ± 0.2°, 23.8° ± 0.2°, 24.7° ± 0.2°, 25.3° ± 0.2°, 25.8° ± 0.2°, 26.5° ± 0.2°, 27.6° ± 0.2°, 28.8° ± 0.2° and 29.6° ± 0.2° 2θ.
[0742] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising peaks at 4.0° ± 0.2°, 7.7° ± 0.2°, 9.1° ± 0.2°, 9.4° ± 0.2°, 10.5° ± 0.2°, 11.1° ± 0.2°, 11.9° ± 0.2°, 12.9° ± 0.2°, 13.6° ± 0.2°, 15.4° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 21.0° ± 0.2°, 21.4° ± 0.2°, 22.4° ± 0.2°, 22.7° ± 0.2°, 23.1° ± 0.2°, 23.8° ± 0.2°, 24.7° ± 0.2°, 25.3° ± 0.2°, 25.8° ± 0.2°, 26.5° ± 0.2°, 27.6° ± 0.2°, 28.8° ± 0.2° and 29.6° ± 0.2° 2θ.
[0743] In certain embodiments, the material comprising a crystalline form of the compound of formula (I) comprising XRPD peaks at 4.0° ± 0.2°, 7.7° ± 0.2°, 9.1° ± 0.2°, 9.4° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, pp. 138 / 289 133 / 280 10.5° ± 0.2°, 11.1° ± 0.2°, 11.9° ± 0.2°, 12.9° ± 0.2°, 13.6° ± 0.2°, 15.4° ± 0.2°, 15.8° ± 0.2°, 16.7° ± 0.2°, 18.4° ± 0.2°, 18.8° ± 0.2°, 19.4° ± 0.2°, 19.9° ± 0.2°, 20.2° ± 0.2°, 21.0° ± 0.2°, 21.4° ± 0.2°, 22.4° ± 0.2°, 22.7° ± 0.2°, 23.1° ± 0.2°, 23.8° ± 0.2°, 24.7° ± 0.2°, 25.3° ± 0.2°, 25.8° ± 0.2°, 26.5° ± 0.2°, 27.6° ± 0.2°, 28.8° ± 0.2° and 29.6° ± 0.2° may be referred to herein as “Material F.”
[0744] In certain embodiments, Material F of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 48. In certain embodiments, Material F of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2θ) revealed in Table 44.
[0745] In certain embodiments, Material F of the compound of formula (I) comprises an anhydrous crystalline form of the compound of formula (I). (8) Material G
[0746] In various embodiments, a material (for example, a pharmaceutical material) comprising a crystalline form of a compound of formula (I) is provided here H2N N OH
[0747] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 8.7°, about 9.9° and about 10.7° 2θ.
[0748] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 6.9°, about 7.3°, about 8.9°, about 9.5°, about 9.9°, about 10.4°, about 11.0°, about 11.3°, about 11.5°, about 11.7°, about 12.3°, about 12.8°, about 13.8° and about 14.8° 2θ.
[0749] In certain forms, the XRPD standard comprises Petition 870260106343, dated 10 / 15 / 2026, pp. 139 / 289 134 / 280 additionally one or more peaks at approximately 17.5°, approximately 18.6°, approximately 21.3°, approximately 21.5°, approximately 22.3° and approximately 22.6° 2θ.
[0750] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 15.2°, about 15.3°, about 15.7°, about 16.5°, about 16.8°, about 17.8°, about 19.0°, about 19.4°, about 19.8°, about 20.5°, about 20.8°, about 22.1°, about 23.7°, about 24.1°, about 24.4°, about 24.7° and about 25.0° 2θ.
[0751] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at about 25.3°, about 25.6° and about 26.1° 2θ.
[0752] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at approximately 26.7°, approximately 27.0°, approximately 27.5°, approximately 27.9°, approximately 28.3° and approximately 28.9° 2θ.
[0753] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at about 6.9°, about 7.3°, about 8.7°, about 8.9°, approximately 10.7°, approximately 11.7°, approximately 14.8°, approximately 16.5°, approximately 18.6°, approximately 20.5°, approximately 22.1°, approximately 24.1°, approximately 25.3°, approximately 27.0°, approximately 9.5°, approximately 11.0°, approximately 12.3°, approximately 15.2°, approximately 16.8°, approximately 19.0°, approximately 20.8°, approximately 22.3°, approximately 24.4°, approximately 25.6°, approximately 27.5°, approximately 9.9°, approximately 11.3°, approximately 12.8°, approximately 15.3°, approximately 17.5°, approximately 19.4°, approximately 21.3°, approximately 22.6°, approximately 24.7°, approximately 26.1°, approximately 27.9°, approximately 10.4°, approximately 11.5°, approximately 13.8°, approximately 15.7°, approximately 17.8°, approximately 19.8°, approximately 21.5°, approximately 23.7°, approximately 25.0°, approximately 26.7°, approximately 28.3° and approximately 28.9° 2θ.
[0754] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising peaks at about Petition 870260106343, dated 10 / 15 / 2026, pp. 140 / 289 135 / 280 of 6.9°, about 9.5°, about 11.0°, about 12.3°, about 15.2°, about 16.8°, about 19.0°, about 20.8°, about 22.3°, about 24.4°, about 25.6°, about 27.5°, about 7.3°, about 9.9°, approximately 11.3°, approximately 12.8°, approximately 15.3°, approximately 17.5°, approximately 19.4°, approximately 21.3°, approximately 22.6°, approximately 24.7°, approximately 26.1°, approximately 27.9°, approximately 8.7°, approximately 10.4°, approximately 11.5°, approximately 13.8°, approximately 15.7°, approximately 17.8°, approximately 19.8°, approximately 21.5°, approximately 23.7°, approximately 25.0°, approximately 26.7°, approximately 28.3° and about 8.9°, about 10.7°, about 11.7°, about 14.8°, about 16.5°, about 18.6°, about 20.5°, about 22.1°, about 24.1°, about 25.3°, about 27.0°, about 28.9° 2Θ.
[0755] In certain embodiments, the material comprising a crystalline form of the compound of formula (I) comprising XRPD peaks at about 6.9°, about 7.3°, about 8.7°, about 8.9°, approximately 10.7°, approximately 11.7°, approximately 14.8°, approximately 16.5°, approximately 18.6°, approximately 20.5°, approximately 22.1°, approximately 24.1°, approximately 25.3°, approximately 27.0°, approximately 9.5°, approximately 11.0°, approximately 12.3°, approximately 15.2°, approximately 16.8°, approximately 19.0°, approximately 20.8°, approximately 22.3°, approximately 24.4°, approximately 25.6°, approximately 27.5°, approximately 9.9°, approximately 11.3°, approximately 12.8°, approximately 15.3°, approximately 17.5°, approximately 19.4°, approximately 21.3°, approximately 22.6°, approximately 24.7°, approximately 26.1°, approximately 27.9°, approximately 10.4°, approximately 11.5°, approximately 13.8°, approximately 15.7°, approximately 17.8°, approximately 19.8°, approximately 21.5°, approximately 23.7°, approximately 25.0°, approximately 26.7°, approximately 28.3° and approximately 28.9° 2Θ can be referred to here as “Material G.
[0756] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.7° ± 0.3°, 9.9° ± 0.3° and 10.7° ± 0.3°2Θ.
[0757] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 6.9° ± 0.3°, 7.3° ±0.3°, 8.9° ± 0.3°, 9.5° ± 0.3°, 9.9° ± 0.3°, 10.4° ± 0.3°, 11.0° ± Petition 870260106343, dated 10 / 15 / 2026, page 141 / 289 136 / 280 0.3°, 11.3° ± 0.3°, 11.5° ± 0.3°, 11.7° ± 0.3°, 12.3° ± 0.3°, 12.8° ± 0.3°, 13.8° ± 0.3° and 14.8° ± 0.3° 2θ.
[0758] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 17.5° ± 0.3°, 18.6° ± 0.3°, 21.3° ± 0.3°, 21.5° ± 0.3°, 22.3° ± 0.3° and 22.6° ± 0.3° 2θ.
[0759] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.2° ± 0.3°, 15.3° ± 0.3°, 15.7° ± 0.3°, 16.5° ± 0.3°, 16.8° ± 0.3°, 17.8° ± 0.3°, 19.0° ± 0.3°, 19.4° ± 0.3°, 19.8° ± 0.3°, 20.5° ± 0.3°, 20.8° ± 0.3°, 22.1° ± 0.3°, 23.7° ± 0.3°, 24.1° ± 0.3°, 24.4° ± 0.3°, 24.7° ± 0.3° and 25.0° ± 0.3° 2θ.
[0760] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.3° ± 0.3°, 25.6° ± 0.3° and 26.1° ± 0.3° 2θ.
[0761] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.7° ± 0.3°, 27.0° ± 0.3°, 27.5° ± 0.3°, 27.9° ± 0.3°, 28.3° ± 0.3° and 28.9° ± 0.3° 2θ.
[0762] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.9° ± 0.3°, 7.3° ± 0.3°, 8.7° ± 0.3°, 8.9° ± 0.3°, 9.5° ± 0.3°, 9.9° ± 0.3°, 10.4° ± 0.3°, 10.7° ± 0.3°, 11.0° ± 0.3°, 11.3° ± 0.3°, 11.5° ± 0.3°, 11.7° ± 0.3°, 12.3° ± 0.3°, 12.8° ± 0.3°, 13.8° ± 0.3°, 14.8° ± 0.3°, 15.2° ± 0.3°, 15.3° ± 0.3°, 15.7° ± 0.3°, 16.5° ± 0.3°, 16.8° ± 0.3°, 17.5° ± 0.3°, 17.8° ± 0.3°, 18.6° ± 0.3°, 19.0° ± 0.3°, 19.4° ± 0.3°, 19.8° ± 0.3°, 20.5° ± 0.3°, 20.8° ± 0.3°, 21.3° ± 0.3°, 21.5° ± 0.3°, 22.1° ± 0.3°, 22.3° ± 0.3°, 22.6° ± 0.3°, 23.7° ± 0.3°, 24.1° ± 0.3°, 24.4° ± 0.3°, 24.7° ± 0.3°, 25.0° ± 0.3°, 25.3° ± 0.3°, 25.6° ± 0.3°, 26.1° ± 0.3°, 26.7° ± 0.3°, 27.0° ± 0.3°, 27.5° ± 0.3°, 27.9° ± 0.3°, 28.3° ± 0.3° and 28.9° ± 0.3° 2θ.
[0763] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising peaks at 6.9° ± 0.3°, 7.3° ± 0.3°, 8.7° ± 0.3°, 8.9° ± 0.3°, 9.5° ± 0.3°, 9.9° Petition 870260106343, dated 10 / 15 / 2026, page 142 / 289 137 / 280 ± 0.3°, 10.4° ± 0.3°, 10.7° ± 0.3°, 11.0° ± 0.3°, 11.3° ± 0.3°, 11.5° ± 0.3°, 11.7° ± 0.3°, 12.3° ± 0.3°, 12.8° ± 0.3°, 13.8° ± 0.3°, 14.8° ± 0.3°, 15.2° ± 0.3°, 15.3° ± 0.3°, 15.7° ± 0.3°, 16.5° ± 0.3°, 16.8° ± 0.3°, 17.5° ± 0.3°, 17.8° ± 0.3°, 18.6° ± 0.3°, 19.0° ± 0.3°, 19.4° ± 0.3°, 19.8° ± 0.3°, 20.5° ± 0.3°, 20.8° ± 0.3°, 21.3° ± 0.3°, 21.5° ± 0.3°, 22.1° ± 0.3°, 22.3° ± 0.3°, 22.6° ± 0.3°, 23.7° ± 0.3°, 24.1° ± 0.3°, 24.4° ± 0.3°, 24.7° ± 0.3°, 25.0° ± 0.3°, 25.3° ± 0.3°, 25.6° ± 0.3°, 26.1° ± 0.3°, 26.7° ± 0.3°, 27.0° ± 0.3°, 27.5° ± 0.3°, 27.9° ± 0.3°, 28.3° ± 0.3° and 28.9° ± 0.3° 2Θ.
[0764] In certain embodiments, the material comprising a crystalline form of the compound of formula (I) comprising XRPD achieves peaks at 6.9° ± 0.3°, 7.3° ± 0.3°, 8.7° ± 0.3°, 8.9° ± 0.3°, 9.5° ± 0.3°, 9.9° ± 0.3°, 10.4° ± 0.3°, 10.7° ± 0.3°, 11.0° ± 0.3°, 11.3° ± 0.3°, 11.5° ± 0.3°, 11.7° ± 0.3°, 12.3° ± 0.3°, 12.8° ± 0.3°, 13.8° ± 0.3°, 14.8° ± 0.3°, 15.2° ± 0.3°, 15.3° ± 0.3°, 15.7° ± 0.3°, 16.5° ± 0.3°, 16.8° ± 0.3°, 17.5° ± 0.3°, 17.8° ± 0.3°, 18.6° ± 0.3°, 19.0° ± 0.3°, 19.4° ± 0.3°, 19.8° ± 0.3°, 20.5° ± 0.3°, 20.8° ± 0.3°, 21.3° ± 0.3°, 21.5° ± 0.3°, 22.1° ± 0.3°, 22.3° ± 0.3°, 22.6° ± 0.3°, 23.7° ± 0.3°, 24.1° ± 0.3°, 24.4° ± 0.3°, 24.7° ± 0.3°, 25.0° ± 0.3°, 25.3° ± 0.3°, 25.6° ± 0.3°, 26.1° ± 0.3°, 26.7° ± 0.3°, 27.0° ± 0.3°, 27.5° ± 0.3°, 27.9° ± 0.3°, 28.3° ± 0.3° and 28.9° ± 0.3° 2Θ can be referred to here as Material G”.
[0765] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 8.7° ± 0.2°, 9.9° ± 0.2° and 10.7° ± 0.2° 2Θ.
[0766] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 6.9° ± 0.2°, 7.3° ± 0.2°, 8.9° ± 0.2°, 9.5° ± 0.2°, 9.9° ± 0.2°, 10.4° ± 0.2°, 11.0° ± 0.2°, 11.3° ± 0.2°, 11.5° ± 0.2°, 11.7° ± 0.2°, 12.3° ± 0.2°, 12.8° ± 0.2°, 13.8° ± 0.2° and 14.8° ± 0.2° 2Θ.
[0767] In certain forms, the XRPD standard comprises Petition 870260106343, dated 10 / 15 / 2026, page 143 / 289 138 / 280 additionally one or more peaks at 17.5° ± 0.2°, 18.6° ± 0.2°, 21.3° ± 0.2°, 21.5° ± 0.2°, 22.3° ± 0.2° and 22.6° ± 0.2° 2θ.
[0768] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 15.2° ± 0.2°, 15.3° ± 0.2°, 15.7° ± 0.2°, 16.5° ± 0.2°, 16.8° ± 0.2°, 17.8° ± 0.2°, 19.0° ± 0.2°, 19.4° ± 0.2°, 19.8° ± 0.2°, 20.5° ± 0.2°, 20.8° ± 0.2°, 22.1° ± 0.2°, 23.7° ± 0.2°, 24.1° ± 0.2°, 24.4° ± 0.2°, 24.7° ± 0.2° and 25.0° ± 0.2° 2θ.
[0769] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 25.3° ± 0.2°, 25.6° ± 0.2° and 26.1° ± 0.2° 2θ.
[0770] In certain embodiments, the XRPD pattern additionally comprises one or more peaks at 26.7° ± 0.2°, 27.0° ± 0.2°, 27.5° ± 0.2°, 27.9° ± 0.2°, 28.3° ± 0.2° and 28.9° ± 0.2° 2θ.
[0771] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising one or more peaks at 6.9° ± 0.2°, 7.3° ± 0.2°, 8.7° ± 0.2°, 8.9° ± 0.2°, 9.5° ± 0.2°, 9.9° ± 0.2°, 10.4° ± 0.2°, 10.7° ± 0.2°, 11.0° ± 0.2°, 11.3° ± 0.2°, 11.5° ± 0.2°, 11.7° ± 0.2°, 12.3° ± 0.2°, 12.8° ± 0.2°, 13.8° ± 0.2°, 14.8° ± 0.2°, 15.2° ± 0.2°, 15.3° ± 0.2°, 15.7° ± 0.2°, 16.5° ± 0.2°, 16.8° ± 0.2°, 17.5° ± 0.2°, 17.8° ± 0.2°, 18.6° ± 0.2°, 19.0° ± 0.2°, 19.4° ± 0.2°, 19.8° ± 0.2°, 20.5° ± 0.2°, 20.8° ± 0.2°, 21.3° ± 0.2°, 21.5° ± 0.2°, 22.1° ± 0.2°, 22.3° ± 0.2°, 22.6° ± 0.2°, 23.7° ± 0.2°, 24.1° ± 0.2°, 24.4° ± 0.2°, 24.7° ± 0.2°, 25.0° ± 0.2°, 25.3° ± 0.2°, 25.6° ± 0.2°, 26.1° ± 0.2°, 26.7° ± 0.2°, 27.0° ± 0.2°, 27.5° ± 0.2°, 27.9° ± 0.2°, 28.3° ± 0.2°, and 28.9° ± 0.2° 2θ.
[0772] In certain embodiments, the crystalline form of the compound of formula (I) has an XRPD pattern comprising peaks at 6.9° ± 0.2°, 7.3° ± 0.2°, 8.7° ± 0.2°, 8.9° ± 0.2°, 9.5° ± 0.2°, 9.9° ± 0.2°, 10.4° ± 0.2°, 10.7° ± 0.2°, 11.0° ± 0.2°, 11.3° ± 0.2°, 11.5° ± 0.2°, 11.7° ± 0.2°, 12.3° ± 0.2°, 12.8° ± 0.2°, 13.8° ± 0.2°, 14.8° ± 0.2°, 15.2° ± 0.2°, 15.3° ± 0.2°, 15.7° ± 0.2°, Petition 870260106343, dated 10 / 15 / 2026, page 144 / 289 139 / 280 16.5° ± 0.2°, 16.8° ± 0.2°, 17.5° ± 0.2°, 17.8° ± 0.2°, 18.6° ± 0.2°, 19.0° ± 0.2°, 19.4° ± 0.2°, 19.8° ± 0.2°, 20.5° ± 0.2°, 20.8° ± 0.2°, 21.3° ± 0.2°, 21.5° ± 0.2°, 22.1° ± 0.2°, 22.3° ± 0.2°, 22.6° ± 0.2°, 23.7° ± 0.2°, 24.1° ± 0.2°, 24.4° ± 0.2°, 24.7° ± 0.2°, 25.0° ± 0.2°, 25.3° ± 0.2°, 25.6° ± 0.2°, 26.1° ± 0.2°, 26.7° ± 0.2°, 27.0° ± 0.2°, 27.5° ± 0.2°, 27.9° ± 0.2°, 28.3° ± 0.2°, and 28.9° ± 0.2° 2Θ.
[0773] In certain embodiments, the material comprising a crystalline form of the compound of formula (I) comprising XRPD peaks at 6.9° ± 0.2°, 7.3° ± 0.2°, 8.7° ± 0.2°, 8.9° ± 0.2°, 9.5° ± 0.2°, 9.9° ± 0.2°, 10.4° ± 0.2°, 10.7° ± 0.2°, 11.0° ± 0.2°, 11.3° ± 0.2°, 11.5° ± 0.2°, 11.7° ± 0.2°, 12.3° ± 0.2°, 12.8° ± 0.2°, 13.8° ± 0.2°, 14.8° ± 0.2°, 15.2° ± 0.2°, 15.3° ± 0.2°, 15.7° ± 0.2°, 16.5° ± 0.2°, 16.8° ± 0.2°, 17.5° ± 0.2°, 17.8° ± 0.2°, 18.6° ± 0.2°, 19.0° ± 0.2°, 19.4° ± 0.2°, 19.8° ± 0.2°, 20.5° ± 0.2°, 20.8° ± 0.2°, 21.3° ± 0.2°, 21.5° ± 0.2°, 22.1° ± 0.2°, 22.3° ± 0.2°, 22.6° ± 0.2°, 23.7° ± 0.2°, 24.1° ± 0.2°, 24.4° ± 0.2°, 24.7° ± 0.2°, 25.0° ± 0.2°, 25.3° ± 0.2°, 25.6° ± 0.2°, 26.1° ± 0.2°, 26.7° ± 0.2°, 27.0° ± 0.2°, 27.5° ± 0.2°, 27.9° ± 0.2°, 28.3° ± 0.2°, and 28.9° ± 0.2° 2Θ can be referred to here as Material G.
[0774] In certain embodiments, Material G of the compound of formula (I) has an XRPD pattern substantially the same as that shown in Figure 49. In certain embodiments, Material G of the compound of formula (I) has an XRPD pattern comprising one or more diffraction peaks (2Θ) revealed in Table 45.
[0775] In certain embodiments, Material G of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 124°C. In certain embodiments, Material G of the compound of formula (I) has a DSC thermogram comprising an endotherm with a peak starting at about 194°C. In certain embodiments, Material G of the compound of formula (I) has a DSC thermogram comprising one or more endotherms. Petition 870260106343, dated 10 / 15 / 2026, pp. 145 / 289 140 / 280 with peaks starting at about 124°C and about 194°C. In certain embodiments, Material G of the compound of formula (I) has a DSC thermogram comprising an exotherm with a peak starting at about 124°C. In certain embodiments, Material G of the compound of formula (I) has a DSC thermogram substantially the same as shown in Figure 50.
[0776] In certain embodiments, Material G of compound formula (I) exhibits a weight loss of less than or equal to about 3.2% by weight when heated Material G of compound formula (I) from about 25°C to about 169°C. The weight loss exhibited by a crystalline form (e.g., Material G of compound formula (I)) can be determined, for example, using TGA. In certain embodiments, Material G of compound formula (I) has a TGA thermogram substantially the same as that shown in Figure 51.
[0777] In certain embodiments, Material G of the compound of formula (I) comprises an anhydrous crystalline form of the compound of formula (I). Pharmaceutical Compositions
[0778] In one aspect, pharmaceutical compositions are provided herein which generally comprise crystalline forms (e.g., crystalline free base forms and crystalline salt forms) of a compound of formula (I) described herein.
[0779] In one aspect, pharmaceutical compositions are provided herein which generally comprise a salt form of the compound of formula (I) described herein (for example, a fumarate salt form described herein, an L-tartrate salt form described herein, a tosylate salt form described herein or a succinate salt form described herein), (I) Petition 870260106343, dated 10 / 15 / 2026, pp. 146 / 289 141 / 280 and a pharmaceutically acceptable excipient.
[0780] In various embodiments, pharmaceutical compositions are provided here which generally comprise: (i) a fumarate salt of the compound with formula (I) (ii) a pharmaceutically acceptable excipient.
[0781] In various embodiments, pharmaceutical compositions are provided here which generally comprise: (i) a crystalline fumarate salt of the compound of formula (I) and (ii) a pharmaceutically acceptable excipient.
[0782] In certain embodiments, the crystalline fumarate salt is a crystalline fumarate salt described herein.
[0783] In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is a crystalline monofumarate salt of the compound of formula (I) described herein. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is Form A of a monofumarate salt of the compound of formula (I) described herein. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is Form B of a monofumarate of the compound of formula (I) described herein. In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is Form C of a monofumarate salt of the compound of formula (I) described herein.
[0784] In certain embodiments, the crystalline fumarate salt of the compound of formula (I) is a crystalline hemifumarate salt of the compound of formula (I) described herein. In certain embodiments, the Petition 870260106343, dated 10 / 15 / 2026, pp. 147 / 289 142 / 280 crystalline fumarate salt of compound formula (I) is Form A of the hemifumarate salt of compound formula (I) described herein. In certain embodiments, the crystalline fumarate salt of compound formula (I) is Form B of the hemifumarate salt of compound formula (I) described herein.
[0785] In various forms, pharmaceutical compositions comprising: (i) an L-tartrate salt of the compound with formula (I) (ii) a pharmaceutically acceptable excipient.
[0786] In various forms, pharmaceutical compositions comprising: (i) a crystalline L-tartrate salt of the compound with formula (I) and (ii) a pharmaceutically acceptable excipient.
[0787] In certain embodiments, the crystalline L-tartrate salt of the compound of formula (I) is a crystalline L-tartrate salt of the compound of formula (I) described herein.
[0788] Pharmaceutical compositions comprising various forms are provided here: (i) a tosylate salt of the compound of formula (I) F (ii) a pharmaceutically acceptable excipient. Petition 870260106343, dated 10 / 15 / 2026, pp. 148 / 289 143 / 280
[0789] Pharmaceutical compositions comprising various forms are provided here: (i) a crystalline tosylate salt of the compound of formula (I) and (ii) a pharmaceutically acceptable excipient.
[0790] In certain embodiments, the crystalline tosylate salt of the compound of formula (I) is a crystalline tosylate salt of the compound of formula (I) described herein. In certain embodiments, the crystalline tosylate salt of the compound of formula (I) is Form A of a tosylate salt of the compound of formula (I) described herein.
[0791] In various forms, pharmaceutical compositions comprising: (i) a succinate salt of the compound of formula (I) and (ii) a pharmaceutically acceptable excipient.
[0792] In various forms, pharmaceutical compositions comprising: (i) a crystalline succinate salt of the compound of formula (I) F (ii) a pharmaceutically acceptable excipient.
[0793] In certain embodiments, the crystalline succinate salt of the compound of formula (I) is a crystalline succinate salt of Petition 870260106343, dated 10 / 15 / 2026, pp. 149 / 289 144 / 280 compound of formula (I) described herein. In certain embodiments, the crystalline succinate salt of compound of formula (I) is Form A of a succinate salt of compound of formula (I) described herein.
[0794] In various embodiments, pharmaceutical compositions comprising a crystalline monofumarate salt of the compound of formula (I) described herein (for example, Form A, Form B or Form C of the monofumarate salt of the compound with formula (I)) H2N N IHOH (I), and a pharmaceutically acceptable excipient.
[0795] In various embodiments, pharmaceutical compositions comprising a crystalline hemifumarate salt of the compound of formula (I) described herein (for example, Form A or Form B of the hemifumarate salt of the compound with formula (I)) (I), and a pharmaceutically acceptable excipient.
[0796] In various embodiments, pharmaceutical compositions comprising Form A of the monofumarate salt of the compound of formula (I) described herein are provided herein. (I), and a pharmaceutically acceptable excipient.
[0797] In various embodiments, pharmaceutical compositions comprising Form B of the monofumarate salt of Petition 870260106343, dated 10 / 15 / 2026, pp. 150 / 289 145 / 280 compound of formula (I) described herein, and a pharmaceutically acceptable excipient.
[0798] In various embodiments, pharmaceutical compositions comprising Form C of the monofumarate salt of the compound of formula (I) described herein are provided herein, (I) , and a pharmaceutically acceptable excipient.
[0799] In various embodiments, pharmaceutical compositions comprising Form A of the hemifumarate salt of the compound of formula (I) described herein are provided herein, (I) , and a pharmaceutically acceptable excipient.
[0800] In various embodiments, pharmaceutical compositions comprising Form B of the hemifumarate salt of the compound of formula (I) described herein are provided here (I) , and a pharmaceutically acceptable excipient.
[0801] Pharmaceutical compositions comprising various forms are provided here: Petition 870260106343, dated 10 / 15 / 2026, pp. 151 / 289 146 / 280 (ii) a pharmaceutically acceptable excipient.
[0802] Pharmaceutical compositions comprising various forms are provided here: (ii) a pharmaceutically acceptable excipient.
[0803] Pharmaceutical compositions comprising various forms are provided here: (iii) a crystalline camsylate salt of the compound of formula (I) (iv) a pharmaceutically acceptable excipient.
[0804] In various forms, pharmaceutical compositions are provided here which generally comprise: (i) a crystalline phosphate salt of the compound with formula (I) (ii) a pharmaceutically acceptable excipient.
[0805] Compositions are provided here in various forms. Petition 870260106343, dated 10 / 15 / 2026, pp. 152 / 289 147 / 280 pharmaceuticals that generally comprise: Material A of the phosphate salt of the compound with formula (i) F OH (i); and (ii) a pharmaceutically acceptable excipient.
[0806] In various forms, pharmaceutical compositions are provided here which generally comprise: Material B of the phosphate salt of the compound with the formula F F OH (I); and a pharmaceutically acceptable excipient.
[0807] In certain embodiments, the crystalline camsylate salt is a crystalline camsylate salt described herein.
[0808] In certain embodiments, the crystalline phosphate salt is a crystalline phosphate salt described herein.
[0809] In certain embodiments, the crystalline camsylate salt of the compound of formula (I) is Form A of the crystalline camsylate salt of the compound of formula (I) described herein.
[0810] In various embodiments, pharmaceutical compositions comprising Form A of the crystalline camsylate salt of the compound of formula (I) described herein are provided herein. H2N N IHOH (I), and a pharmaceutically acceptable excipient. Petition 870260106343, dated 10 / 15 / 2026, pp. 153 / 289 148 / 280
[0811] In another aspect, pharmaceutical compositions are provided herein comprising Form A of the crystalline camsylate salt of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0812] In another aspect, pharmaceutical compositions are provided herein comprising Material A of the phosphate salt of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0813] In another aspect, pharmaceutical compositions are provided herein comprising Material B of the phosphate salt of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0814] In another aspect, pharmaceutical compositions are provided herein comprising a salt form of the compound of formula (I) described herein (for example, a crystalline monofumarate salt of the compound of formula (I) described herein, a crystalline hemifumarate salt of the compound of formula (I) described herein, a crystalline L-tartrate salt of the compound of formula (I) described herein, a crystalline tosylate salt of the compound of formula (I) described herein, or a crystalline succinate salt of the compound of formula (I) described herein), and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0815] In another aspect, pharmaceutical compositions comprising a crystalline monofumarate salt of the compound of formula (I) described herein are provided herein (for example, Form A, Petition 870260106343, dated 10 / 15 / 2026, pp. 154 / 289 149 / 280 Form B or Form C of the monofumarate salt of the compound of formula (I)) and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, cancer) in an individual in need.
[0816] In another aspect, pharmaceutical compositions are provided herein comprising a crystalline hemifumarate salt of the compound of formula (I) described herein (for example, Form A or Form B of the hemifumarate salt of the compound of formula (I)) and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0817] In another aspect, pharmaceutical compositions are provided herein comprising a crystalline L-tartrate salt of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0818] In another aspect, pharmaceutical compositions are provided herein comprising a crystalline tosylate salt of the compound of formula (I) described herein (for example, Form A of the tosylate salt of the compound of formula (I)) and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0819] In another aspect, pharmaceutical compositions are provided herein comprising a crystalline succinate salt of the compound of formula (I) described herein (for example, Form A of the succinate salt of the compound of formula (I)) and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0820] In another aspect, pharmaceutical compositions comprising Form A of the monofumarate salt of are provided herein. Petition 870260106343, dated 10 / 15 / 2026, pp. 155 / 289 150 / 280 compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, cancer) in an individual in need.
[0821] In another aspect, pharmaceutical compositions are provided herein comprising Form B of the monofumarate salt of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0822] In another aspect, pharmaceutical compositions are provided herein comprising Form C of the monofumarate salt of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0823] In another aspect, pharmaceutical compositions are provided herein comprising Form A of the hemifumarate salt of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0824] In another aspect, pharmaceutical compositions are provided herein comprising Form B of the hemifumarate salt of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0825] In one aspect, pharmaceutical compositions are provided herein which generally comprise a crystalline free base of a compound of formula (I) described herein. Petition 870260106343, dated 10 / 15 / 2026, pp. 156 / 289 151 / 280 (I) , and a pharmaceutically acceptable excipient.
[0826] In certain embodiments, the crystalline form of the compound of formula (I) is a free base crystalline form. In certain embodiments, the crystalline form of the compound of formula (I) is an anhydrous crystalline form. In certain embodiments, the crystalline form of the compound of formula (I) is Form A of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form B of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form C of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form D of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form E of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is Form H of the compound of formula (I). In certain embodiments, the crystalline form of the compound of formula (I) is a crystalline solvate.In certain embodiments, the crystalline solvate is a crystalline solvate of acetonitrile. In certain embodiments, the crystalline solvate is a crystalline solvate of acetone. In certain embodiments, the crystalline solvate is a crystalline solvate of ethyl acetate. In certain embodiments, the crystalline form of the compound of formula (I) is a crystalline hydrate.
[0827] In certain embodiments, a pharmaceutical composition described herein comprises Material F of the compound of formula (I). In certain embodiments, a pharmaceutical composition described herein comprises Material G of the compound of formula (I).
[0828] In various embodiments, pharmaceutical compositions comprising Form A of the compound of formula (I) are provided here Petition 870260106343, dated 10 / 15 / 2026, pp. 157 / 289 152 / 280 described here (I) , and a pharmaceutically acceptable excipient.
[0829] In various embodiments, pharmaceutical compositions comprising Form B of the compound of formula (I) described herein are provided here (I), and a pharmaceutically acceptable excipient.
[0830] In various embodiments, pharmaceutical compositions comprising Form C of the compound of formula (I) described herein are provided here (I), and a pharmaceutically acceptable excipient.
[0831] In various embodiments, pharmaceutical compositions comprising Form D of the compound of formula (I) described herein are provided here (I), and a pharmaceutically acceptable excipient.
[0832] In various embodiments, pharmaceutical compositions comprising Form E of the compound of formula (I) are provided here Petition 870260106343, dated 10 / 15 / 2026, pp. 158 / 289 153 / 280 described here (I) , and a pharmaceutically acceptable excipient.
[0833] In various embodiments, pharmaceutical compositions comprising Form H of the compound of formula (I) described herein are provided herein. (I), and a pharmaceutically acceptable excipient.
[0834] In various embodiments, pharmaceutical compositions comprising Material F of the compound of formula (I) described herein are provided herein. (I), and a pharmaceutically acceptable excipient.
[0835] In various embodiments, pharmaceutical compositions comprising Material G of the compound of formula (I) described herein are provided herein. (I), and a pharmaceutically acceptable excipient.
[0836] In another aspect, pharmaceutical compositions comprising a crystalline form of the compound are provided herein. Petition 870260106343, dated 10 / 15 / 2026, pp. 159 / 289 154 / 280 formula (I) described herein (for example, a crystalline free base form described herein and / or a crystalline salt form described herein) and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, cancer) in an individual in need.
[0837] In another aspect, pharmaceutical compositions are provided herein comprising a crystalline freebase form of the compound of formula (I) described herein (for example, Form A, Form B, Form C, Form D, Form E or Form H) and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0838] In another aspect, pharmaceutical compositions are provided herein comprising a crystalline camsylate salt of the compound of formula (I) described herein (for example, Form A of the crystalline camsylate salt of the compound of formula (I)) and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0839] In another aspect, pharmaceutical compositions are provided herein comprising a material comprising a crystalline phosphate salt of the compound of formula (I) described herein (for example, Material A of the phosphate salt of the compound of formula (I) or Material B of the phosphate salt of the compound of formula (I)), and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0840] In another aspect, pharmaceutical compositions comprising Form A of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, are provided herein for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0841] In another aspect, compositions are provided here. Petition 870260106343, dated 10 / 15 / 2026, pp. 160 / 289 155 / 280 pharmaceuticals comprising Form B of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, for the treatment of a condition, disease or disorder described herein (for example, cancer) in an individual in need.
[0842] In another aspect, pharmaceutical compositions comprising Form C of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, are provided herein for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0843] In another aspect, pharmaceutical compositions comprising Form D of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, are provided herein for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0844] In another aspect, pharmaceutical compositions comprising Form E of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, are provided herein for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0845] In another aspect, pharmaceutical compositions comprising Form H of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, are provided herein for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0846] In another aspect, pharmaceutical compositions comprising Material F of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, are provided herein for the treatment of a condition, disease or disorder described herein (for example, a cancer) in an individual in need.
[0847] In another aspect, pharmaceutical compositions comprising Material G of the compound of formula (I) described herein, and a pharmaceutically acceptable excipient, are provided herein for the treatment of a described condition, disease or disorder. Petition 870260106343, dated 10 / 15 / 2026, pp. 161 / 289 156 / 280 here (for example, cancer) in an individual who needs it.
[0848] In certain embodiments, the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is from about 22 mg to about 226 mg, from about 35 mg to about 226 mg, from about 45 mg to about 226 mg, from about 55 mg to about 226 mg, from about mg to about 226 mg, from about 75 mg to about 226 mg, from about 85 mg to about 226 mg, from about 95 mg to about 226 mg, from about 105 mg to about 226 mg, from about 115 mg to about 226 mg, from about 125 mg to 226 mg, from about 135 mg to about 226 mg, from about 145 mg to about 226 mg, from about 155 mg to about 226 mg, about 165 mg to about 226 mg, about 175 mg to about 226 mg, about 185 mg to about 226 mg, about 195 mg to about 226 mg, about 22 mg to about 190 mg, about mg to about 180 mg, about 22 mg to about 170 mg, about 22 mg to about 160 mg, about 22 mg to about 150 mg, about 22 mg to about 140 mg,about 22 mg to about 130 mg, about 22 mg to about 120 mg, about 22 mg to about, 110 mg, about 22 mg to about 100 mg, about 22 mg to about 90 mg, about 22 mg to about 80 mg, about 22 mg to about 70 mg, about 22 mg to about 60 mg, about 22 mg to about 50 mg, about 22 mg to about 40 mg, about 22 mg to about 30 mg, about 35 mg to about 185 mg, about 45 mg to about 175 mg, about 55 mg to about 165 mg, about 65 mg to about 155 mg, about 75 mg to about 145 mg, about 85 mg to about 135 mg, about 95 mg to about 125 mg, or about 105 mg to about 115 mg.
[0849] In certain embodiments, the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is from about 177 mg to about 900 mg, from about 250 mg to about 900 mg, about 300 mg to about 900 mg, about 350 mg to about 900 mg, about 400 mg to about 900 mg, about 450 mg to about Petition 870260106343, dated 10 / 15 / 2026, pp. 162 / 289 157 / 280 900 mg, approximately 500 mg to approximately 900 mg, approximately 550 mg to approximately 900 mg, approximately 600 mg to approximately 900 mg, approximately 650 mg to approximately 900 mg, approximately 700 mg to approximately 900 mg, approximately 750 mg to approximately 900 mg, approximately 800 mg to approximately 900 mg, approximately 850 mg to approximately 900 mg, approximately 177 mg to approximately 850 mg, approximately 177 mg to approximately 800 mg, approximately 177 mg to approximately 750 mg, approximately 177 mg to approximately 700 mg, approximately 177 mg to approximately 650 mg, approximately 177 mg to approximately 600 mg, approximately 177 mg to approximately 550 mg about 177 mg to about 500 mg, about 177 mg to about 450 mg, about 177 mg to about 400 mg, about 177 mg to about 350 mg, about 177 mg to about 300 mg, about 177 mg to about 250 mg, about 250 mg to about 850 mg, about 300 mg to about 800 mg, about 350 mg to about 750 mg, about 400 mg to about 700 mg, about 450 mg to about 650 mg, about 500 mg to about 600 mg, or about 550 mg to about 600 mg.
[0850] In certain embodiments, the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is from about 22 mg to about 451 mg, about 50 mg to about 451 mg, about 75 mg to about 451 mg, about 100 mg to about 451 mg, about 125 mg to about 451 mg, about 150 mg to about 451 mg, about 175 mg to about 451 mg, about 200 mg to about 451 mg, about 225 mg to about 451 mg, about 250 mg to about 451 mg, about 275 mg to about 451 mg, about 300 mg to about 451 mg, about 325 mg to about 451 mg, about 350 mg to about 451 mg, about 375 mg to about 451 mg, about 22 mg to about 375 mg, about 22 mg to about 350 mg, about 22 mg to about 325 mg, about 22 mg to about 300 mg, about 22 mg to about 275 mg, about 22 mg to about 250 mg, about 22 mg to about 225 mg, about 22 mg to about 200 mg, about 22 mg to about 175 mg,about 22 mg to about 150 mg, about 22 mg to about 125 mg, about, Petition 870260106343, dated 10 / 15 / 2026, page 163 / 289 158 / 280 from 22 mg to about 100 mg, about 22 mg to about 75 mg, about 22 mg to about 50 mg, about 50 mg to about 375 mg, about 75 mg to about 350 mg, about 100 mg to about 325 mg, about 125 mg to about 300 mg, about 150 mg to about 275 mg, about 175 mg to about 250 mg, about 200 mg to about 225 mg, about 50 mg to about 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to about 250 mg, about 250 mg to about 300 mg, about 300 mg to about 350 mg or about 350 mg to about 451 mg.
[0851] In certain embodiments, the amount of the compound of formula (I), or a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 22 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, fence 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, fence 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, fence 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 Petition 870260106343, dated 10 / 15 / 2026, pp. 164 / 289 159 / 280 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, approximately 660 mg, approximately 670 mg, approximately 680 mg, approximately 690 mg, approximately 700 mg, approximately 710 mg, approximately 720 mg, approximately 730 mg, approximately 740 mg, approximately 750 mg, approximately 760 mg, approximately 770 mg, approximately 780 mg, approximately 790 mg, approximately 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg or about 900 mg.
[0852] In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 22 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 50 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 75 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 100 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 125 mg.In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 150 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 175 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 200 mg. In certain embodiments, the amount of the compound of formula (I), or a... Petition 870260106343, dated 10 / 15 / 2026, pp. 165 / 289 The amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 250 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 300 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 350 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 400 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 450 mg.In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 500 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 550 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 600 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 650 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 700 mg.In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 750 mg. In certain embodiments, the amount of the compound of formula (I), or a... Petition 870260106343, dated 10 / 15 / 2026, pp. 166 / 289 161 / 280 pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 800 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 850 mg. In certain embodiments, the amount of the compound of formula (I), or of a pharmaceutically acceptable salt thereof, in a pharmaceutical composition described herein is about 900 mg.
[0853] In certain embodiments, the amount of the pharmaceutically acceptable salt of a compound of formula (I) in a pharmaceutical composition described herein is from about 22 mg to about 226 mg, from about 35 mg to about 226 mg, from about 45 mg to about 226 mg, from about 55 mg to about 226 mg, from about 65 mg to about 226 mg, from about 75 mg to about 226 mg, from about 85 mg to about 226 mg, from about 95 mg to about 226 mg, from about 105 mg to about 226 mg, from about 115 mg to about 226 mg, from about 125 mg to about 226 mg, from about 135 mg to about 226 mg, from about 145 mg to about 226 mg, from about 155 mg to about 226 mg, about 165 mg to about 226 mg, about 175 mg to about 226 mg, about 185 mg to about 226 mg, about 195 mg to about 226 mg, about 22 mg to about 190 mg, about 22 mg to about 180 mg, about 22 mg to about 170 mg, about 22 mg to about 160 mg, about 22 mg to about 150 mg, about 22 mg to about 140 mg,about 22 mg to about 130 mg, about 22 mg to about 120 mg, about 22 mg to about 110 mg, about 22 mg to about 100 mg, about 22 mg to about 90 mg, about 22 mg to about 80 mg, about 22 mg to about 70 mg, about 22 mg to about 60 mg, about from 22 mg to about 50 mg, about 22 mg to about 40 mg, about 22 mg to about 30 mg, about 35 mg to about 185 mg, about 45 mg to about 175 mg, about 55 mg to about 165 mg, about 65 mg to about 155 mg, about 75 mg to about 145 mg, about 85 mg at about 135 mg, approximately 95 mg, Petition 870260106343, dated 10 / 15 / 2026, pp. 167 / 289 162 / 280 of 125 mg or approximately 105 mg to approximately 115 mg.
[0854] In certain embodiments, the amount of the pharmaceutically acceptable salt of a compound of formula (I) in a pharmaceutical composition described herein is from about 177 mg to about 900 mg, about 250 mg to about 900 mg, about 300 mg to about 900 mg, about 350 mg to about 900 mg, about 400 mg to about 900 mg, about 450 mg to about 900 mg, about 500 mg to about 900 mg, about 550 mg to about 900 mg, about 600 mg to about 900 mg, about 650 mg to about 900 mg, about 700 mg to about 900 mg, about 750 mg to about 900 mg, about 800 mg to about 900 mg, about 850 mg to about 900 mg, about 177 mg to about 850 mg, about 177 mg to about 800 mg, about 177 mg to about 750 mg, about 177 mg to about 700 mg, about 177 mg to about 650 mg, about 177 mg to about 600 mg, about 177 mg to about 550 mg, about 177 mg to about 500 mg, about 177 mg to about 450 mg, about 177 mg to about 400 mg,about 177 mg to about 350 mg, about 177 mg to about 300 mg, about 177 mg to about 250 mg, about 250 mg to about 850 mg, about 300 mg to about 800 mg, about 350 mg to about 750 mg, about 400 mg to about 700 mg, about 450 mg to about 650 mg, about 500 mg to about 600 mg, or about 550 mg to about 600 mg.
[0855] In certain embodiments, the amount of the pharmaceutically acceptable salt of a compound of formula (I) in a pharmaceutical composition described herein is from about 22 mg to about 451 mg, about 50 mg to about 451 mg, about 75 mg to about 451 mg, about 100 mg to about 451 mg, about 125 mg to about 451 mg, about 150 mg to about 451 mg, about 175 mg to about 451 mg, about 200 mg to about 451 mg, about 225 mg to about 451 mg, about 250 mg to about 451 mg, about 275 mg to about 451 mg, about 300 mg to about 451 mg, about 325 mg to about 451 mg, about 350 Petition 870260106343, dated 10 / 15 / 2026, pp. 168 / 289 163 / 280 mg to approximately 451 mg, approximately 375 mg to approximately 451 mg, approximately 22 mg to approximately 375 mg, approximately 22 mg to approximately 350 mg, approximately 22 mg to approximately 325 mg, approximately 22 mg to approximately 300 mg, approximately 22 mg to approximately 275 mg, approximately 22 mg to approximately 250 mg, approximately 22 mg to approximately 225 mg, approximately 22 mg to approximately 200 mg, approximately 22 mg to approximately 175 mg, approximately 22 mg to approximately 150 mg, approximately 22 mg to approximately 125 mg, approximately 22 mg to approximately 100 mg, approximately 22 mg to approximately 75 mg, approximately 22 mg to approximately 50 mg, approximately 50 mg to approximately 375 mg, approximately 75 mg to approximately 350 mg, approximately 100 mg to approximately 325 mg, approximately 125 mg to approximately 300 mg, approximately 150 mg to approximately 275 mg, approximately 175 mg to approximately 250 mg, approximately 200 mg to approximately 225 mg, approximately 50 mg to approximately 100 mg, approximately 100 mg to approximately 150 mg, approximately 150 mg to approximately 200 mg, approximately 200 mg to approximately 250 mg, approximately 250 mg to approximately 300 mgapproximately 300 mg to approximately 350 mg or approximately 350 mg to approximately 451 mg.
[0856] In certain embodiments, the amount of the pharmaceutically acceptable salt of a compound of formula (I) in a pharmaceutical composition described herein is about 22 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about of 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg,approximately 350 mg Petition 870260106343, dated 10 / 15 / 2026, pp. 169 / 289 164 / 280 about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 680 mg, about 690 mg, about 700 mg, about 710 mg, about 720 mg, about 730 mg, approximately 740 mg, approximately 750 mg, approximately 760 mg, approximately 770 mg, approximately 780 mg, approximately 790 mg, approximately 800 mg, approximately 810 mg, approximately 820 mg, approximately 830 mg, approximately 840 mg, approximately 850 mg, approximately 860 mg, approximately 870 mg, approximately 880 mg, about 890 mg or about 900 mg.
[0857] In certain embodiments, the amount of the pharmaceutically acceptable salt of a compound of formula (I) in a pharmaceutical composition described herein is about 22 mg. In certain embodiments, the amount of the pharmaceutically acceptable salt of a compound of formula (I) in a pharmaceutical composition described herein is about 50 mg. In certain embodiments, the amount of the pharmaceutically acceptable salt of a compound of formula (I) in a pharmaceutical composition described herein is about 75 mg. In certain embodiments, the amount of the pharmaceutically acceptable salt of a compound of formula (I) in a pharmaceutical composition described herein is about 100 mg. In certain...
Claims
1. Fumarate salt characterized by being a compound with the formula (I) F (I) . according 2. Fumarate salt, of claim 1, characterized in that the fumarate salt is a monofumarate salt.
3. Fumarate salt, according to claim 1, characterized in that the fumarate salt is a hemifumarate salt.
4. Crystalline fumarate salt characterized in that it is a compound with formula (I) in that according to claim 4, characterized crystalline fumarate salt has an X-ray powder diffraction pattern (XRPD) comprising one or more peaks at about 16.9°, about 17.9° and about 24.1° 2θ.
6. Crystalline fumarate salt, according to claim 4 or 5, characterized in that the crystalline fumarate salt is a crystalline monofumarate salt.
7. Crystalline fumarate salt, according to any one of claims 4 to 6, characterized in that the crystalline fumarate salt has an XRPD pattern substantially the same as that shown in Figure 1.
8. Crystalline fumarate salt, according to any of claims 4 to 6, characterized in that the crystalline fumarate salt has an XRPD pattern substantially the same as that shown in Figure 3.
9. Crystalline fumarate salt, according to any one of claims 4 to 6, characterized in that the crystalline fumarate salt has an XRPD pattern substantially the same as that shown in Figure 5.
10. Crystalline fumarate salt, according to any one of claims 4 to 6, characterized in that the crystalline fumarate salt is a crystalline hemifumarate salt.
11. Crystalline fumarate salt, according to any one of claims 4, 5 or 10, characterized in that the crystalline fumarate salt has an XRPD pattern substantially the same as that shown in Figure 8.
12. Crystalline fumarate salt, according to any one of claims 4, 5 or 10, characterized in that the crystalline fumarate salt has an XRPD pattern substantially the same as that shown in Figure 14.
13. Crystalline fumarate salt, according to any one of claims 4 to 12, characterized in that the crystalline fumarate salt is an anhydrous crystalline fumarate salt.
14. Crystalline fumarate salt, according to any one of claims 4 to 12, characterized in that the crystalline fumarate salt is a crystalline hydrate.
15. Crystalline fumarate salt, according to claim 14, characterized in that the crystalline hydrate is a crystalline monohydrate.
16. Crystalline monofumarate salt characterized by being a compound with formula (I) (I) Petition 870250088442, dated 09 / 30 / 2025, page 11 / 28 3 / 18 17. Crystalline monofumarate salt, according to claim 16, characterized in that the crystalline monofumarate salt has an XRPD pattern comprising one or more peaks at about 5.2° 2θ.
18. Crystalline monofumarate salt, according to claim 17, characterized in that the XRPD pattern additionally comprises one or more peaks at about 7.6° and about 14.4° 2θ.
19. Crystalline monofumarate salt, according to claim 17 or 18, characterized in that the XRPD pattern additionally comprises one or more peaks at about 15.8°, about 21.2°, about 24.5° and about 25.0° 2θ.
20. Crystalline monofumarate salt, according to any one of claims 17 to 19, characterized in that the XRPD pattern additionally comprises one or more peaks at about 15.1°, about 16.7°, about 17.3°, about 17.9°, about 19.4°, about 19.9°, about 20.6° and about 22.7° 2θ.
21. Crystalline monofumarate salt, according to any one of claims 17 to 20, characterized in that the XRPD pattern additionally comprises one or more peaks at about 30.4° and about 31.4° 2θ.
22. Crystalline monofumarate salt, according to any one of claims 16 to 21, characterized in that the crystalline monofumarate salt has an XRPD pattern substantially the same as that shown in Figure 1.
23. Crystalline monofumarate salt, according to any one of claims 16 to 21, characterized in that the crystalline monofumarate salt has an XRPD pattern substantially the same as that shown in Figure 3.
24. Crystalline monofumarate salt, according to any one of claims 16 to 21, characterized in that the crystalline monofumarate salt has a pattern of XRPD Petition 870250088442, dated 09 / 30 / 2025, page 12 / 28 4 / 18 substantially the same as that shown in Figure 5.
25. Crystalline monofumarate salt, according to any one of claims 16 to 24, characterized in that the crystalline monofumarate salt is a crystalline hydrate.
26. Crystalline monofumarate salt, according to claim 25, characterized in that the crystalline hydrate is a crystalline monohydrate.
27. Form A of a monofumarate salt characterized by being a compound with formula (I) (I) 28. Form A of the monofumarate salt, according to claim 27, characterized in that Form A of the monofumarate salt has an XRPD pattern comprising one or more peaks at about 5.0°, about 7.4° and about 8.2° 2θ.
29. Form A of the monofumarate salt, according to claim 28, characterized in that the XRPD pattern additionally comprises one or more peaks at about 9.7°, about 10.1°, about 10.7°, about 11.4°, about 11.9°, about 13.2°, about 14.7° and about 14.8° 2θ.
30. Form A of the monofumarate salt, according to claim 28 or 29, characterized in that the XRPD pattern additionally comprises one or more peaks at about 15.2°, about 16.1°, about 16.6°, about 17.5°, about 19.5°, about 20.2°, about 21.1°, about 23.9° and about 24.2° 2θ.
31. Form A of the monofumarate salt, according to any one of claims 28 to 30, characterized in that the XRPD pattern additionally comprises one or more peaks at about 17.9°, about 18.4°, about 19.2°, about 19.9°, Petition 870250088442, dated 09 / 30 / 2025, page 13 / 28 5 / 18 about 20.8°, about 21.9°, about 22.9°, about 23.1°, about 23.5° and about 24.8° 2θ.
32. Form A of the monofumarate salt, according to any one of claims 28 to 31, characterized in that the XRPD pattern additionally comprises one or more peaks at about 25.1°, about 25.4°, about 27.4° and about 27.8° 2θ.
33. Form A of the monofumarate salt, according to any one of claims 28 to 32, characterized in that the XRPD pattern additionally comprises one or more peaks at about 28.9°, about 30.1°, about 30.4°, about 31.3°, about 31.5°, about 32.8° and about 33.6° 2θ.
34. Form A of the monofumarate salt, according to any one of claims 28 to 33, characterized in that approximately ± 0.3° 2θ means.
35. Form A of the monofumarate salt, according to any one of claims 27 to 34, characterized in that Form A of the monofumarate salt has an XRPD pattern substantially the same as that shown in Figure 1.
36. Form A of the monofumarate salt, according to any one of claims 27 to 35, characterized in that Form A of the monofumarate salt has a differential scanning calorimetry (DSC) thermogram comprising one or more endotherms with peaks starting at about 32 °C and about 133 °C.
37. Form A of the monofumarate salt, according to any one of claims 27 to 36, characterized in that Form A of the monofumarate salt has a DSC thermogram substantially the same as that shown in Figure 2.
38. Form A of the monofumarate salt, according to any one of claims 27 to 37, characterized in that Form A of the monofumarate salt exhibits a weight loss of less than or equal to about 1.2% by weight when heating Form A of the monofumarate salt from about 25°C to about 130°C.
39. Form A of the monofumarate salt, according to any one of claims 27 to 38, characterized in that Form A of the monofumarate salt is a crystalline hydrate.
40. Form B of a monofumarate salt characterized by being a compound with formula (I) 41. Form B of the monofumarate salt, according to claim 40, characterized in that Form B of the monofumarate salt has an XRPD pattern comprising a peak at about 7.5° 2θ.
42. Form B of the monofumarate salt, according to claim 41, characterized in that the XRPD pattern additionally comprises one or more peaks at about 4.7°, about 9.7°, about 13.3°, about 13.8°, about 14.0°, about 14.2° and about 15.0° 2θ.
43. Form B of the monofumarate salt, according to claim 41 or 42, characterized in that the XRPD pattern additionally comprises one or more peaks at about 17.4°, about 21.5°, about 22.2°, about 22.6°, about 23.1°, about 23.4°, about 24.4° and about 24.7° 2θ.
44. Form B of the monofumarate salt, according to any one of claims 41 to 43, characterized in that the XRPD pattern additionally comprises one or more peaks at about 15.4°, about 15.8°, about 16.6°, about 17.0°, about 17.8°, about 18.5°, about 18.8°, about 19.5°, about 19.8°, about 20.3°, about 20.6° and about 24.1° 2θ.
45. Form B of the monofumarate salt, according to any Petition 870250088442, dated 09 / 30 / 2025, p. 15 / 28 7 / 18 one of claims 41 to 44, characterized in that the XRPD pattern additionally comprises one or more peaks at about 26.8°, about 28.1° and about 29.7° 2θ.
46. Form B of the monofumarate salt, according to any one of claims 41 to 45, characterized in that the XRPD pattern additionally comprises one or more peaks at about 25.3°, about 26.0°, about 27.6°, about 30.2°, about 30.8°, about 31.5° and about 33.5° 2θ.
47. Form B of the monofumarate salt, according to any one of claims 41 to 46, characterized in that approximately ± 0.3° 2θ means.
48. Form B of the monofumarate salt, according to any one of claims 40 to 47, characterized in that Form B of the monofumarate salt has a substantially the same XRPD pattern as that shown in Figure 3.
49. Form B of the monofumarate salt, according to any one of claims 40 to 48, characterized in that Form B of the monofumarate salt has a DSC thermogram comprising one or more endotherms with peaks starting at about 41°C, about 112°C and about 122°C.
50. Form B of the monofumarate salt, according to any one of claims 40 to 49, characterized in that Form B of the monofumarate salt has a DSC thermogram substantially the same as that shown in Figure 4.
51. Form B of the monofumarate salt, according to any one of claims 40 to 50, characterized in that Form B of the monofumarate salt exhibits a weight loss of less than or equal to about 4.6% by weight when heated from about 25°C to about 155°C.
52. Form B of the monofumarate salt, according to any one of claims 40 to 51, characterized in that Form B of the monofumarate salt is a crystalline hydrate.
53. Form C of a monofumarate salt characterized by the fact Petition 870250088442, dated 09 / 30 / 2025, page 16 / 28 8 / 18 of being a compound with formula (I) (I) 54. Form C of the monofumarate salt, according to claim 53, characterized in that Form C of the monofumarate salt has an XRPD pattern comprising a peak at about 5.2° 2θ.
55. Form C of the monofumarate salt, according to claim 54, characterized in that the XRPD pattern additionally comprises one or more peaks at about 7.6°, about 10.6°, about 13.8° and about 14.4° 2θ.
56. Form C of the monofumarate salt, according to claim 54 or 55, characterized in that the XRPD pattern additionally comprises one or more peaks at about 15.8°, about 21.2°, about 24.5° and about 25.0° 2θ.
57. Form C of the monofumarate salt, according to any one of claims 54 to 56, characterized in that the XRPD pattern additionally comprises one or more peaks at about 15.1°, about 16.7°, about 17.3°, about 17.9°, about 19.4°, about 19.9°, about 20.6° and about 22.7° 2θ.
58. Form C of the monofumarate salt, according to any one of claims 54 to 57, characterized in that the XRPD pattern additionally comprises one or more peaks at about 25.7°, about 26.6°, about 28.9°, about 30.4°, about 31.4° and about 32.0° 2θ.
59. Form C of the monofumarate salt, according to any one of claims 54 to 58, characterized in that approximately ± 0.3° 2θ means.
60. Form C of the monofumarate salt, according to any Petition 870250088442, dated 09 / 30 / 2025, p. 17 / 28 9 / 18 one of claims 53 to 59, characterized in that Form C of the monofumarate salt has a substantially the same XRPD pattern as shown in Figure 5.
61. Form C of the monofumarate salt, according to any one of claims 53 to 60, characterized in that Form C of the monofumarate salt has a DSC thermogram comprising one or more endotherms with peaks starting at about 30°C and about 125°C.
62. Form C of the monofumarate salt, according to any one of claims 53 to 61, characterized in that Form C of the monofumarate salt has a DSC thermogram substantially the same as that shown in Figure 6.
63. Form C of the monofumarate salt, according to any one of claims 53 to 62, characterized in that Form C of the monofumarate salt exhibits a weight loss of less than or equal to about 0.9% by weight when heated from about 25°C to about 80°C.
64. Crystalline hemifumarate salt characterized by being a compound with formula (I) 65. Crystalline hemifumarate salt, according to claim 64, characterized in that the crystalline hemifumarate salt has an XRPD pattern comprising one or more peaks at about 8.5°, about 11.0° and about 12.0° 2θ.
66. Crystalline hemifumarate salt according to claim 65, characterized in that the XRPD pattern additionally comprises one or more peaks at about 16.9°, about 17.9° and about 24.1° 2θ. Petition 870250088442, dated 09 / 30 / 2025, page 18 / 28 10 / 18 67. Crystalline hemifumarate salt, according to claim 65 or 66, characterized in that the XRPD pattern additionally comprises one or more peaks at about 25.7°, about 27.7° and about 34.1° 2θ.
68. Crystalline hemifumarate salt, according to any one of claims 65 to 67, characterized in that approximately ± 0.3° 2θ means.
69. Crystalline hemifumarate salt, according to any one of claims 64 to 68, characterized in that the crystalline hemifumarate salt has an XRPD pattern substantially the same as that shown in Figure 8.
70. Crystalline hemifumarate salt, according to any one of claims 64 to 68, characterized in that the crystalline hemifumarate salt has an XRPD pattern substantially the same as that shown in Figure 13.
71. Crystalline hemifumarate salt, according to any one of claims 64 to 70, characterized in that the crystalline hemifumarate salt is an anhydrous crystalline form.
72. Crystalline hemifumarate salt, according to any one of claims 64 to 70, characterized in that the crystalline hemifumarate salt is a crystalline hydrate.
73. Form A of a hemifumarate salt characterized by being a compound with formula (I) (I) 74. Form A of the hemifumarate salt, according to claim 73, characterized in that Form A of the hemifumarate salt has an XRPD pattern comprising one or more peaks at about 9.9° and about 11.0° 2θ.
75. Form A of the hemifumarate salt, according to Petition 870250088442, dated 09 / 30 / 2025, page 19 / 28 11 / 18, claim 74, characterized in that the XRPD pattern additionally comprises one or more peaks at about 6.4°, about 8.3°, about 12.1°, about 13.2°, about 14.3° and about 14.5° 2θ.
76. Form A of the hemifumarate salt, according to claim 74 or 75, characterized in that the XRPD pattern additionally comprises one or more peaks at about 16.9°, about 17.2°, about 17.8°, about 18.5°, about 20.2°, about 22.1° and about 22.5° 2θ.
77. Form A of the hemifumarate salt, according to any one of claims 74 to 76, characterized in that the XRPD pattern additionally comprises one or more peaks at about 15.1°, about 16.1°, about 19.5°, about 19.8°, about 21.2°, about 21.5°, about 23.3°, about 24.3°, about 24.5° and about 25.0° 2θ.
78. Form A of the hemifumarate salt, according to any one of claims 74 to 77, characterized in that the XRPD pattern additionally comprises one or more peaks at about 25.5°, about 26.3°, about 27.2°, about 28.9° and about 31.1° 2θ.
79. Form A of the hemifumarate salt, according to any one of claims 74 to 78, characterized in that the XRPD pattern additionally comprises one or more peaks at about 27.8°, about 28.0°, about 28.3°, about 29.5°, about 31.9°, about 32.5°, about 32.7°, about 33.6°, about 34.1° and about 34.4° 2θ.
80. Form A of the hemifumarate salt, according to any one of claims 74 to 79, characterized in that approximately ± 0.3° 2θ means.
81. Form A of the hemifumarate salt, according to any one of claims 73 to 80, characterized in that Form A of the hemifumarate salt has a substantially the same XRPD pattern as that shown in Figure 8. Petition 870250088442, dated 09 / 30 / 2025, page 20 / 28 12 / 18 82. Form A of the hemifumarate salt, according to any one of claims 73 to 81, characterized in that Form A of the hemifumarate salt has a DSC thermogram comprising an endotherm with a peak beginning at about 206°C.
83. Form A of the hemifumarate salt, according to any one of claims 73 to 82, characterized in that Form A of the hemifumarate salt has a DSC thermogram substantially the same as that shown in Figure 9.
84. Form A of the hemifumarate salt, according to any one of claims 73 to 83, characterized in that Form A of the hemifumarate salt exhibits a weight loss of less than or equal to about 0.5% by weight when heated from about 25°C to about 150°C.
85. Form A of the hemifumarate salt, according to any one of claims 73 to 84, characterized in that Form A of the hemifumarate salt is an anhydrous crystalline form.
86. Form B of a hemifumarate salt characterized by the fact 87. Form B of the hemifumarate salt, according to claim 86, characterized in that Form B of the hemifumarate salt has an XRPD pattern comprising one or more peaks at about 5.4° and 8.7° 2θ.
88. Form B of the hemifumarate salt, according to claim 87, characterized in that the XRPD pattern additionally comprises one or more peaks at about 10.4°, about 11.0°, about 11.9° and about 12.6° 2θ.
89. Form B of the hemifumarate salt, according to Petition 870250088442, dated 09 / 30 / 2025, page 21 / 28 13 / 18, claim 87 or 88, characterized in that the XRPD pattern additionally comprises one or more peaks at about 16.5°, about 16.9°, about 17.4°, about 17.9° and about 23.9° 2θ.
90. Form B of the hemifumarate salt, according to any one of claims 87 to 89, characterized in that the XRPD pattern additionally comprises one or more peaks at about 25.7°, about 27.7° and about 34.1° 2θ.
91. Form B of the hemifumarate salt, according to any one of claims 87 to 90, characterized in that approximately ± 0.3° 2θ means.
92. Form B of the hemifumarate salt, according to any one of claims 86 to 91, characterized in that Form B of the hemifumarate salt has a substantially the same XRPD pattern as that shown in Figure 13.
93. Form B of the hemifumarate salt, according to any one of claims 86 to 92, characterized in that Form B of the hemifumarate salt has a DSC thermogram comprising one or more endotherms with peaks starting at about 118°C, about 182°C and about 202°C.
94. Form B of the hemifumarate salt, according to any one of claims 86 to 93, characterized in that Form B of the hemifumarate salt has a DSC thermogram substantially the same as that shown in Figure 14.
95. Form B of the hemifumarate salt, according to any one of claims 86 to 94, characterized in that Form B of the hemifumarate salt exhibits a weight loss of less than or equal to about 1.1% by weight when heated from about 25°C to about 150°C.
96. Form B of the hemifumarate salt, according to any one of claims 86 to 95, characterized in that Form B of the hemifumarate salt is a crystalline hydrate.
97. Pharmaceutical composition characterized by the fact that Petition 870250088442, dated 09 / 30 / 2025, page 22 / 28 14 / 18 comprises: (i) a fumarate salt of a compound of formula (I) (ii) a pharmaceutically acceptable excipient.
98. Pharmaceutical composition characterized in that it comprises: (i) a crystalline fumarate salt of a compound of formula (I) (ii) a pharmaceutically acceptable excipient 99. Pharmaceutical composition according to claim 98, characterized in that the crystalline fumarate salt is the crystalline fumarate salt as defined in any one of claims 4 to 15.
100. Pharmaceutical composition characterized in that it comprises: (i) a crystalline monofumarate salt of a compound of (ii) a pharmaceutically acceptable excipient 101. Pharmaceutical composition, according to claim Petition 870250088442, dated 09 / 30 / 2025, page 23 / 28 15 / 18 100, characterized in that the crystalline monofumarate salt is the crystalline monofumarate salt as defined in any one of claims 16 to 26.
102. Pharmaceutical composition characterized in that it comprises: (i) Form A of the monofumarate salt of the compound of formula (I) as defined in any one of claims 27 to 39; and (ii) a pharmaceutically acceptable excipient.
103. Pharmaceutical composition characterized in that it comprises: (i) Form B of the monofumarate salt of the compound of formula (I) as defined in any one of claims 40 to 52; and (ii) a pharmaceutically acceptable excipient.
104. Pharmaceutical composition characterized in that it comprises: (i) Form C of the monofumarate salt of the compound of formula (I) as defined in any one of claims 53 to 63; and (ii) a pharmaceutically acceptable excipient.
105. Pharmaceutical composition characterized in that it comprises: (i) a crystalline hemifumarate salt of a compound of formula (I) (ii) a pharmaceutically acceptable excipient.
106. Pharmaceutical composition, according to claim 105, characterized in that the crystalline hemifumarate salt is the crystalline hemifumarate salt as defined in any one of claims 64 to 72.
107. Pharmaceutical composition characterized in that it comprises: (i) Form A of the hemifumarate salt of the compound of formula (I) as defined in any one of claims 73 to 85; and (ii) a pharmaceutically acceptable excipient.
108. Pharmaceutical composition characterized in that it comprises: (i) Form B of the hemifumarate salt of the compound of formula (I) as defined in any one of claims 86 to 96; and (ii) a pharmaceutically acceptable excipient. 10 9. Dosage form characterized in that it comprises a pharmaceutical composition as defined in any one of claims 97 to 108.
110. Dosage form according to claim 109, characterized in that the dosage form is a solid dosage form.
111. Dosage form, according to claim 109 or 110, characterized in that the dosage form is an oral dosage form.
112. Dosage form, according to any one of claims 109 to 111, characterized in that the dosage form is a capsule.
113. Method for treating cancer in an individual in need, characterized in that it comprises administering to the individual an effective amount of the fumarate salt of the compound of formula (I) as defined in any one of claims 1 to 3; of the crystalline fumarate salt of the compound of formula (I) as defined in any one of claims 4 to 15; of the crystalline monofumarate salt of Petition 870250088442, dated 09 / 30 / 2025, p.25 / 28 17 / 18 compound of formula (I) as defined in any one of claims 16 to 26; of Form A of the monofumarate salt of compound of formula (I) as defined in any one of claims 27 to 39; of Form B of the monofumarate salt of compound of formula (I) as defined in any one of claims 40 to 52; of Form C of the monofumarate salt of compound of formula (I) as defined in any one of claims 53 to 63; of the crystalline hemifumarate salt of compound of formula (I) as defined in any one of claims 64 to 72; of Form A of the hemifumarate salt of compound of formula (I) as defined in any one of claims 73 to 85; of Form B of the monofumarate salt of compound of formula (I) as defined in any one of claims 86 to 96; or the pharmaceutical composition as defined in any one of claims 97 to 108.
114. Method according to claim 113, characterized in that the cancer is selected from the group consisting of bladder cancer, breast cancer, carcinoma, cervical cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, kidney cancer, lung cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer and thyroid cancer.
115. Method, according to claim 114, characterized in that the breast cancer is triple-negative breast cancer or metastatic breast cancer; the carcinoma is carcinoma of unknown primary (CUP), endometrial carcinoma, squamous cell carcinoma of the head and neck, Merkel cell carcinoma, squamous cell carcinoma or urothelial carcinoma; the gastric cancer is adenocarcinoma or gastrointestinal stromal tumor; the kidney cancer is renal cell carcinoma (RCC); the lung cancer is small cell lung cancer (SCLC) or non-small cell lung cancer; the hepatocellular carcinoma is hepatocellular carcinoma; or the skin cancer is malignant melanoma.
116. Method according to claim 113, characterized in that the cancer is selected from the group consisting of a renal cell carcinoma, a gastric cancer, a breast cancer, and a small cell lung cancer.
117. Method, according to claim 113, characterized in that the cancer is selected from the group consisting of classic Hodgkin lymphoma, primary thymic mediastinal lymphoma, multiple myeloma and a B-cell malignancy.
118. Method, according to claim 117, characterized in that the B-cell malignancy is non-Hodgkin lymphoma or chronic lymphocytic leukemia.
